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ABSTRACT 
Gretja L. Schnell 
HIV-1 SUBTYPE B DETERMINANTS OF NEUROPATHOGENESIS: VIRAL 
CHARACTERISTICS ASSOCIATED WITH DEMENTIA 
(Under the direction of Dr. Ronald Swanstrom) 
 
Human immunodeficiency virus type 1 (HIV-1)-associated dementia (HAD) is a 
severe neurological disease resulting from HIV-1 infection of cells in the central nervous 
system (CNS).  Significant genetic compartmentalization has been detected between virus in 
the periphery and virus in the cerebrospinal fluid (CSF)/CNS in subjects with dementia.  
Although progress has been made over the past thirty years in understanding HIV-1-
associated dementia, the mechanisms leading to the development of neurological disease 
during HIV-1 infection remain unclear.  In this dissertation, I examine the neuropathogenesis 
of HIV-1 over the course of infection by determining the viral characteristics associated with 
the development of dementia in HIV-1-infected adults.  Compartmentalization between the 
periphery and the CNS has not been previously described for subjects with primary HIV-1 
infection.  I detected compartmentalized HIV-1 variants in the CSF of a subset of primary 
infection subjects, and using longitudinal analyses I found that compartmentalization in the 
CSF can be resolved during primary infection.   
 Compartmentalized HIV-1 variants in the CNS/CSF of subjects with dementia are 
thought to replicate in long-lived perivascular macrophages and/or microglia in the CNS.  I 
examined the source of compartmentalized HIV-1 in the CSF of subjects with neurological 
disease and in neurologically-asymptomatic subjects who were initiating antiretroviral 
iii 
 
therapy.  In subjects with neurological disease, I found that rapid decay of CSF-
compartmentalized variants was associated with high CSF pleocytosis, whereas slow decay 
measured for CSF-compartmentalized variants in subjects with neurological disease was 
correlated with low peripheral CD4 cell count and reduced CSF pleocytosis.  The longer 
half-lives I detected suggest that compartmentalized HIV-1 in the CSF of some HAD 
subjects may be originating from a long-lived cell type in the brain.  I also examined the viral 
genotypes and phenotypes associated with the CSF-compartmentalized variants with 
differential decay rates.  I detected significant compartmentalization in the CSF HIV-1 
population for subjects with neurological disease, and the envelope phenotype 
characterization revealed two distinct classes of viral encephalitis associated with extensive 
genetic compartmentalization and the clinical diagnosis of dementia.  These results will form 
the basis of future studies to decipher the biology underlying viral evolution and enhanced 
HIV-1 replication in the CNS. 
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HIV-1 REPLICATION AND PATHOGENESIS 
 
HIV-1 genome organization and replication strategy 
Human immunodeficiency virus type 1 (HIV-1) belongs to the Lentivirus genus 
within the family Retroviridae.  HIV-1 has a single-stranded positive-sense RNA genome, 
and two copies of the genome are encapsulated per virion.  The HIV-1 DNA, the provirus, is 
approximately 9.7 kilobases in length, and the genome consists of ten genes that are flanked 
on the 5’ and 3’ ends by the HIV-1 long terminal repeats (LTRs).  The HIV-1 genes encode 
the structural proteins Gag (a polyprotein precursor that includes the matrix protein, capsid 
protein, and nucleocapsid) and Env, the non-structural enzymes Pro and Pol (a polyprotein 
precursor containing the reverse transcriptase and integrase), the accessory proteins (Vif, 
Vpr, Vpu, and Nef), and the regulatory proteins (Tat, Rev) (88).   
In a mature HIV-1 virion, the full-length dimeric RNA genome is associated with the 
nucleocapsid protein (NC).  NC relies on a short packaging signal located near the 5’ end of 
the viral RNA to target the unspliced RNA genome into virions (88, 102).  In the mature 
virion the NC-RNA complex is surrounded by the capsid protein (CA) arranged in a conical 
structure.  Several copies of the protease (PR), integrase (IN), and reverse transcriptase (RT) 
enzymes are also encapsulated in the virion, with RT and IN activities needed for infection of 
new cells (106).  This core structure is encircled with a spherical layer of the matrix protein 
(MA) that resides immediately below the viral envelope.  The envelope is a lipid bilayer 
acquired during viral budding from an infected cell, and contains both cellular proteins and a 
few trimers of the HIV-1 envelope protein (106).   
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The HIV-1 lifecycle begins with attachment to the main cellular receptor CD4, and 
the coreceptors CCR5 or CXCR4.  The viral envelope protein mediates both receptor 
attachment and viral membrane fusion with the target cell.  The viral core is then internalized 
into the cytoplasm of the cell where RT converts the genomic RNA to double-stranded DNA.  
The viral DNA moves into the nucleus and is integrated into the host chromosome by the 
viral integrase, forming the provirus.  The integration step has been reported to occur more 
frequently in areas of active gene transcription where the chromatin structure is in an open 
conformation (273).   
Cellular transcription factors interact with specific domains located in the HIV-1 5’ 
LTR and drive the initial round of transcription from the provirus (230).  Production of the 
Tat protein during this process increases the level of transcription from the provirus by over 
several hundred-fold (102, 187).  Tat binds to the transactivation response region (TAR) 
located on the transcribing viral RNA and stimulates transcription elongation of RNA 
polymerase II (178).  Another HIV-1 regulatory protein, Rev, is important for nuclear export 
of unspliced or partially spliced viral mRNAs (102).  Rev binds to the Rev-responsive 
element (RRE) located in the viral mRNA and brings the RNA together with the nuclear 
export protein CRM1 (44).  Translation of the viral RNAs then generates viral precursor 
polyproteins, and viral assembly and budding occurs at the plasma membrane.  Maturation of 
immature virions happens during or immediately after budding when the polyproteins are 
cleaved by the viral protease (106, 150).  The HIV-1 accessory proteins (Vif, Vpr, Vpu, and 
Nef) serve various functions during viral replication, including evasion of cellular restriction 
factors (192, 323).   
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The path to AIDS 
 The course of HIV-1 infection in a person can be divided into three main stages: 
primary infection, chronic infection, and acquired immune deficiency syndrome (AIDS) (77).  
During all stages of HIV-1 infection, the main target cells for productive infection include 
activated memory CD4+ T cells and monocytes/macrophages, although naïve CD4+ T cells 
can be infected by CXCR4-tropic viruses (X4) which generally evolve later during the course 
of infection (39).  Primary HIV-1 infection includes the acute and early phases of infection 
during which peak plasma viremia often occurs and a viral ‘set point’ may be reached (45, 
179).  Shortly after HIV-1 infection the memory CD4+ T cell population declines drastically, 
including the substantial depletion of CD4+ T cells in the gut-associated lymphoid tissue (6).  
Several weeks post-infection the HIV-1 load decreases in response to the generation of virus-
specific CD8+ cytolytic T lymphocytes (CTL) (15, 221).  The humoral immune response to 
HIV-1 infection occurs at the end of the primary stage of infection, coinciding with a partial 
rebound in peripheral CD4+ T cell counts.   
 The chronic phase of infection is a long asymptomatic period that can last for years.  
This period is characterized by persistent viral replication and evolution, and a steady loss of 
peripheral CD4+ T cells leading to immune exhaustion and immunodeficiency (54).  Leading 
up to the clinical onset of AIDS there is a drop in CD4+ T cell counts and increased viral 
replication (38).   The clinical diagnosis of AIDS occurs with the appearance of an AIDS-
defining illness or when CD4+ T cell counts fall below 200 cells/µl, and this leads to the 
development of opportunistic infections and cancers associated with HIV-1 infection (14).  
Early clinical symptoms of immunodeficiency include the appearance of candidiasis and 
shingles, while more severe AIDS-defining illnesses include HIV-associated dementia (14), 
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histoplasmosis, cryptococcosis, pneumonia caused by Pneumocystis carinii, tuberculosis, 
Toxoplasma gondii infection of the brain, lymphomas, and Kaposi’s sarcoma (54).  
Eventually, HIV-1 infection weakens the immune system to a point of no return, and the 
HIV-1-infected individual succumbs to an opportunistic infection during the final stage of 
disease. 
 
 
HIV-1 NEUROPATHOGENESIS 
 
HIV-1-associated dementia 
Neurological dysfunction is an important complication of HIV-1 infection of cells in 
the central nervous system (CNS), and neurological problems associated with HIV-1 
infection have been well described in the literature since the epidemic first began (149, 208, 
209).  HIV-1-infected individuals can develop mild to severe neurological symptoms 
associated with HIV-1 infection, including the development of HIV-1-associated dementia 
(HAD) (14, 107).  HAD is characterized by severe neurological dysfunction, and affected 
individuals have greatly impaired cognitive and motor functions, including extensive 
behavioral changes (209).  Prior to the advent of highly active antiretroviral therapy 
(HAART), 20-30% of HIV-1-infected adults developed dementia (107, 261), and upwards of 
50% of affected children developed neurological impairment and encephalitis (202).  
Widespread use of HAART has decreased the prevalence of dementia to around 10% of 
HIV-1-infected adults, although minor neurological problems are still common (107). 
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Diagnosis of neurological disease resulting from HIV-1 infection is conducted 
according to the AIDS dementia complex (ADC) stages (245).  An ADC stage number of 
zero is assigned to subjects with clinically normal mental and motor function.  The diagnosis 
of minor cognitive motor disorder (MCMD) is assigned an ADC stage 1, and indicates that 
the HIV-1-infected subject has decreases in memory and computational intellectual skills 
and/or mild motor impairment (210).  ADC staging of 2-4 includes mild to severe dementia 
resulting from HIV-1 infection.  Even during the less severe stages, individuals diagnosed 
with dementia have substantial motor disabilities and intellectual impairment such that they 
cannot maintain a job or provide basic care for themselves (210).   
 Some HAD subjects are also diagnosed with HIV-1 encephalitis (HIVE); however, 
not all subjects with HIV-1-associated neuro-impairment suffer from physiological brain 
damage.  HIVE is characterized by neurological impairment coupled with HIV-specific 
neuropathology evident in brain tissue obtained from either a brain biopsy or post-mortem 
autopsy (24).  Histopathological changes in brain tissue are the hallmarks of HIVE diagnosis, 
especially the presence of multinucleated giant cells of the macrophage/microglia origin (22, 
23, 208).  HIVE brain lesions exist as foci and are generally widespread (24), and the foci are 
associated with inflammatory changes including reactive astrocytes and increased 
macrophage infiltrates (24, 208). 
The incidence of HAD and MCMD has decreased due to the widespread use of 
HAART; however, these disorders continue to affect a substantial proportion of the HIV-1-
infected population (14, 107).  The insufficient CNS penetration of some antiretroviral drugs 
may allow HIV-1 to persist in the CNS during the course of therapy (103, 107, 239, 272).  In 
addition, higher prevalence of HAART has lead to an increased lifespan and an older 
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demographic of HIV-infected subjects, and these subjects in particular have an increased risk 
of developing HAD due to their enhanced age (11, 146).  Minor neurological problems 
associated with HIV-1 infection, including MCMD and peripheral neuropathies, are also on 
the rise (4, 107), indicating that neurological disorders will remain a problem for HIV-1-
infected subjects in the future. 
 
Patterns of neuropathogenesis for other neurovirulent viruses 
 Several DNA and RNA viruses are able to infect and replicate within cells of the 
central nervous system (CNS).  Infections of the CNS are particularly difficult to eliminate 
due to the immune-privileged nature of the CNS and the longevity of cells that comprise the 
nervous system.  RNA virus infection of the CNS results in either viral clearance, long-term 
persistence, or death of the infected individual (110).  DNA viruses have both lytic and latent 
stages during viral infection, and the viral genome is maintained in the nucleus of the 
infected cell either by integration into the host chromosome, or by a viral episome (110).  
Viral latency generally causes persistent infection of the CNS due to viral evasion of immune 
detection, and many DNA virus infections are reactivated when the host becomes immune 
compromised.   
 Proper CNS function is maintained by five important cell types located in the brain 
parenchyma, all of which are targets for viral infection.  Astrocytes regulate CNS 
homeostasis by maintaining blood-brain barrier (BBB) function and regulating the levels of 
neurotransmitters and toxic materials to provide an optimal extracellular environment for 
neurons (2).  Microglia are brain-resident macrophages located within the brain parenchyma, 
while perivascular macrophages reside in close proximity to blood vessels.  Perivascular 
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macrophages and microglia play important roles in immune responses to CNS injury and 
infection.  Neurons use electrical impulses to control both cognitive and motor function, 
while oligodendrocytes produce the myelin sheath surrounding the axons of neurons, which 
promotes efficient transfer of neuronal signals (107, 110).  
 Viruses have been shown to infect all cell types present in the brain parenchyma, and 
neurotropic viruses gain access to target cells by invading CNS tissue in very disparate ways.  
Human herpesvirus 6 and JC virus both infect oligodendrocytes, while HIV-1 targets 
perivascular macrophages/microglia and human T lymphotropic virus I infects astrocytes 
(110).  However, neurons are the most common target cell for viral infection of the CNS, and 
are targets for viruses like rabies, West Nile, and mosquito-borne alphaviruses.  As an 
example, rabies virus (RV) is neurotropic and the causative agent of the neurological disease 
rabies (58).  Transmission of RV occurs though the bite of an infected animal by inoculation 
of infectious virus in the saliva (58).  Infectious virions invade neurons at the site of 
inoculation, and travel via retrograde axonal transport to the central nervous system (CNS) 
where the virus continues to replicate and spread (58, 79).  Wild-type RV does not kill 
infected neurons, and it is thought that neuron impairment is responsible for the death of 
infected individuals (58).  Other neurotropic viruses invade the CNS by directly infecting 
brain endothelial cells that comprise the BBB (41), while others enter via diapedesis 
(movement of blood cells through intact capillary walls) of infected monocytes and 
lymphocytes (85, 121). 
 Innate and adaptive immune responses are required for RNA virus clearance from 
CNS tissue.  Interferon (IFN)-α/β production in response to viral infection induces the 
expression of pro-inflammatory cytokines and chemokines, which stimulates the migration of 
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immune cells to the site of viral infection, and promotes the development of an adaptive 
immune response (95, 144).  In the CNS, resident cells that can respond to IFN-α/β include 
astrocytes, neurons, microglia, and endothelial cells (110, 225, 226).  Astrocytes (regulators 
of brain homeostasis) and microglia (resident brain macrophages) are both activated in 
response to neuronal insult, and can rapidly produce a vast array of cytokines and 
chemokines (IL-6, TNF, MIP-1β, MCP-1, RANTES, and more) (75, 110, 193, 303).  
Production of IFN-α/β and other pro-inflammatory molecules in the CNS induces: 1) 
activation of neighboring cells, 2) amplification of local innate immune responses, 3) up-
regulation of MHC molecule expression, 4) increased expression of adhesion molecules on 
endothelial cells, 5) modification of BBB permeability, and 6) attraction of circulating 
immune cells into the CNS (75, 95, 110, 303).   
The production of IFN-α/β is important for host survival during a viral infection of 
the CNS.  Accordingly, many viruses have evolved mechanisms for subverting the interferon 
response in the CNS.  West Nile virus (WNV) encodes several non-structural proteins that 
attenuate the IFN response, and studies in mice have shown that WNV virulence is 
determined largely by resistance to IFN-α/β induction (156, 184, 263).  In vitro studies found 
that WNV fails to activate interferon regulatory factor (IRF)-3 (87) and the nonstructural 
protein 1 was found to inhibit signal transduction from Toll-like receptor 3 (318).  Rabies 
virus P protein was also identified as an antagonist of the type I interferon system by 
interfering with STAT1 (21, 304, 305) and IRF-3 (20) function.   
Adaptive immune responses are necessary for RNA virus clearance from infected 
cells in the CNS.  Viral clearance from neurons generally requires antibody-secreting B cell 
migration into the CNS (128, 300), although the exact mechanism by which antibodies 
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inhibit viral replication within neurons is not understood.  Studies using rabies virus (141) 
and Sindbis virus (176) in mice have found that the local detection of B cells and production 
of virus-neutralizing antibodies in the CNS are required for the clearance of RV.  Migration 
of T cells into the CNS is also known to be important in the clearance of RNA virus 
infections in the CNS from both neurons and glial cells (110).  Trafficking CD4+ and CD8+ T 
cells have been reported in the CNS during infection of rabies (74, 235, 258) and Sindbis 
virus (12) infection.  Additionally, it has been reported that T cell-mediated clearance of 
mouse hepatitis virus (strain JHM) is cell-type specific (110).  Mouse hepatitis virus 
clearance from oligodendrocytes requires IFN-γ (223), but CD8+ T cells are needed for 
clearance from microglia (290).  In the absence of an appropriate adaptive immune response, 
failure to clear a viral infection in the CNS ultimately leads to death of the infected individual 
through neuron dysfunction by direct viral insult (ex. rabies) or persistent immune activation 
(ex. HIV-1). 
 
 
HIV-1 BIOLOGY AND NEUROVIRULENCE 
 
Crossing the blood-brain barrier: neuroinvasion by HIV 
 The blood-brain barrier (BBB) is a specialized barrier that regulates brain 
homeostasis, and restricts the movement of molecules and cells between the peripheral blood 
and the brain parenchyma (1, 2, 127, 157).  The BBB is formed by tight junctions between 
endothelial cells that line capillaries in the brain (1, 2, 201).  The brain microvascular 
endothelial cells are surrounded by astrocyte foot processes, and many studies have shown 
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that astrocytes regulate BBB permeability through the secretion of compounds that alter tight 
junction proteins and adherens junctions proteins (1, 2, 75, 174, 193, 247, 252, 274).  In 
addition, the close proximity of pericytes (cells present around the outer surface of 
capillaries), microglia, and neurons to endothelial cells has prompted studies evaluating their 
roles in BBB regulation (2).  Molecules known to affect BBB permeability include MCP-1 
(287, 288), TNF-α (86), apolipoprotein E (90, 99, 171, 200), many of the interleukins (1, 2, 
157), and steriods (47).  BBB permeability is also increased during periods of inflammation, 
including HIV-1 infection (57). 
 HIV-1 infection of the CNS occurs shortly after peripheral infection, most likely 
through the trafficking of infected lymphocytes and monocytes across the blood-brain barrier 
(BBB) (168, 186, 197, 216).  Due to the selective permeability of the BBB, HIV-1 may 
persist in the CNS during therapy due to the insufficient CNS penetration of some 
antiretroviral drugs (103, 107, 239, 272).  Several mechanisms have been proposed for HIV-
1 infection of the CNS.  The first two theories focus on HIV-1 interactions with the brain 
microvascular endothelial cells.  One hypothesis is that HIV-1 may directly infect the 
endothelial cells; however in vitro studies have shown that HIV-1 infection of endothelial 
cells is highly restricted and non-productive (204, 237).  The second hypothesis focuses on 
the transcytosis of HIV-1 by the endothelial cells, and several studies have reported the 
internalization of HIV-1 pseudovirions (10) or SIV particles (227) by brain endothelial cells.  
However, this model of HIV infection of the CNS is not widely supported, and no studies 
have shown how the internalized virus leaves the endothelial cell to replicate in the 
parenchyma. 
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 The most widely supported theory is the “Trojan horse” hypothesis which proposes 
that HIV-1 enters the CNS through the trafficking of infected monocytes and lymphocytes 
across the BBB.  This idea was first proposed by Peluso et al. (121, 228) using visna virus to 
examine the spread of lentiviruses into the CNS of sheep.  A small number of leukocytes are 
known to cross the BBB during normal physiological conditions to carry out immune 
surveillance of the CNS, and this process is highly regulated and requires cell-specific 
interactions with endothelial cells.  Leukocyte transmigration across the BBB involves 
rolling of leukocytes across the brain endothelial cells, activation, leukocyte adhesion to the 
endothelial cells, and subsequent diapedesis (248).  Lymphocyte homing to the CNS is 
determined by both the expression of adhesion molecules (ICAM-1, VCAM-1) on brain 
endothelial cells (110, 248), and the expression of chemoattractant cytokines and chemokines 
in the brain parenchyma and perivascular spaces (248, 288).   
CNS inflammation caused by viral infection can induce the migration of lymphocytes 
from the periphery into the CNS through the production of homing chemokines (72, 248).  
The key determinants for B cell migration are not well defined, but some chemokines 
(CXCL10, MCP-1, MIP-1α) are known to attract B cells to the CNS (198).  In addition, T 
cell migration into the CNS is assisted by ICAM-1 and VCAM-1 (72, 73, 110), and studies 
found increased expression of the ICAM-1 ligand LFA-1 on HIV-1-infected PBMCs (167, 
214).  The adhesion molecule VCAM-1 was also found to be upregulated on endothelial cells 
in the brains of macaques with SIV encephalitis (265).  MCP-1 is also a strong 
chemoattractant for monocytes and activated T cells.  Previous studies have reported that 
MCP-1 induces the transmigration of leukocytes across a model of the human BBB (89, 
312), and MCP-1 is known to be elevated in the CSF of HIV-1-infected subjects with 
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dementia (33, 155, 276).  Additional studies have also reported that HIV-1-infected 
monocytes/macrophages secrete higher levels of MIP-1α and MIP-1β (16, 268), TNF-α and 
IL-1β (101, 215), and matrix metalloproteinase (MMP)-9 (55, 167) compared to uninfected 
monocytes/macrophages.  The increased levels of these chemokines serve to induce high 
levels of adhesion molecules on brain endothelial cells for altered attachment and 
transmigration of HIV-1-infected cells across the BBB (56).   
 In addition to crossing the BBB, HIV-1-infected cells can enter the CNS via two 
other routes from the peripheral blood.  The first alternative pathway of leukocyte migration 
is from the blood to the CSF across the choroid plexus, a cellular membrane that produces 
CSF.  The choroid plexus is comprised of choroid plexus epithelial cells, a central stroma, 
and an endothelial lumen (248).  The choroid plexus epithelial cells are linked with tight 
junctions to prevent the passive transfer of molecules from the blood to the CSF.  Leukocytes 
can be detected in the CSF of healthy individuals at low levels, and this process seems to be 
highly regulated due to the skewed ratios of leukocytes in the CSF compared to the plasma 
(137, 294).  Leukocytes in the CSF are mostly T cells, with an increased ratio of CD4+ 
central memory cells (137, 160, 294).  The blood-CSF route of leukocyte migration most 
likely contributes to viral burden and entry into the CNS during HIV-1 infection.  Subjects 
with HAD have higher HIV-1 RNA concentrations in the CSF compared to the peripheral 
blood (70, 71, 307), and increased CSF white blood cell counts are correlated with CSF HIV-
1 RNA concentrations (195, 286).  The final pathway of leukocyte migration is from the 
peripheral blood to the subarachnoid space, although not much is known about this route of 
entry into the brain. 
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 After crossing the BBB HIV-1 comes in contact with resident cells in the brain 
parenchyma, including perivascular macrophages, microglia, astrocytes, oligodendrocytes, 
and neurons (107).  Perivascular macrophages and brain-resident microglia are known to 
sustain productive HIV-1 infection (40, 97, 107, 232, 295, 315), although astrocytes may be 
non-productively infected by HIV-1 (97, 107, 232, 260).  Perivascular macrophages are 
located in the brain parenchyma adjacent to capillaries, and it has been estimated that around 
30% of the cell population is replaced in 2-3 months (135) by infiltrating monocytes (134).  
Parenchymal microglia are resident macrophages of the brain that are populated during fetal 
development, and the repopulation rate is thought to be extremely slow with only a small 
percentage of cells replaced over the course of several years (135, 172, 302).  In addition to 
being targets for HIV-1 infection, macrophages and microglia constitute the 
immunoregulatory cells of the brain and can become activated in response to HIV-1 in the 
CNS. 
 
HIV-1 envelope: cellular attachment and entry in the CNS 
 The HIV-1 envelope glycoprotein (Env) is produced as a 160 kilo-dalton polyprotein 
precursor (gp160) that is heavily glycosylated during translation (88).  Translation of the 
gp160 polyprotein is initiated in the cytoplasm, and the first translated amino acids include a 
signal peptide that targets the protein to the rough endoplasmic reticulum (ER) (106).  
Translation is completed in the rough ER where the signal peptide is removed, and the newly 
synthesized gp160 polyprotein interacts with host chaperones for proper folding and 
oligomerization into trimers (66, 316).  The gp160 polyproteins then move to the trans-Golgi 
network where gp160 is cleaved by a cellular furin-like protease into the gp120 surface and 
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gp41 transmembrane subunits (205).  After cleavage the gp120 and gp41 subunits remain 
non-covalently associated, and this forms the functional envelope trimer of heterodimers that 
is transported to the cell membrane.  A substantial amount of gp120 is shed from the surface 
of HIV-infected cells due to the weak interaction between gp120 and gp41 (88, 102).   
 The main functions of the HIV-1 Env protein include receptor and coreceptor 
binding, which determines the cellular tropism of HIV-1 variants, and membrane fusion with 
the target cell.  Due to the exposure of gp120 (and to a lesser degree gp41) on the surface of 
the virion, epitopes in the glycoprotein are the main targets of neutralizing antibodies in 
response to HIV infection.  The surface gp120 subunit has interspersed conserved (C1-C5) 
and variable (V1-V5) domains, and the V1-V5 domains are surface-exposed and evolve 
rapidly in response to antibody selection, serving as a protective shield for the conserved 
regions (297).  In addition, some studies have reported a neurotoxic effect of gp120 in 
neuronal cultures (61, 136, 181, 267), which is discussed in a later section.   
 The major cellular surface receptor for HIV-1 is CD4 (46), a member of the 
immunoglobulin family that is highly expressed on CD4+ T cells and expressed at low levels 
on the surface of macrophages (42, 173).  In order to enter target cells, HIV-1 gp120 also 
interacts with the coreceptors CCR5 (31, 53) or CXCR4 (78).  Crystal structures of the gp120 
monomer lacking some of the variable domains have shown that the CD4 binding site on 
gp120 is located in a deep binding pocket that is thought to be protected from antibodies by 
the glycosylated variable loops (142, 165, 166).  Specific residues in both CD4 (Phe-43) and 
gp120 (C3 and C4 domains, and others) are important for this interaction (88).   
CD4 binding induces conformational changes in gp120 and gp41, which is required 
for envelope fusogenicity (266) and exposes epitopes on gp120 that are required for 
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coreceptor binding by the V3 loop (35) and other structures (166, 255).  One crystal structure 
of gp120 bound to CD4 revealed that the V3 loop extends away from the gp120 core 
structure to enhance coreceptor binding after CD4 has been engaged (142).  Coreceptor 
binding to gp120 completes viral attachment to the target cell and induces a new 
conformational change which stimulates insertion of the gp41fusion peptide into the target 
cell membrane.  The gp41 trimer then rearranges to form a six-helix bundle (91) which 
brings the viral and cellular membranes together to facilitate fusion. 
Perivascular macrophages and brain-resident microglia are the two main cell types in 
the CNS that are known to sustain productive HIV-1 infection (40, 97, 107, 232, 295, 315).  
Perivascular macrophages and microglia in the CNS express low receptor densities of CD4, 
CCR5 and CXCR4, similar to other macrophage populations (112).  Studies examining the 
characteristics of CNS variants have reported that brain-derived HIV-1 envelopes from 
subjects with HIVE have increased macrophage tropism and low CD4 dependence compared 
to envelopes obtained from lymph node tissue (63, 109, 233, 256, 298).  The majority of 
macrophage-tropic envelopes use the CCR5 coreceptor for infection of macrophages and 
microglia (92); however, a study by Gorry et al. (108) reported that some HIV-1 variants can 
enter macrophages and microglia using the CXCR4 coreceptor. 
HIV-1 infection has been reported in microglia (40) and perivascular macrophages 
(82, 161, 295, 315) using in situ hybridization and immunohistochemistry techniques.  It is 
generally accepted that the main reservoir of HIV-1-infected cells in the CNS is the 
perivascular macrophage population, while infection of parenchymal microglia is more 
controversial.  HIV-1 isolates have been shown to productively infect primary human 
microglia in vitro (278, 292, 310).  However, studies of brains from HIVE subjects have 
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shown significant increases in the number of infiltrating perivascular macrophages (81, 82, 
105, 322), whereas these cells are mostly absent from the brain tissue of asymptomatic 
subjects.  In addition, multinucleated giant cells found in the brains of subjects with HIVE 
express the CD14 and CD45 antigens, which indicate the presence of perivascular 
macrophage instead of microglia (80, 82, 107).  SIV studies in macaques have also reported 
SIV infection of macrophage/microglia in the CNS (158, 317) and the amplification of SIV 
DNA from brain tissue (34, 259). 
 
Virological and immunological markers of HIV-1 neuropathogenesis 
In general, subjects with severe neurological complications resulting from HIV-1 
infection have higher viral burden in the CSF compared to the peripheral blood, including 
subjects with HIV-1-associated dementia (HAD) (70, 71, 307).  Substantial HIV-1 genetic 
compartmentalization has also been reported between the blood and the cerebrospinal fluid 
(CSF) of subjects with HAD (126, 236, 254, 291).  In addition, previous studies have 
reported that neurotropic HIV-1 variants can infect macrophages (108, 109, 233, 298).  The 
association of viral compartmentalization with dementia is described in detail in the next 
section. 
Specific amino acid substitutions in the Env protein have been reported to be 
associated with macrophage tropism and dementia.  One study by Dunfee et al. (64) reported 
that the HIV Env variant N283 was found more frequently in brain-derived env sequences, 
and was associated with HIV-associated dementia.  This study also found that N283 
enhances viral entry in macrophages and microglia by contributing to low CD4 dependence 
(64).  However, a more recent study reported that the N283 variant is not the only 
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determinant of macrophage tropism, and identified amino acid residues on the CD4 binding 
loop flanks and residues in the V3 loop that conferred macrophage tropism to HIV-1 
envelopes (62).  A separate report found an HIV variant in the V4 region of Env, D386, that 
occurs more frequently in subjects with HAD (65).  This Env variant was thought to change 
cell tropism by eliminating an N-linked glycosylation site at position 386 in the envelope 
protein, and reportedly enhances HIV entry in macrophages but not microglia (65).  Other 
studies have shown that the V1/V2 and V3 regions of gp120 from brain-derived envelopes 
contribute to reduced CD4 dependence and enhanced fusogenicity associated with 
macrophage tropism (108, 243, 256, 298).   
In addition to viral features associated with dementia, immunological markers of 
neuropathogenesis have been reported for HIV-1-infected individuals.  The levels of CSF 
neopterin, a pteridine produced by activated macrophages and associated with intrathecal 
immunoactivation (18, 104), and CSF light-chain neurofilament protein (NFL), a biomarker 
of CNS injury (3, 104, 199), are significantly elevated in subjects with HIV-1-associated 
dementia.  The levels of the chemokines interferon-γ-inducible protein 10 (IP-10) and 
monocyte chemoattractant protein-1 (MCP-1) have also been detected at elevated levels in 
the CSF of HAD subjects compared to asymptomatic subjects (32, 33, 155, 276).  In 
addition, a more recent study reported that plasma lipopolysaccharide levels, an indicator of 
microbial translocation across the gut membrane and known to activate monocytes, are 
elevated in HAD subjects compared to controls (5).   
One easily measured marker of inflammation in the CNS is pleocytosis, the presence 
of white blood cells (WBC) in the CSF.  Lymphocytes are not commonly present in the CNS, 
and clinical studies have defined CSF pleocytosis as CSF WBC >5 cells/µl (194, 286).  
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Although pleocytosis can occur at any stage of neurological disease, increased CSF WBC 
counts are correlated with CSF HIV-1 RNA concentrations (195, 286).  The levels of some 
chemokines associated with inflammation have also been correlated with CSF pleocytosis, 
including CSF IP-10 concentrations (32) and CSF MCP-1 concentrations (203).  Coinciding 
with reports of increased CNS inflammation associated with the development of HAD, 
several studies have reported an increase in the total number of brain perivascular 
macrophages in subjects with HIVE (81, 82, 105).  A more general feature of neurological 
disease progression is the constitutive activation of the immune system (32, 33, 104, 155, 
276).  Ultimately, a complete understanding of neuropathogenesis will need to integrate all of 
these genetic and pathological features. 
 
 
HIV-1 COMPARTMENTALIZATION IN THE CNS 
 
Compartmentalization of HIV-1 between the periphery and the central nervous system is 
associated with dementia 
Compartmentalized HIV-1 variants have been detected in the brains of HAD subjects 
at autopsy, and these brain-derived variants are genetically distinct from virus detected in the 
periphery (64, 65, 109, 218, 242, 256, 298).  Viral genetic compartmentalization has also 
been reported between the blood and the cerebrospinal fluid (CSF) of HAD subjects later 
during the course of infection (126, 236, 254, 291).  Previous studies have reported increased 
HIV-1 compartmentalization in the CNS/CSF of subjects with neurological disease (126, 
213, 254, 272, 289).  However, compartmentalized viral variants have also been detected in 
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the CSF of asymptomatic subjects, indicating that the simple detection of CSF-
compartmentalized variants is not related to the degree of neurological disease (126, 254).  A 
separate study found that in subjects without severe neurological disease CSF pleocytosis 
was associated with viral population mixing between the periphery and CSF, resulting in 
decreased CSF compartmentalization (283). 
Studies conducted by Ritola et al. (254) and Harrington et al. (126) examined HIV-1 
env compartmentalization between the blood plasma and CSF using the heteroduplex 
tracking assay (HTA) (51, 52) to distinguish between HIV-1 genetic variants in the CSF that 
were either compartmentalized in the CSF or equilibrated with the peripheral blood.  These 
studies reported that the fraction of compartmentalized virus in the CSF is significantly 
higher in HAD subjects compared to both asymptomatic or MCMD subjects (126, 254).  In 
addition, Harrington et al. reported that increased env compartmentalization in HAD subjects 
was not simply a function of low CD4 counts in HAD subjects (126).    
Another group of studies, most originating from Dana Gabuzda’s group, have focused 
on examining the biological characteristics of HIV-1 envelopes obtained from autopsy brain 
and lymph node tissue of subjects with varying degrees of neurological impairment and 
encephalitis.  These studies have reported that brain-derived HIV-1 envelopes from subjects 
with encephalitis have increased macrophage tropism and low CD4 dependence compared to 
envelopes obtained from lymph node tissue (63, 109, 233, 256, 298).  Due to the enhanced 
capacity to use low CD4 levels, it is thought that macrophage-tropic envelopes have a more 
exposed CD4 binding pocket to allow efficient gp120-receptor interactions.  Studies by 
Dunfee et al. (63) and Peters et al. (233) reported that macrophage-tropic envelopes have 
increased sensitivity to CD4 binding site antibodies.  In addition, neutralizing antibody titers 
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are much lower in the CNS compared to the plasma, providing an immune-isolated 
anatomical site for macrophage-tropic HIV-1 variants to evolve.   
Compartmentalization between the periphery and the CSF has also been reported in 
macaques infected with simian immunodeficiency virus (SIV) (123).  In a small pilot study, 
Harrington et al. (123) reported that discordance between SIV populations in the blood and 
CSF was associated with elevated CSF MCP-1 levels and increased numbers of infiltrating 
perivascular macrophages.  Other studies using SIV-infected macaques have reported SIV 
infection of macrophage/microglia in the CNS (158, 317) and the amplification of SIV DNA 
from brain tissue (34, 259), indicating that SIV infection of local cells in the CNS occurs 
during the course of infection. 
Extensive compartmentalization between the periphery and the CNS has been 
reported in subjects with HAD; however, it is not yet known when compartmentalization 
occurs during the course of HIV-1 infection.  Studies examining compartmentalization in the 
CNS during primary HIV-1 infection have been limited, and compartmentalization has not 
been detected in the CSF of primary infection subjects (126, 253).  Determining whether 
compartmentalization in the CSF begins during the primary stage of HIV-1 infection could 
have major implications for antiretroviral treatment regimens, including the timing of CNS-
penetrating drugs.   
 
The source of compartmentalized HIV-1 in the CNS 
HIV-1 invades the CNS shortly after infection, and after crossing the BBB it comes in 
contact with resident cells in the brain parenchyma, including perivascular macrophages, 
microglia, astrocytes, oligodendrocytes, and neurons (107).  Perivascular macrophages and 
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brain-resident microglia are the two cell types in the CNS that are known to sustain 
productive HIV-1 infection (40, 97, 107, 232, 295, 315), although non-productive infection 
may occur in astrocytes (97, 107, 232, 260).  Perivascular macrophages and microglia in the 
CNS also express low receptor densities of CD4, CCR5, and CXCR4, and previous studies 
have reported that neurotropic HIV-1 variants can infect macrophages (108, 109, 161, 256, 
298).   
The population dynamics of HIV-1 replication have been studied extensively in the 
periphery (139, 231, 311), but the extent of viral replication in specific cell types in the CNS 
over the course of disease is not yet known.  The use of antiretroviral drugs to prevent HIV-1 
infection of uninfected cells can be used as a tool to examine the rate of decay for cell-free 
virus and virally-infected cells.  Previous studies have reported that HIV-1 decay in the 
peripheral blood after the initiation of HAART occurs in at least two phases (139, 311).  The 
first phase of decay is rapid and represents the turnover of cell-free virions and productively 
infected CD4+ T cells (139, 231, 281, 311).  The second phase is slower and may reflect the 
decay of long-lived infected cells, possibly cells of the monocyte lineage and latently 
infected resting CD4+ T cells (139, 279, 281, 311).  A more recent study using the integrase 
inhibitor raltegravir, which targets a later step in the HIV-1 lifecycle than HAART, reported 
altered HIV-1 decay kinetics and a reduction of the second viral decay phase (207).  The 
reduction in the second phase of HIV-1 decay suggests that integration is a rate-limiting step 
in a subset of infected cells, and may indicate that longer-lived HIV-1-infected cells 
contribute less to total viral load than previously thought (207, 275).  However, the results 
from this study do not negate the possibility that the second phase of HIV-1 decay may 
reflect the turnover of long-lived cells 
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One problem with studying viral population dynamics in the CNS is that human brain 
tissue samples are difficult to obtain.  In order to examine viral evolution in the CNS over the 
course of HIV-1 infection, most studies have examined viral populations in the CSF, which 
reflects virus originating from both local CNS tissue and the peripheral blood (69, 70, 96, 
119).  Several studies examining viral decay rates in the CSF of HIV-1-infected subjects 
reported similar viral decay kinetics in both CSF and plasma for most individuals; however, 
some subjects displayed a slower clearance of virus from the CSF (68, 69, 246, 289).  
Additionally, slower clearance of HIV-1 from the CSF has been associated with the presence 
of neurological disease (68, 69, 246, 289).  A study conducted by Harrington et al. (124) 
examined the cellular sources of HIV-1 in the CNS by utilizing the HTA to measure viral 
decay rates in HIV-1-infected subjects initiating antiretroviral therapy (124).  This study 
reported that the subset of compartmentalized virus detected in the CSF of four 
asymptomatic subjects decayed rapidly after the initiation of therapy, suggesting that the 
compartmentalized virus is coming from a short-lived cell type, such as CD4+ T cells (124). 
HIV-1 persistence in the CNS can be described by two pathways based on previous 
studies (289).  The first pathway is based on the continuous trafficking of short-lived infected 
CD4+ T cells into the CNS.  Virus in the CNS is constantly replenished from the periphery, 
resulting in similar HIV-1 populations in both the periphery and the CSF (254, 289).  In this 
model, virus in both the CSF and plasma should decay rapidly upon the initiation of 
HAART.  This type of CNS infection has been described in previous studies involving 
asymptomatic HIV-1-infected subjects (124, 289).   
The second pathway is based on HIV-1 infection of long-lived perivascular 
macrophages and microglia in the CNS.  Here, virus originates from local CNS tissue 
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resulting in large differences in HIV-1 populations in the CSF and periphery (126, 254).  The 
second model predicts that virus in the CSF will have slower decay kinetics compared to the 
periphery due to the much slower turnover time of macrophages and microglia (135, 172, 
302).  Previous studies involving subjects with severe neurological disease that are initiating 
HAART have described strong compartmentalization between the CSF and plasma (126, 
254), and slower elimination of HIV-1 from the CSF (68, 69, 246, 289), suggesting a longer-
lived cell as the source of this virus.  However, the exact cellular origin of 
compartmentalized HIV-1 detected in the CSF has not been established.   
 
 
NEUROPATHOLOGICAL DAMAGE IN THE CNS DURING HIV-1 INFECTION 
  
 HIV-1 infection and replication in cells of the CNS can lead to tissue damage in the 
brains of some subjects with HAD, a disorder known as HIV encephalitis (HIVE).  During 
HIVE, productively infected macrophages and microglia fuse together to form 
multinucleated giant cells (22, 23, 208), microgliosis and astrogliosis also occur (26, 208), 
and neuron loss has been observed (25, 26, 314).  Two mechanisms have been proposed to 
explain neurodegeneration in the CNS resulting from HIV-1 infection: 1) direct injury 
resulting from neurotoxic viral proteins, and 2) bystander inflammation due to activation of 
CNS immune cells and astrocytes (107).  Activation of glial cells in the CNS is thought to 
result from both direct viral infection (activation of infected cells) and secreted inflammatory 
products (activation of uninfected cells). 
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Neurotoxic HIV-1 proteins in the CNS 
 The HIV-1 proteins gp120, Tat, and Vpr have demonstrated neurotoxicity in vitro.  
As mentioned previously, gp120 is shed from the surface of infected cells and virions due to 
a weak non-covalent interaction with gp41 (61, 153).  In vitro studies have reported gp120-
induced neuron death resulting from interactions with the viral coreceptors expressed on 
neurons (8, 133, 321).  Other studies have shown that gp120 interacts with the N-methyl-D-
aspartate (NMDA) receptor on neurons to induce neuronal cell death (320).  Neuronal cell 
death is thought to occur via disruption of the intracellular calcium environment, which 
induces neuron apoptosis (61, 169).  The neurotoxic effects of Tat have been studied 
extensively due to the finding that Tat is secreted in high amounts in vitro (28).  Tat has been 
found to directly interact with the NMDA receptor on neurons, leading to neuronal apoptosis 
(129, 285); however, most of the neurotoxic effects of Tat are a result of toxic products 
released from infected macrophages/microglia (238, 301).  Finally, some studies have 
reported that soluble Vpr induces neuron apoptosis in culture (224).  The actual extracellular 
concentrations of gp120, Tat, and Vpr in the CNS are not known, which prompts the caveat 
that the neurotoxic data generated in vitro from these proteins may not translate to what 
actually occurs in the CNS.  The interaction of immune cells in the CNS with extracellular 
viral proteins would also activate inflammatory responses. 
 
Inflammation in the CNS 
 The most widely accepted mechanism of neurodegeneration during HIV-1 infection is 
the induction of inflammation due to the presence of viral antigen in the CNS.  The 
persistence of HIV-1 cell-free virus and virus-infected cells in the CNS stimulates a state of 
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constitutive immune-activation in the CNS.  Increases in CSF viral load generally correlate 
with increased levels of inflammatory markers in the CSF of HAD subjects (195, 286).  
Inflammation in the CNS disrupts the homeostatic environment of the CNS and leads to 
activation of glial cells, including perivascular macrophages, microglia and astrocytes.  
Activated glial cells are known to secrete pro-inflammatory cytokines, chemokines and other 
toxic products, which activate other uninfected cells and stimulates the migration of 
additional lymphocytes and monocytes into the CNS (98).   
 Inflammation-induced neurological disease is amplified in subjects with HAD.  
Multiple pro-inflammatory cytokines and chemokines are amplified in the CSF of HAD 
subjects compared to subjects without neurological symptoms, including IP-10 and MCP-1 
(32, 33, 155, 276), IL-1β (17, 94), TNF-α (111, 319), and M-CSF levels are increased in the 
CSF of HIV-1-infected subjects (93, 219).  Markers of macrophage and microglia activation 
have also been detected in subjects with HAD.  HIV-1 infection induces macrophages to 
secrete quinolinic acid (114, 322), which is also produced in response to stimulation by TNF-
α and IFN-γ (229, 322).  Quinolinic acid also stimulates secretion of MCP-1 from astrocytes 
(113).  Activated macrophages also secrete platelet activating factor, an arachidonic acid 
metabolite that contributes to neurotoxicity in HAD subjects (100, 101).  In addition, 
activated microglia and astrocytes have increased levels of inducible nitric-oxide synthase, an 
enzyme that generates the free radical nitric oxide (NO) from L-arginine (322).  Previous 
studies have reported that NO production from activated glial cells contributes to 
neurodegeneration in HAD subjects (185, 217).  Astrocyte activation results in the 
production of inflammatory cytokines and disrupts the glutamate regulatory pathway (107).  
Increased concentrations of glutamate in the extracellular environment cause neuron death 
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due to uninhibited calcium entry into neuronal cells (84).  In general, all of these 
inflammatory molecules (and others) contribute to immune activation and neurodegeneration 
in the CNS, eventually leading to the development of dementia in a subset of HIV-1-infected 
individuals. 
 
 
SIGNIFICANCE AND OBJECTIVES 
 
HIV-1-associated dementia occurs in a subset of infected individuals, and results in 
significant neurological dysfunction.  The incidence of HAD is higher in countries with 
limited access to antiretroviral drugs and in older HIV-infected subjects.  In individuals that 
develop neurological disease, HIV-1 found in the CNS can include viral variants that are 
distinct from variants in the peripheral blood (64, 65, 126, 218, 236, 242, 254, 256, 291).  
However, it is currently unknown why a subset of HIV-1-infected individuals develop HAD 
or MCMD, nor is it known to what extent independent replication of HIV-1 in the CNS is a 
factor in CNS pathogenesis.  Previous research in our laboratory has shown that distinct 
compartmentalized HIV-1 variants are associated with HAD and neurological disease.  The 
degree of CSF-compartmentalization also seems to be associated with HAD, such that 
subjects with HAD have an increased abundance of compartmentalized HIV-1 variants in 
their CSF (126, 254).  Due to the lack of predictive markers for HAD, treatment with CNS-
penetrating drugs is not usually started until neurodegeneration is apparent.   
The main objective of this dissertation is to characterize viral genetic determinants 
associated with CNS compartmentalization and the development of neurological disease in 
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HIV-1-infected adults.  Genetic differences in compartmentalized virus could arise via two 
pathways:  a founder effect or adaptation to enhanced replication in the CNS.  I hypothesize 
that immunodeficiency allows viral replication to occur in the CNS, which can lead to viral 
genetic adaptation.  In addition, viral adaptation to the CNS environment leads to 
compartmentalization and preferential replication in the CNS, resulting directly or indirectly 
(through an inflammatory response) in CNS damage and the development of neurological 
disease.  The projects outlined in this dissertation focus on characterizing HIV-1 genetic 
compartmentalization over the course of HIV-1 infection, examining the genotypic and 
phenotypic differences between compartmentalized and non-compartmentalized HIV-1 
variants in subjects with HAD or no neurological symptoms, and defining the cellular origin 
of compartmentalized HIV-1 variants.  The discovery of specific viral genetic determinants 
associated with the development of HAD will establish why a subset of HIV-1-infected 
individuals develop HAD.  In addition, viral determinants that are detectable prior to the 
onset of dementia could be used as a screening tool for the diagnosis of HAD. 
  
 
CHAPTER TWO 
 
COMPARTMENTALIZATION AND CLONAL AMPLIFICATION OF HIV-1 VARIANTS 
IN THE CEREBROSPINAL FLUID DURING PRIMARY INFECTION 
 
 
Reprinted from: Schnell, G., R.W. Price, R. Swanstrom, and S. Spudich. 2010. 
Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal 
Fluid during Primary Infection. J Virol 84:2395-407. 
Reproduced/amended with permission from American Society for Microbiology. 
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ABSTRACT  
 
 Human immunodeficiency virus type 1 (HIV-1)-associated dementia (HAD) is a 
severe neurological disease that affects a subset of HIV-1-infected individuals.  Increased 
compartmentalization has been reported between blood and cerebrospinal fluid (CSF) HIV-1 
populations in subjects with HAD, but it is still not known when compartmentalization arises 
during the course of infection.  To assess HIV-1 genetic compartmentalization early during 
infection, we compared HIV-1 populations between the peripheral blood and CSF in 11 
primary infection subjects, with analysis of longitudinal samples over the first 18 months for 
a subset of subjects.  We used heteroduplex tracking assays targeting the variable regions of 
env, and single genome amplification and sequence analysis of the full length env gene, to 
identify CSF-compartmentalized variants and examine viral genotypes within the 
compartmentalized populations.  Most subjects had equilibrated HIV-1 populations between 
the blood and CSF compartments.  However, compartmentalized HIV-1 populations were 
detected in the CSF of three primary infection subjects, and longitudinal analysis of one 
subject revealed that compartmentalization during primary HIV-1 infection was resolved.  
Clonal amplification of specific HIV-1 variants was identified in the CSF population of one 
primary infection subject.  Our data show that compartmentalization can occur in the CNS of 
subjects in primary HIV-1 infection in part through persistence of the putative transmitted 
parental variant, or via viral genetic adaptation to the CNS environment.  The presence of 
distinct HIV-1 populations in the CSF indicates that independent HIV-1 replication can occur 
in the CNS, even early after HIV-1 transmission.  
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INTRODUCTION 
 
Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous 
system (CNS) can lead to neurological disease in a subset of HIV-1-infected individuals, 
including the development of HIV-1-associated dementia (HAD) (14, 107).  HAD is 
characterized by severe neurological dysfunction, and affected individuals generally have 
impaired cognitive and motor functions.  HIV-1 enters the CNS during primary infection, 
most likely via the migration of infected monocytes and lymphocytes across the blood-brain 
barrier (168, 186, 216).  The main cell types in the CNS that HIV-1 can productively infect 
are the perivascular macrophages and microglial cells, which express low receptor densities 
of CD4, CCR5, and CXCR4 (40, 107, 295, 315).  Previous studies have also reported that 
neurotropic HIV-1 variants are generally macrophage-tropic (108, 109, 161, 233, 256, 298).  
Although cells in the CNS may be infected with HIV-1 during the course of disease, it is still 
unclear whether productive HIV-1 replication occurs in the CNS early during infection. 
 Genetically compartmentalized HIV-1 variants have been detected in the brains of 
HAD subjects at autopsy (64, 65, 218, 242, 256), and in the cerebrospinal fluid (CSF) of 
HAD subjects sampled over the course of infection (126, 236, 254, 291).  Extensive 
compartmentalization between the periphery and the CNS has been reported in subjects with 
HAD; however, it is not yet known when compartmentalization occurs during the course of 
HIV-1 infection.  Primary HIV-1 infection refers to the acute and early phases of infection 
during which peak plasma viremia often occurs and a viral ‘set point’ may be reached (45, 
179), within up to the first year after HIV exposure (324).  Studies examining 
compartmentalization between the blood plasma and CSF during primary infection have been 
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limited, and extensive compartmentalization has not been detected in primary infection 
subjects (126, 253).   
 In this study we examined HIV-1 genetic compartmentalization between the 
peripheral blood and CSF during primary HIV-1 infection.  Cross-sectional and longitudinal 
blood plasma and CSF samples were analyzed for viral compartmentalization using the 
heteroduplex tracking assay (HTA) and single genome amplification (SGA).  We used the 
HTA to differentiate between HIV-1 variants in the CSF that were either compartmentalized 
to the CSF or equilibrated with the peripheral blood.  Previous studies have used the HTA to 
separate HIV-1 genetic variants in different anatomical compartments (50, 124, 131, 254), 
and to follow HIV-1 evolutionary variants over the course of infection (49, 125, 159, 212, 
251, 253).  We also conducted SGA on a subset of subjects to further examine viral genetic 
compartmentalization during primary infection.  Here we report the detection of 
compartmentalized and clonally amplified HIV-1 variants in the CSF of subjects in the 
primary stage of HIV-1 infection.  Our results suggest that minor to extensive HIV-1 genetic 
compartmentalization can occur between the periphery and the CNS during primary HIV-1 
infection, and that viral compartmentalization, as measured in the CSF, is transient in some 
subjects.   
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MATERIALS AND METHODS 
 
Subject population. 
 Study subjects were individuals enrolled in a neurological study of acute and early 
HIV-1 infection at the University of California at San Francisco.  Diagnosis of primary HIV-
1 infection at enrollment followed the previously described Serologic Testing Algorithm for 
Recent HIV Seroconversion (STARHS) (206).  In brief, subjects had positive HIV-1 nucleic 
acid testing and either had negative antibody tests in the past 12 months, or had a less-
sensitive EIA result supportive of infection within the previous six months.  Further 
estimation of days since HIV-1 exposure (days post infection, dpi) was based upon either the 
presence of symptoms of an acute seroconversion reaction or taken as the halfway point 
between last negative and first positive antibody test (180, 182).  Serial blood plasma and 
cerebrospinal fluid (CSF) samples were collected for study purposes as early as possible after 
initial diagnosis and at varying intervals thereafter.  Plasma and CSF HIV-1 RNA 
concentrations were determined using the Amplicor HIV Monitor kit (Roche).  The study 
was approved by the Committee for Human Research at the University of California at San 
Francisco, and all subjects provided written informed consent for the collection of samples. 
 
Markers of inflammation. 
 Entry blood and CSF determinations including cell counts, differential, protein, and 
albumin were performed by the San Francisco General Hospital Clinical Laboratories.  CSF 
neopterin was assayed using a commercially available ELISA assay according to the 
vendor’s methods (Henning Berlin GMBH, Berlin, Germany). 
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Viral RNA isolation, RT-PCR, HTA, and PhosphorImager analysis. 
Procedures for viral RNA isolation, RT-PCR, and HTA have been previously 
described (51, 52, 124, 159, 212, 251).  HIV-1 RNA was isolated from blood plasma and 
CSF samples (140 μl) using the QIAmp Viral RNA kit (Qiagen).  All CSF samples were 
centrifuged at 1,000 x g for 5 minutes prior to RNA isolation to remove contaminating 
cellular debris.  To increase template number, samples with viral RNA levels less than 
10,000 copies/ml were pelleted (0.5-1.0 ml) by centrifugation at 25,000 x g for 1.5 hours 
prior to RNA isolation.  Reverse transcription and PCR amplification of the V1/V2 and 
V4/V5 regions of env were conducted with 5 μl of purified RNA (from 60 μl column elution 
volume) using the Qiagen One-Step RT-PCR kit (Qiagen) as per manufacturer’s instructions, 
and using previously described primers for V1/V2 (159, 251) and V4/V5 (251).   
The heteroduplex annealing reactions have been previously described (159, 212).  
Heteroduplexes were separated by 6% native polyacrylamide gel electrophoresis for V1/V2 
and V4/V5 HTA (124, 159).  The HTA probes used in these studies include the V1/V2 Ba-L 
probe (159, 251), V1/V2 JRFL probe (159, 251), V4/V5 NL4-3 probe (124), and the V4/V5 
YU2 probe (251).  The HTA gels were dried under vacuum, and bands were visualized by 
autoradiography.  The dried HTA gels were exposed to a PhosphorImager screen, and the 
relative abundance of each detected viral variant (heteroduplex) was calculated using 
ImageQuant software (Molecular Dynamics).  The variant RNA concentration was calculated 
by multiplying the relative abundance of each individual variant by the total HIV-1 RNA 
concentration for that sample.  Template sampling was validated by analyzing duplicate RT-
PCR products by HTA for each sample.  For any time point where the HTA patterns between 
the two replicates differed significantly (>20%), the samples were not used in data analysis.  
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Percent difference values between plasma and CSF viral populations were calculated as 
previously described (159, 251). 
 
Single genome amplification (SGA). 
 HIV-1 RNA was isolated as described in the previous section.  Viral RNA was 
reverse transcribed using the Superscript III Reverse Transcriptase (Invitrogen) and oligo(dT) 
as per manufacturer’s instructions.  SGA of the full-length HIV-1 env gene through the 3’ U3 
region was conducted as previously described (154, 220, 262).  Briefly, cDNA was endpoint 
diluted and nested PCR (67, 280) was conducted using the Platinum Taq High Fidelity 
polymerase (Invitrogen) as described by Salazar-Gonzalez et al. (262).  The primers B5853 
UP0 (5’- TAGAGCCCTGGAAGCATCCAGGAAG-3’) and LTR DN1 (5’- 
GACTCTCGAGAAGCACTCAAGGCAAGCTTTATTGAG-3’) were used for the first 
round of PCR.  The primers B5957 UP1 (5’- 
GATCAAGCTTTAGGCATCTCCTATGGCAGGAAGAAG-3’) and LTR DN1 were used 
for the second round of PCR.  The SGA amplicons were then sequenced from the start of V1 
through the ectodomain of gp41 [Hxb2 numbering of positions 6600-8000].   
 
Phylogenetic and compartmentalization analyses. 
 Nucleotide sequences of the env genes were aligned using Clustal W (30, 299) or 
MAFFT software (152).  Maximum likelihood phylogenetic trees were generated using 
PhyML (116) with the following parameters: HKY85 nucleotide substitution model, four 
substitution rate categories, estimation of the transition/transversion rate ratio, estimation of 
the proportion of invariant sites, and estimation of the gamma distribution parameter (115).  
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All sequences were subjected to quality control analysis to ensure that sequences from 
different subjects were not mislabeled. 
Variants in the CSF were considered compartmentalized by HTA if they were either 
unique to the CSF or if they had a substantially higher copy number in the CSF compared to 
the plasma.  Compartmentalization of CSF viral populations by sequence was determined 
using the Slatkin-Maddison test for compartmentalization (282) implemented in the HyPhy 
software (240) and using 10,000 permutations. 
 
Nucleotide sequence accession numbers. 
 Nucleotide sequences determined in this study have been deposited in GenBank 
under the accession numbers GQ49667 to GQ497076 and GU206564 to GU206786. 
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RESULTS 
 
Study population characteristics and inflammatory markers. 
 Our study included 17 subjects enrolled in a neurological primary HIV-1 infection 
cohort for which we attempted to examine CNS compartmentalization during primary 
infection (see Table 2.1 for clinical and laboratory characteristics).  Eleven subjects had 
sufficient viral RNA loads in both the plasma and CSF compartments for HTA and SGA 
analyses of the viral populations.  All subjects in this study had higher HIV-1 RNA 
concentrations in the plasma than in the CSF, and a substantial proportion (35%, 6 of 17) of 
the subjects had extremely low CSF HIV-1 RNA concentrations at study entry (mean=232 
copies/ml, ± 197), in contrast to the other 11 subjects (mean=22,986  copies/ml, ± 49,492).  
Viral population characteristics were not analyzed for six subjects with low CSF viral load at 
entry (subjects 9003, 9010, 9012, 9014, 9016, 9017).   
We measured inflammation and cell migration into the CNS for each subject through 
several indirect analyses, including CSF/plasma albumin ratios, CSF white blood cell (WBC) 
counts, and CSF neopterin levels.  The CSF/plasma albumin ratios were calculated as a 
measure of blood-brain barrier (BBB) disruption, while CSF WBC levels were measured as a 
simple marker of inflammation and inflammatory cell migration into the CNS.  Additionally, 
the level of CSF neopterin, a pteridine produced by activated macrophages and associated 
with intrathecal immunoactivation, is elevated in HIV-infected subjects and characteristically 
particularly high (>22 nmol/L) in those with HIV-1-associated dementia (18, 104).  All 17 
subjects were enrolled within the first year of infection, with a median dpi at baseline of 143 
(interquartile range 58-165 days).  Subjects were naïve to antiretroviral treatment at 
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enrollment, and only one subject started treatment during the study intervals reported here 
(subject 7146, after 11/10/03).   
Based on published normal values of CSF WBC (0-5 cells/µl) (83) and CSF/albumin 
ratio (< 6.8) (13), most subjects had mild to moderate CNS inflammation and blood brain 
barrier disruption during this early stage of infection.  Subject 7146 was symptomatic at the 
time of enrollment with clinical meningitis that was presumed secondary to HIV-1 
seroconversion (extensive laboratory evaluation for standard bacteria, tuberculosis, 
spirochetes, and fungal organisms was negative), and had the highest levels of CSF WBC, 
CSF/plasma albumin ratio, and CSF neopterin in the group (see Table 2.1).  All other 
subjects with HTA or SGA performed were neurologically asymptomatic at study 
enrollment. 
 
Compartmentalization of HIV-1 variants in the CSF during primary infection. 
The heteroduplex tracking assay (HTA) is a useful tool for resolving and quantifying 
complex viral populations based on their genotype, and is able to detect minor variants 
within the viral population.  We utilized HTAs targeting the hypervariable regions V1/V2 
and V4/V5 of the env gene to detect and distinguish between compartmentalized and non-
compartmentalized HIV-1 variants in the CSF and plasma of primary infection subjects.  
Cross-sectional HTA analyses were conducted on 7 primary infection subjects, and we were 
able to classify the relationship between the blood and CSF viral populations into two 
groups.  Five subjects (9001, 9002, 9006, 9007, and 9019; see Figure 2.1A) showed 
concordance (% difference between blood and CSF >20%) between the blood plasma and 
CSF viral populations at the earliest time point sampled.    
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The second group (subjects 9018, 7146) had evidence of compartmentalization when 
comparing the blood and CSF viral populations at study entry (Figure 2.1B). In this small 
study, the two subjects with compartmentalized variants in the CSF had higher CSF viral 
loads compared to subjects with concordant populations in the plasma and CSF (Table 2.1).  
HIV-1 populations in the plasma and CSF were also discordant in subjects with CSF-
compartmentalized variants as measured by percent difference (9018 = 29.2% different at 
198 dpi; 7146 = 23.9% different at 156 dpi).  In this group, subject 9018 had only mild CNS 
inflammation, while subject 7146 had evidence of significant inflammation in the CNS (see 
Table 2.1).  These results show that HIV-1 compartmentalization in the CSF can occur 
during primary infection, and as early as 5 months after HIV-1 transmission. 
 
Compartmentalization during primary HIV-1 infection can be transient. 
Longitudinal HTA analyses were conducted to examine compartmentalization in the 
CSF over the course of primary HIV-1 infection (subjects 9001, 9002, 9006, 9007, and 
7146).  HIV-1 populations in the plasma and CSF were concordant over time for subjects 
9001, 9002, 9006, and 9007, with some minor variations (see Table 2.1 for percent difference 
values).  In subject 9001, viral populations between the plasma and CSF were concordant at 
each time point; however, the viral population underwent substantial divergence between 
time points, demonstrating equilibration between these compartments even as the virus was 
evolving in the periphery.  Conversely, HTA analysis of subject 9002 revealed concordance 
between the plasma and CSF populations over time, with only a small amount of viral 
diversification detected at 597 dpi. Results for subjects 9006 and 9007 are summarized in 
Figure 2.1 and Table 2.1.   We conclude that for these subjects most of the virus detected in 
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the CSF was recently imported from the periphery and underwent little independent 
replication in the CNS.   
Longitudinal HTA analysis of subject 7146 revealed one viral variant that was 
compartmentalized in the CSF at 156 and 177 dpi, although by 177 dpi this variant 
comprised a small minority of the total CSF viral population.  We also noticed that a new 
viral variant was significantly enriched in the CSF viral population at day 203 post-infection 
(Figure 2.1B).  However, the plasma and CSF viral populations had equilibrated again by 
530 dpi.  At this time point, the CSF variant that was enriched at 203 dpi still seemed to be 
slightly enriched in the CSF compared to the plasma population, although this difference was 
now minor.  These results indicate that when compartmentalization occurs during primary 
HIV-1 infection it can be transient, and the CSF viral population can change substantially 
over the course of primary HIV-1 infection.   
 
Single genome amplification confirms compartmentalization and identifies clonal 
amplification of HIV-1 variants in the CSF of primary infection subjects. 
We examined the genetically compartmentalized viral variants in more detail by 
conducting single genome amplification (SGA) on plasma and CSF samples from subjects 
with detectable compartmentalization in the CSF by HTA (subjects 9018, 7146).  We also 
conducted SGA on two subjects (9002 and 9007) with equilibrated HIV-1 populations 
between the plasma and CSF, and on an additional 4 subjects that were not analyzed by HTA 
(9025, 9037, 9039, 9040; see Figure 2.2 and Table 2.2).  The structure of the phylogenetic 
trees and limited env sequence diversity suggest that subjects 9002, 9007, 9025, 9037, and 
9039 were each infected with a single HIV-1 variant during transmission.  We found that 
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plasma and CSF env sequences for subjects 9002, 9025, 9037, and 9039 mixed together 
throughout their respective phylogenetic trees, indicating that the two compartments were 
well equilibrated for each subject (Figure 2.2A).  In addition, the CSF env sequences for 
these subjects were not considered compartmentalized using the Slatkin-Maddison test (9002 
p=0.56; 9025 p=0.84; 9037 p=0.057; 9039 p=0.97).  Subject 9007 had plasma and CSF HIV-
1 populations that were well equilibrated at 149 dpi (Slatkin-Maddison test, p=0.6928), 
although the viral populations were somewhat discordant 406 dpi (see Figure 2.2B; Slatkin-
Maddison test, p=0.0397).  These data confirm the HTA analysis showing that the plasma 
and CSF can be fully equilibrated.   
 SGA was also conducted on the cross-sectional plasma and CSF samples for subject 
9018, which had one compartmentalized variant detected by HTA, and subject 9040.   We 
detected significant compartmentalization between the blood plasma and CSF HIV-1 
populations for subject 9040 (see Figure 2.2C; Slatkin-Maddison test, p<0.0001), and further 
sequence analysis demonstrated that all of the compartmentalized variants encoded  a 
common V169R amino acid substitution in the V1/V2 stem region of the Env protein.  
Similarly, phylogenetic analysis of subject 9018 revealed a subset of env sequences derived 
from the CSF that branched separately from the rest of the sequences in the tree (Figure 
2.3A).  In addition, the compartmentalized population in the CSF had a unique Q170R amino 
acid substitution in the V1/V2 stem of envelope.  However, the CSF viral population was not 
considered compartmentalized by the Slatkin-Maddison test (p=0.1078).  Even though the 
entire CSF viral population was not considered compartmentalized, a small HIV-1 population 
in the CSF appears compartmentalized based on the phylogenetic tree structure and good 
bootstrap support for this node (Figure 2.3A).   
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Based on the sequence and phylogenetic data, subject 9018 was likely infected with at 
least two viral variants during transmission.  The two sequences that are likely closest to the 
parental viruses are 9018 C 13 / 9018 P 1 and 9018 C 14 (Figure 2.3B), and recombination 
between the transmitted viruses appears to account for much of the env genetic diversity 
detected in both the plasma and CSF populations.  This interpretation also leads to the 
conclusion that one of the putative transmitted sequences was underrepresented in the 
periphery and maintained in the CNS. 
Longitudinal SGA analysis for subject 7146 revealed transient compartmentalization 
and clonal amplification in the CSF HIV-1 population.  Based on the phylogenetic tree 
structure and env sequence diversity at the first time point sampled (156 dpi), we believe that 
subject 7146 was infected with two HIV-1 variants during the transmission event (Figure 
2.4A).  The viral variants that appear to be most closely related to the parental viruses are 
7146 1P 1 and 7146 1C 1 (Figure 2.4B), and extensive recombination between the two 
transmitted viruses can account for most of the variants.  Similar to what we detected in the 
phylogenetic analysis of subject 9018, one of the transmitted variants was maintained in the 
CSF but largely absent from the plasma viral population. 
Phylogenetic analysis of the first time point for subject 7146 (156 dpi) revealed 
compartmentalization between the plasma and CSF viral populations (Figure 2.4A), and this 
was associated with increased inflammation in the CNS (see Table 2.1).  In particular, one 
HIV-1 variant was clonally amplified in the CSF population (see bracket in Figure 2.4A).  
Compartmentalization was confirmed using the Slatkin-Maddison test (p=0.0047), and the 
CSF population was still considered compartmentalized when the clonally amplified viral 
variants were removed from the analysis (p=0.0437).  The plasma and CSF populations in 
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subject 7146 were equilibrated by 177 dpi (Figure 2.5A; Slatkin-Maddison test, p=0.2964), 
coincident with elevated measures of BBB disruption (Table 2.1).  The CSF viral population 
was considered compartmentalized again at 203 dpi based on phylogenetic analysis (Figure 
2.5B; Slatkin-Maddison test, p=0.0048) and in the setting of a reduced CSF/plasma albumin 
ratio.  We also detected a small cluster of clonally amplified sequences in the CSF-
compartmentalized population at 203 dpi, although the viral populations were equilibrated 
again by 530 dpi (data not shown; Slatkin-Maddison test, p=0.877).   
A phylogenetic tree containing representative data from all four time points sampled 
for subject 7146 revealed that the clonally amplified variants in the CSF at 156 dpi had died 
out of the CSF population by 177 dpi, and did not give rise to any additional CSF viral 
variants (noted with a bracket in Figure 2.6).  In addition, HIV-1 variants in the CSF that 
were compartmentalized at 203 dpi (noted with arrows) arose from one main branch in the 
phylogenetic tree, and these variants were lost by 530 dpi.  Clonally amplified variants 
detected in the CSF at 203 dpi were also lost from the viral population by 530 dpi.  We 
noticed that CSF sequences compartmentalized at 203 dpi branched with sequences detected 
in the CSF at 156 and 177 dpi, even though no compartmentalized variants were detected in 
the CSF at 177 dpi.  This indicates that CSF variants detected at entry were maintained over 
the course of several months in the CNS of this subject.  These data suggest that 
compartmentalization during primary infection can be resolved and recur later during 
infection.  Additionally, transient clonal amplification can occur in the CSF-
compartmentalized viral population.  
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DISCUSSION 
  
Extensive HIV-1 genetic compartmentalization between the periphery and the CNS 
has been reported in subjects with HAD (64, 65, 126, 218, 236, 242, 254, 256, 291).  
Compartmentalized viral variants present in the CSF of HAD subjects are thought to 
originate from long-lived cells in the CNS (271), and are maintained in the population by 
independent viral replication in the brain.  The time that compartmentalization occurs during 
the course of HIV-1 infection has been a subject of debate, and the absence of CSF-
compartmentalized variants during primary infection has supported the idea that 
compartmentalization occurs later during chronic infection (126, 254).  The goal of our 
current work was to determine whether compartmentalized HIV-1 variants are present in the 
CSF of primary infection subjects, and to examine the evolution of CSF variants over the 
course of early HIV-1 infection.   
In this study, we used heteroduplex tracking assays (HTAs) and single genome 
amplification (SGA) to identify CSF-compartmentalized variants and examine the 
compartmentalized viral populations.  Cross-sectional HTA analysis revealed several 
examples of compartmentalized HIV-1 variants in the CSF early during HIV-1 infection.  We 
also observed that compartmentalization during primary HIV-1 infection could be transient, 
and the compartmentalized variants in the CSF changed over time.  Our SGA analyses 
confirmed the detection of compartmentalized variants in the CSF and identified clonal 
amplification of CSF variants in one subject with primary infection (subject 7146). 
 A proportion of the primary infection subjects enrolled in our study had low baseline 
CSF viral loads, even though the plasma viral loads were high.  One explanation is that 
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plasma virus is not efficiently entering the CNS in these subjects, while another possibility is 
that HIV-1 that enters the CSF/CNS is being rapidly cleared.  In either case, our data 
suggests that substantial autonomous viral replication is not occurring in the CNS of this 
subset of primary infection subjects. This is consistent with our finding that the majority of 
primary infection subjects in our study had concordant viral populations between the plasma 
and CSF compartments.  The detection of equilibrated viral populations in the CSF early 
during HIV-1 infection indicates that the CSF compartment is accessible to most of the 
peripheral HIV-1 variants, and supports an absence of sustained viral replication in the CNS, 
although independent viral replication in the CNS may be occurring at a level below our limit 
of detection.   
Three of the primary infection subjects that we analyzed had compartmentalized 
HIV-1 variants present in their CSF viral population, indicating that local viral replication 
can occur in the CNS at this stage.  Subjects 9018 and 7146 had a multiple variant 
transmission event based on our sequence and phylogenetic data, where one HIV-1 lineage 
was detected in both the plasma and CSF, while a second transmitted virus lineage was only 
detected in the CSF virus population (Figure 2.3 and Figure 2.4).  These data suggest that 
some CSF variants have properties that permit enhanced replication in the CNS, even early 
after viral transmission.   
Phylogenetic and sequence analysis from subject 9040 revealed a V169R single 
amino acid substitution in the V1/V2 stem region of Env for CSF variants that were 
compartmentalized, and this change was not detected in any of the plasma env sequences.  
The compartmentalized HIV-1 variants in the CSF of subject 9018 had a similar Q170R 
substitution to a basic amino acid in the same region of the Env protein, and HIV-1 variants 
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in the plasma and CSF of 7146 had an R/K170 genotype.  This suggests that perhaps basic 
amino acid substitutions in the V1/V2 stem of Env enhance viral replication in the CNS 
environment.  One possibility is that additional basic amino acids in the V1/V2 stem could 
enhance the binding and entry of these viral variants to cells with low receptor densities on 
the surface, such as perivascular macrophages and microglia in the CNS.  However, basic 
amino acid substitutions in the V1/V2 stem do not completely explain compartmentalization 
during primary infection since several subjects without compartmentalized variants in the 
CSF have additional basic amino acid substitutions within their plasma and CSF HIV-1 
populations (data not shown).   
 Studies examining viral populations in the CSF of primary HIV-1 infection subjects 
have been limited; however, a small study by Harrington et al. (2007) examined the 
population dynamics of SIVsm E660 in the blood and CSF of macaques over the course of 
infection (123).  A comparison of the blood and CSF viral populations revealed two distinct 
patterns of evolution:  viral genetic concordance between the blood and CSF populations in 
two macaques, and discordance in the blood/CSF populations in a third macaque (123).  
Notably, the blood/CSF population discordance that was detected in animal C002 arose early 
after transmission (day 27) and persisted over the course of infection (123).  Similarly, we 
detected concordance between the blood plasma and CSF viral populations for eight of the 
primary infection subjects in our study.  Three subjects in our study showed discordance and 
compartmentalization in the CSF viral population, and this disturbance was apparent early 
after transmission (5 months).  Additionally, Harrington et. al (2007) reported increased 
levels of CSF monocyte chemoattractant protein-1 (MCP-1) and statistically significant 
numbers of infiltrating CD68+ macrophages in brain sections of macaque C002 compared to 
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other animals in the study (123).  Human studies have also shown that the levels of 
chemokines such as interferon-γ-inducible protein 10 (IP-10) and MCP-1 are elevated in the 
CSF of HAD subjects compared to asymptomatic subjects (32, 33, 155, 276).  Although our 
measures of CNS inflammation differ from the macaque study, we detected elevated levels of 
CSF neopterin and pleocytosis in one subject with moderate CSF compartmentalization.    
One easily measured marker of inflammation in the CNS is pleocytosis, defined as 
CSF WBC >5 cells/µl (194, 286).  Although pleocytosis can occur at any stage of 
neurological disease, during chronic infection increased CSF WBC counts are correlated with 
CSF HIV-1 RNA concentrations (195, 286).  Subject 7146 had elevations in CSF WBC, as 
well as CSF neopterin and albumin ratio prior to initiation of antiretroviral therapy (see Table 
2.1).  We believe this inflammatory environment in the CNS resulted from both independent 
HIV-1 replication and the correlated meningitis detected at entry in subject 7146.  The 
detection of BBB disruption also suggests an increased ability of lymphocytes to traverse the 
BBB and move into the CNS.  Subjects 9018 and 9040 also had evidence of 
compartmentalization of CSF variants; however, CSF WBC, CSF neopterin, and albumin 
ratio levels were not distinct from those in subjects without compartmentalization.  Thus, 
marked inflammation at a given time point is not necessary for the production or 
maintenance of compartmentalized variants. 
One specific viral lineage in subject 7146 was clonally amplified in the CSF viral 
population at 156 dpi, and our longitudinal SGA analysis determined that this viral lineage 
died out in both the CSF and plasma populations by 177 dpi.   We believe that an influx of 
inflammatory cells may have resulted in the clonal amplification of specific CSF viral 
variants at entry.  Monocytes and CD4+ T cells migrating into the CNS would provide a 
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larger target cell population for HIV-1 infection, and may stimulate increased HIV-1 
replication in the CNS.  A small population of clonally amplified variants was also detected 
in the CSF at 203 dpi when CSF pleocytosis was still apparent.  These data suggest that 
independent HIV-1 replication may occur in the CNS of primary infection subjects with 
detectable compartmentalized variants, and this viral replication may cause increased 
inflammation in the CNS that can result in the clonal expansion of CSF variants. 
 In conclusion, our study illustrates a complex pattern of HIV-1 evolution in the CNS 
during primary/early infection.  The majority of subjects in the primary stage of HIV-1 
infection have equilibrated HIV-1 populations between the blood plasma and CSF; however, 
we detected compartmentalized HIV-1 variants in the CSF populations of three primary 
infection subjects.  Two subjects with compartmentalized variants in the CSF were 
asymptomatic and did not show elevated levels of inflammatory markers in the CSF, 
suggesting that compartmentalized virus in the CSF/CNS can occur during primary HIV-1 
infection in the absence of overt neurological symptoms.  Additionally, sequence data from 
env genes obtained from subject 9040 (165 dpi) suggest that HIV-1 can rapidly adapt to 
enhance viral entry and growth in the context of the CNS environment.  Early detection of 
CSF-compartmentalized variants may indentify subjects that will have HIV-associated 
neurological problems later during infection since similar compartmentalization late in 
infection likely indicates a loss of control of viral replication in the periphery and is 
associated with HAD ((126); unpublished observation).  Our results demonstrate that 
compartmentalization in the CNS compartment can arise shortly after HIV-1 transmission, 
and suggests that subjects with compartmentalization of viral variants in the CSF during 
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early infection should be considered for early antiretroviral therapy to reduce viral replication 
in the CNS.   
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Table 2.1. Subject population characteristics and inflammatory markers.  
Subject 
IDa 
Sample 
date DPI
b CD4c CSF WBCd 
Plasma 
HIV 
RNAe 
CSF 
HIV 
RNAe 
Albumin 
ratiof 
CSF 
neoptering 
% 
Diff.h 
9003 3/1/06 78 1044 2 26,400 49 3.38 7.3  
9010 10/10/06 235 497 11 1,030 206 5.55 9.5  
9012 2/8/07 103 601 8 74,131 398 11.09 14.3  
9014 3/20/07 169 751 12 35,481 537 4.13 8.5  
9016 4/24/07 143 353 1 776,247 49 5.44 6.6  
9017 6/20/07 49 361 14 17,378 151 4.51 8.6  
9001 12/14/05 206 488 3 153,000 246 4.55 14.3 NR 
 3/22/06 305 573 4 194,000 1,180 3.50 19.0 19.0 
 6/21/06 393 575 5 74,800 4,120 4.33 20.5 10.4 
9002 2/15/06 86 770 6 7,670 19 6.47 8.9 0 
 4/6/06 137 686 2 16,500 208 6.69 11.3 0 
 8/22/06 273 539 8 44,800 4,560 7.35 21.0 0 
 9/26/06 306 542 14 32,400 4,630 9.29 21.3 0 
 10/26/06 336 501 14 37,200 12,000 9.61 17.0 0 
 12/14/06 384 640 12 198,000 8,130 9.67 15.1 0 
 5/8/07 528 546 11 13,800 1,280 9.79 9.0 0 
 7/17/07 597 459 2 40,000 515 8.73 10.1 6.6 
9006 9/14/06 150 435 8 27,700 1,300 4.64 12.9 0 
 11/1/06 197 512 6 29,000 1,310 4.31 n/a 0 
 3/20/07 336 453 6 65,600 1,620 3.75 n/a 15.9 
9007 9/18/06 149 256 4 233,000 426 10.85 33.1 NR 
 11/2/06 193 336 9 183,000 3,250 7.88 23.5 14.4 
 6/5/07 406 292 4 29,500 3,900 6.87 22.9 7.4 
9019 8/13/07 58 750 13 49,300 1,390 5.58 13.9 2.2 
9025 4/21/08 50 752 7 101,000 15,200 3.91 n/a n/a 
9037 5/14/09 46 884 26 507,652 2,682 6.35 n/a n/a 
9039 6/1/09 36 539 53 367,728 19,911 9.31 n/a n/a 
9018 8/2/07 198 350 11 404,000 37,500 6.45 11.6 29.2 
9040 6/15/09 165 705 4 16,710 6,176 7.67 n/a n/a 
7146 9/23/03 156 552 86 429,000 168,000 14.35 56.6 23.9 
 10/14/03 177 476 97 217,000 24,900 14.35 41.2 19.1 
 11/10/03 203 310 53 103,000 26,000 7.12 23.5 41.1 
 4/29/04 372 380 1 13,399 19 4.39 14.5 n/a 
 6/24/04 427 337 2 225,000 36 7.31 n/a n/a 
 10/7/04 530 305 2 308,000 2,630 5.40 20.0 15.9 
  
a= Antibody data. Subject 9003: 1 band (p24) 12/20/05.  Subject 9010: negative Ab 8/2005.  
Subject 9012: not known.  Subject 9014: negative Ab on 8/4/06; positive Ab on 12/6/07. 
Subject 9016: positive HIV RNA, negative Ab 12/27/06. Subject 9017: not known.  Subject 
9001: negative Ab 5/25/05; 10 bands 11/1/05.  Subject 9002: 10 bands 1/3/06.  Subject 9006: 
2 bands (p24, gp160) 5/5/06.  Subject 9007: not known.  Subject 9019: positive HIV RNA, 
negative Ab 6/2007. Subject 9025: negative HIV RNA 1/14/08; HIV RNA 10,000 cps/ml, 
negative Oraquick 3/13/08; positive Ab 3/20/08.  Subject 9037: negative EIA with positive 
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ELISA 4/19/09.  Subject 9039: not known.  Subject 9018: last negative Ab 11/4/06.  Subject 
9040: negative Ab 11/4/08; negative Ab 2/24/09.  Subject 7146: negative Ab 3/25/03. 
b= estimated days post-infection 
c= cells/µl 
d= CSF white blood cell counts (cells/µl) 
e= copies/ml 
f= CSF/plasma albumin ratio 
g= nmol/L; n/a=not applicable 
h = Percent difference values between plasma and CSF viral populations as measured by 
HTA.  Reported values are the average calculated from two independent HTA replicates (see 
refs. (159, 251) for methods).  Percent difference values were not measured for subjects 
9003, 9010, 9012, 9014, 9016, and 9017 due to low CSF HIV-1 RNA levels.  n/a=not 
applicable; NR=not reported due to poor sampling 
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Table 2.2. Single genome amplification results. 
Subject ID Sample date DPIa Plasma amplicons 
CSF 
amplicons 
CSF 
compartmentb 
9002 10/26/06 338 20 26 Eq 
9007 9/18/06 149 29 15 Eq 
 6/5/07 406 20 28 Uneq 
9018 8/2/07 198 29 22 Comp 
9025 4/21/08 50 19 27 Eq 
9037 5/14/09 46 37 29 Eq 
9039 6/1/09 36 40 24 Eq 
9040 6/15/09 165 23 24 Comp 
7146 9/23/03 156 22 27 Comp, Amp 
 10/14/03 177 36 29 Eq 
 11/10/03 203 26 26 Comp, Amp 
 10/7/04 530 33 22 Eq 
 
a= estimated days post-infection 
b= HIV-1 population characteristics in the CSF compartment. Eq=equilibration with the 
blood plasma; Uneq=discordance between the CSF and blood plasma without substantial 
compartmentalization; Comp=compartmentalization in the CSF; Amp=clonal amplification 
of variants detected in the CSF 
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Figure 2.1.  Cross-sectional and longitudinal HTA analysis of HIV-1 in the blood 
plasma and CSF of primary infection subjects.  (A) Longitudinal V1/V2 or V4/V5 HTA 
analysis of HIV-1 using paired blood plasma and CSF samples from 5 subjects without 
compartmentalized CSF variants.  The HTA shown for subject 9007 targeted the V1/V2 
region of env, and the V4/V5 HTA is shown for all other subjects.  Sample time points are 
listed above each HTA gel as days post-infection (DPI).  The HTA gel images for the CSF 
viral population of subject 9001 at 206 dpi and subject 9007 at 149 dpi are not included in the 
figure because there was poor reproducibility between the HTA replicates due to low CSF 
viral load.  (B) Longitudinal V4/V5 HTA analysis of HIV-1 using paired blood and CSF 
samples from 2 subjects with compartmentalized CSF variants.  CSF-compartmentalized 
variants are indicated with a filled black circle next to the gel image.  Variants that are 
enriched in the CSF are indicated with a filled black square next to the gel image. 
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Figure 2.2.  Phylogenetic analysis of plasma and CSF HIV-1 populations.  (A) 
Phylogenetic trees of HIV-1 env sequences for subjects 9002, 9025, 9037, and 9039, which 
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display equilibration between blood plasma and CSF HIV-1 populations.  (B) Phylogenetic 
trees of HIV-1 env sequences for subject 9007 at 149 dpi and 406 dpi.  HIV-1 populations 
were equilibrated at 149 dpi, but became slightly discordant at 406 dpi.  (C) Phylogenetic 
tree of HIV-1 env sequences for subject 9040, which displays significant 
compartmentalization in the CSF.  The blue circle illustrates the node of divergence for the 
compartmentalized CSF sequences.  SGA amplicons were first aligned, and a maximum-
likelihood phylogenetic tree was constructed using PhyML.  Bootstrap numbers ≥70 are 
indicated at the appropriate nodes.  Sequences obtained from the CSF are labeled with solid 
blue circles, and plasma sequences are labeled with solid red rectangles on the tree.  Genetic 
distance between sequences is indicated by the distance scale bar at the bottom of the tree. 
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Figure 2.3.  Phylogenetic and sequence analyses of plasma and CSF HIV-1 populations 
at 198 dpi for subject 9018.  (A) Maximum-likelihood phylogenetic tree.  Sequences from 
the CSF (C) are labeled with solid blue circles, and plasma sequences (P) are labeled with 
solid red rectangles.  Genetic distance between sequences is indicated by the scale bar 
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located at the bottom of the tree.  Bootstrap values >50 are labeled at the appropriate nodes.  
Putative transmitted viruses are labeled with asterisks, and CSF populations that were 
considered compartmentalized based on the phylogenetic analysis are indicated with a solid 
black line.  (B) Highlighter plot of aligned env plasma and CSF sequences.  The HXB2 base 
number is indicated on the x-axis, and the sequence ID is indicated on the y-axis.  Base 
changes are indicated by the following ticks on the highlighter plot: A=green, T=red, 
G=orange, C=light blue, Gaps=gray. 
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Figure 2.4.  Phylogenetic and sequence analyses of subject 7146 HIV-1 populations in 
the plasma and CSF at 156 dpi.  (A) Maximum-likelihood phylogenetic tree.  Sequences 
from the CSF (C) are labeled with solid blue circles, and plasma sequences (P) are labeled 
with solid red rectangles.  Bootstrap values >50 are labeled at the appropriate nodes.  Genetic 
distance between sequences is indicated by the scale bar located at the bottom of the tree.  
The clonally amplified HIV-1 variants in the CSF population are indicated by the black 
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bracket. Putative transmitted viruses are labeled with asterisks, and CSF populations that 
were compartmentalized are indicated with a solid black line.  (B) Highlighter plot of aligned 
plasma and CSF env sequences.  The HXB2 base number is indicated on the x-axis, and the 
sequence ID is indicated on the y-axis.  Base changes are indicated by the following ticks on 
the highlighter plot: A=green, T=red, G=orange, C=light blue, Gaps=gray. 
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Figure 2.5.  Phylogenetic analysis of subject 7146 HIV-1 populations at days 177 and 
203 post-infection.  (A) Phylogenetic tree of plasma and CSF HIV-1 env sequences at 177 
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dpi.  (B) Phylogenetic tree of HIV-1 populations at 203 dpi.  Sequences from the CSF (C) are 
labeled with solid blue circles, and plasma sequences (P) are labeled with solid red 
rectangles.  The CSF sequences that were considered compartmentalized are indicated by the 
solid black lines.  Clonally amplified HIV-1 variants in the CSF population are indicated by 
the black bracket. Bootstrap values >50 are labeled at the appropriate nodes.  Genetic 
distance between sequences is indicated by the scale bar located at the bottom of the tree.    
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Figure 2.6.  Longitudinal phylogenetic analysis of subject 7146 HIV-1 populations.  
Phylogenetic tree of a representative set of plasma and CSF HIV-1 sequences from 156 dpi 
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(1P=light pink square; 1C=light blue circle), 177 dpi (2P=dark pink square; 2C=bright blue 
circle with dark outline), 203 dpi (3P=bright red square; 3C=royal blue circle), and 530 dpi 
(4P=dark red-brown square; 4C=navy blue circle).  CSF sequences that were clonally 
amplified at 156 dpi are indicated by the black bracket, and CSF sequences that were 
considered compartmentalized at 203 dpi are indicated with black arrows. The putative 
transmitted variants are labeled with asterisks.  Bootstrap values >50 are labeled at the 
appropriate nodes.  Genetic distance between sequences is indicated by the scale bar located 
at the bottom of the tree.    
 
  
  
 
CHAPTER THREE 
 
COMPARTMENTALIZED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 
ORIGINATES FROM LONG-LIVED CELLS IN SOME SUBJECTS WITH HIV-1-
ASSOCIATED DEMENTIA 
 
 
Reprinted from: Schnell, G., S. Spudich, P. Harrington, R. W. Price, and R. Swanstrom. 
2009. Compartmentalized human immunodeficiency virus type 1 originates from long-lived 
cells in some subjects with HIV-1-associated dementia. PLoS Pathog 5:e1000395.  
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ABSTRACT 
 
 Human immunodeficiency virus type 1 (HIV-1) invades the central nervous system 
(CNS) shortly after systemic infection, and can result in the subsequent development of HIV-
1-associated dementia (HAD) in a subset of infected individuals.  Genetically 
compartmentalized virus in the CNS is associated with HAD, suggesting autonomous viral 
replication as a factor in the disease process.  We examined the source of compartmentalized 
HIV-1 in the CNS of subjects with HIV-1-associated neurological disease and in 
asymptomatic subjects who were initiating antiretroviral therapy.  The heteroduplex tracking 
assay (HTA), targeting the variable regions of env, was used to determine which HIV-1 
genetic variants in the cerebrospinal fluid (CSF) were compartmentalized and which variants 
were shared with the blood plasma.  We then measured the viral decay kinetics of individual 
variants after the initiation of antiretroviral therapy.  Compartmentalized HIV-1 variants in 
the CSF of asymptomatic subjects decayed rapidly after the initiation of antiretroviral 
therapy, with a mean half-life of 1.57 days.  Rapid viral decay was also measured for CSF-
compartmentalized variants in four HAD subjects (t1/2 mean = 2.27 days).  However, slow 
viral decay was measured for CSF-compartmentalized variants from an additional four 
subjects with neurological disease (t1/2 range = 9.85 days to no initial decay).  The slow 
decay detected for CSF-compartmentalized variants was not associated with poor CNS drug 
penetration, drug resistant virus in the CSF, or the presence of X4 virus genotypes.  We 
found that the slow decay measured for CSF-compartmentalized variants in subjects with 
neurological disease was correlated with low peripheral CD4 cell count and reduced CSF 
pleocytosis.  We propose a model in which infiltrating macrophages replace CD4+ T cells as 
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the primary source of productive viral replication in the CNS to maintain high viral loads in 
the CSF in a substantial subset of subjects with HAD.   
 
 
AUTHOR SUMMARY  
 
 Infection of the central nervous system (CNS) with human immunodeficiency virus 
type 1 (HIV-1) can lead to the development of HIV-1-associated dementia, a severe 
neurological disease that results in cognitive and motor impairment.  Individuals that are 
chronically infected with HIV-1 sometimes display unique viral variants in their 
cerebrospinal fluid (CSF) that are not detected in the blood virus population, termed CSF-
compartmentalized variants.  The cell type that produces CSF-compartmentalized virus 
throughout the course of infection has not been determined.  We used a sensitive assay to 
detect compartmentalized variants in the CSF of subjects with and without neurological 
disease, and then measured the decay kinetics of compartmentalized virus when subjects 
were starting antiretroviral therapy.  We found that compartmentalized virus decays rapidly 
in asymptomatic subjects.  Additionally, we detected differential decay (i.e. rapid or slow) in 
subjects with neurological disease, and this was associated with the number of white blood 
cells in the CSF.  Our data supports a model of HIV-1 infection in the CNS where 
compartmentalized virus is produced by a long-lived cell type (slow decay), and this virus 
can be amplified by short-lived cells (rapid decay) that traffic into the CNS, but is 
increasingly produced from long-lived cells in the immunodeficient state.   
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INTRODUCTION 
 
 Human immunodeficiency virus type 1 (HIV-1)-associated dementia (HAD) is a 
severe neurological disease that affects a subset of HIV-1-infected individuals (14, 107).  
HIV-1 infection of the central nervous system (CNS) occurs shortly after peripheral 
infection, most likely through the trafficking of infected lymphocytes and monocytes across 
the blood-brain barrier (BBB) (197, 216).  Once HIV-1 crosses the BBB it can infect 
perivascular macrophages and brain-resident microglia, and some studies have shown that 
neurotropic viruses preferentially infect macrophages (108, 161, 256, 298).  HIV-1 may 
persist in the CNS during therapy due to the insufficient CNS penetration of some 
antiretroviral drugs (103, 107, 239, 272).   
HIV-1 variants have been detected at autopsy in the brains of HAD subjects, and 
these brain-derived variants are genetically distinct from virus detected in the peripheral 
blood (64, 65, 218, 242, 256).  A principal impediment to studying viral evolution in the 
CNS is that direct sampling of HIV-1 in brain tissue is usually possible only once, at biopsy 
or autopsy.  To examine viral populations in the CNS over the course of HIV-1 infection we 
have relied upon repeated sampling of virus in the cerebrospinal fluid (CSF).  Previous 
studies have shown that virus detected in the CSF originates from both local CNS tissue and 
the peripheral blood (69, 70, 96, 119), indicating that the CSF may act as a site of mixing of 
virus present in the brain and the periphery.  In addition, genetic compartmentalization has 
been reported between blood plasma and CSF viral variants (126, 236, 254, 291).  We 
previously examined the cellular sources of HIV-1 in the CNS by utilizing the heteroduplex 
tracking assay (HTA) to measure viral decay rates in HIV-1-infected subjects initiating 
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antiretroviral therapy (124).  In this study we reported that the subset of compartmentalized 
virus detected in the CSF of four asymptomatic subjects decayed rapidly after the initiation 
of therapy, suggesting that the compartmentalized virus is coming from a short-lived cell 
type, such as CD4+ T cells (124). 
 The population dynamics of systemic HIV-1 replication have been studied 
extensively (139, 231, 311), but the extent of viral replication in specific cell types in the 
CNS over the course of disease is not yet known.  The use of antiretroviral drugs to prevent 
HIV-1 infection of uninfected cells provides a tool for “viewing” the rate of decay for cell-
free virus and virally-infected cells.  HIV-1 decay in peripheral blood after the initiation of 
highly active antiretroviral therapy (HAART) occurs in at least two phases (139, 311).  The 
first phase of decay is rapid and has been proposed to represent the turnover of cell-free 
virions and productively infected CD4+ T cells (139, 231, 281, 311).  The second phase is 
slower and may reflect the decay of long-lived infected cells, possibly latently infected 
resting CD4+ T cells and cells of the monocyte lineage (139, 279, 281, 311), and the release 
of virions from follicular dendritic cells (138, 281).  Recently, a study using the integrase 
inhibitor raltegravir reported altered HIV-1 decay kinetics and a reduction of the second viral 
decay phase (207), suggesting integration as a rate limiting step of infection in a subset of 
cells.  The implications of these data on measured viral decay rates remain to be clarified; 
however, the reduction in the second phase of HIV-1 decay may indicate that longer-lived 
HIV-1-infected cells contribute less to total viral load than previously thought, but it does not 
preclude the possibility that the second phase of HIV-1 decay may reflect the turnover of 
long-lived cells (207, 275).   
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 In this study, we characterized the lifespan of the cellular source of 
compartmentalized HIV-1 in the CNS of subjects with and without symptomatic neurological 
disease by calculating viral decay rates during the initiation of antiretroviral therapy.  The 
heteroduplex tracking assay (HTA) (51, 52) was used to distinguish between HIV-1 genetic 
variants in the CSF that were either compartmentalized to the CSF or equilibrated with the 
peripheral blood.  HTA has been used in previous studies to differentiate between HIV-1 
genetic variants in separate anatomical compartments (50, 124, 131, 254) and HIV-1 
evolutionary variants (49, 125, 159, 212, 251, 253), including drug resistance mutations (151, 
250).  The HTA is a useful tool for resolving and quantifying complex viral populations 
based on their genotype, and is able to detect HIV-1 variants that comprise as little as 1-3% 
of the total viral population.  We targeted the variable regions of the env gene for HTA 
analysis of our subject population in order to resolve multiple HIV-1 genetic variants.  In this 
study we confirm rapid viral decay in the CSF of asymptomatic subjects initiating HAART, 
and we report reduced rates of viral decay of compartmentalized virus in the CSF in a subset 
of neurologically symptomatic subjects initiating antiretroviral therapy.  These results 
suggest a shift in the cell type that produces the bulk of the virus in the CSF late in disease as 
part of the process of viral pathogenesis in the CNS. 
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RESULTS 
 
Subject population characteristics. 
Our analysis included 11 asymptomatic subjects (7 new subjects, 4 subjects reported 
in (124)), 1 subject with minor cognitive motor disorder (MCMD), and 7 subjects with HIV-
1-associated dementia (HAD; see Table 3.1).  In general, subjects with HAD have higher 
viral load in the CSF (70, 71, 307) and increased HIV-1 compartmentalization in the CSF 
(126, 254).  To assess compartmentalization we measured the relative abundance of HIV-1 
variants in the blood plasma and CSF as resolved by the heteroduplex tracking assay (HTA), 
then calculated the percent difference values between the two viral populations (see Table 
3.2).  We found that the CSF and plasma viral populations were different for subjects with 
HIV-associated neurological disease (average = 67% different; range = 36 – 88% different) 
compared to the asymptomatic subjects (average = 42% different; range = 10 – 78% 
different).  This difference approached statistical significance in spite of the small sample 
size (p = 0.054 using a two-tailed Mann-Whitney test), and this trend of increased viral 
compartmentalization in the CSF with HAD is consistent with the difference seen in a larger 
cross-sectional analysis (126).  We next used the HTA to follow differential decay of shared 
and compartmentalized variants when subjects initiated therapy.  In this study, the subjects 
had an average reduction of 91% of the virus in the blood, and 88% of the virus in the CSF, 
over the period of sampling for HTA analysis (Table 3.2). 
 
Compartmentalized HIV-1 in the CSF of asymptomatic subjects decays rapidly. 
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 The HTA is a useful tool for sampling complex viral populations, and is sensitive 
enough to detect minor variants within the population.  We utilized HTAs targeting the 
hyper-variable regions V1/V2 and V4/V5 of the env gene to detect and measure the decay of 
individual HIV-1 variants in the cerebrospinal fluid and plasma of subjects initiating 
HAART.  The HTA that was the most reproducible (V1/V2 or V4/V5) was used for the final 
decay and half-life calculations.  The half-lives for the different variants in the blood for four 
of these subjects have been reported previously (143).   
The V1/V2 and V4/V5 HTA analyses for the seven new asymptomatic subjects 
revealed rapid HIV-1 decay for both compartmentalized and shared variants detected in the 
CSF (see Figure 3.1).  The decay of individual variants was organized into two groups for 
half-life analysis: decay of CSF-compartmentalized variants and decay of variants shared 
between the blood and the CSF.  The HTA gels for the longitudinal samples from the seven 
new asymptomatic subjects are shown in Figure 3.1A, and graphs representing the viral 
decay are shown in Figure 3.1B.  In this analysis, viral variants that decay more slowly will 
make up an increasing percentage of the total viral population over the course of therapy.  
However, if all variants decay at the same rate then the relative percentages will remain the 
same over time.  HIV-1 half-lives for plasma and CSF variants were calculated based on the 
slopes of the decay curves (summarized in Table 3.2).  Based on data generated from the 
seven new asymptomatic subjects analyzed in this study, half-lives calculated for the total 
plasma viral load decay were short (t1/2 mean = 1.46 days; t1/2 range = 0.58 – 2.27 days), and 
total CSF viral load half-lives were short (t1/2 mean = 1.5 days; t1/2 range = 0.77 – 2.04 days).  
These half-lives are similar to the data reported for 4 asymptomatic subjects that were 
previously studied (124).   
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Although some asymptomatic subjects have large percent difference values between 
the blood and CSF viral populations, not all of the variants detected in the CSF met the 
criteria for compartmentalization.  Viral variants in the CSF were considered 
compartmentalized if they were unique to the CSF or they were present in a substantially 
higher concentration in the CSF compared to the plasma.  CSF-compartmentalized variants 
were detected in asymptomatic subjects 5005, 4014, and 4022.  To increase our sample size 
we included the half-life data from the four asymptomatic subjects reported in ref. (124) in 
our analysis of CSF-compartmentalized decay.  Including these additional four subjects (n=7 
total asymptomatic subjects with some compartmentalized virus: 3 new subjects and 4 
previously reported subjects), we found that the half-lives for CSF-compartmentalized 
variants in these subjects were short, with a mean of 1.57 days (t1/2 range = 0.75 – 2.75 days; 
see below).  These data indicate that CSF-compartmentalized virus in asymptomatic subjects 
is most likely originating from a short-lived cell type, such as a CD4+ T cell.  The reported 
half-life of a productively infected CD4+ T cell is approximately 2 days (281), which 
coincides with our average measured half-life of 1.57 days in these subjects.   
 
Differential decay of compartmentalized HIV-1 in the CSF of neurologically 
symptomatic subjects is correlated with immunodeficiency and CSF pleocytosis. 
 We expanded our analysis of viral decay to HIV-1-infected subjects who were 
diagnosed with either MCMD or HAD to address the hypothesis that CSF-
compartmentalized variants in these subjects originate from longer-lived cells.  Viral decay 
in the CSF of eight subjects with neurological disease was analyzed using HTAs targeting the 
V1/V2 and V4/V5 regions of env.  The HTA analyses for the eight subjects with HIV-
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associated neurological disease showed either rapid or slow viral decay among the subjects.  
The longitudinal HTA gels for each neurologically symptomatic subject are shown in Figure 
3.2A, and the graphs of viral decay are shown in Figure 3.2B and 3.2C.  Similar to the 
asymptomatic subject decay analysis, individual variants were grouped as either CSF-
compartmentalized variants or variants shared between the blood and the CSF for the decay 
analysis.   
 Total plasma viral load decay was rapid for all subjects with neurological disease, 
with a mean half-life of 2.11 days (t1/2 range = 1.42 – 2.91 days; summarized in Table 3.2 
and Figure 3.3).  We measured rapid viral decay for CSF-compartmentalized variants after 
the initiation of HAART for four subjects with HAD (4033, 5003, 7036, 4051; t1/2 mean = 
2.27 days; t1/2 range = 1.23 – 3.67 days; Figure 3.2B and 3.3; summarized in Table 3.2), 
similar to asymptomatic subjects.  In contrast, prolonged viral decay was measured for CSF-
compartmentalized variants for the other four subjects with neurological disease (4013, 5002, 
4059, 7115; t1/2 range = 9.85 days to no initial decay), with three subjects displaying biphasic 
decay.  CSF-compartmentalized variants for subjects 4013, 5002, and 7115 displayed a 
biphasic decay (see Figure 3.2C), where the first phase of viral decay was slow (4013 t1/2 = 
28.5 days; 7115 t1/2 = no initial decay; 5002 t1/2 = no initial decay), and the second phase was 
faster (4013 t1/2 = 3.9 days; 7115 t1/2 = 6.4 days; 5002 t1/2 = 4.24 days).  Figure 3.3 and Table 
3.2 report the half-lives calculated for both phases of decay.  Subject 4059 displayed only a 
slower decay rate for the CSF-compartmentalized variants (t1/2 = 9.85 days).  Total CSF viral 
load decay was similar to the decay rates measured for CSF-compartmentalized variants for 
all subjects with neurological disease.  This is due to the fact that most of the virus in the 
CSF was compartmentalized in these HAD subjects.  The decay of the small amounts of 
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shared variants fluctuated in these subjects from decreasing with a rate similar to the virus in 
plasma to decreasing with a slow rate similar to that of the CSF-compartmentalized variants 
(see Table 3.2). 
 For each CSF sample time point the CSF white blood cell (WBC) count was 
measured to determine if any subjects had CSF pleocytosis (defined as >5 cells/µl; (194, 
286)).  We found that all four subjects with rapid CSF-compartmentalized variant decay 
either had high CSF WBC levels at entry (4033 = 28 cells/µl; 5003 = 46 cells/µl; 7036 = 240 
cells/µl; 4051 = 12 cells/µl), or the CSF WBC levels increased while on therapy.  
Conversely, the four subjects with neurological disease that displayed slower CSF-
compartmentalized variant decay either had extremely low levels of CSF WBCs at entry 
(4013 = 10 cells/µl; 5002 = 66 cells/µl; 4059 = 1 cells/µl; 7115 = 12 cells/µl), or the CSF 
WBC levels decreased to low levels after the initiation of antiretroviral therapy .  We 
examined the CSF WBC levels of these two groups in more detail by calculating the CSF 
WBC average for each subject from baseline through the first 14 days of antiretroviral 
therapy.  The subjects with rapid CSF-compartmentalized variant decay had higher CSF 
WBC averages, while subjects with slower or biphasic CSF-compartmentalized variant decay 
had lower CSF WBC averages (see Table 3.1), and this difference was statistically 
significant (p=0.029 using a two-tailed Mann-Whitney test).  It has been reported that HIV-1-
infected subjects with CD4 counts below 50 cells/µl have reduced CSF pleocytosis (286).  
We also examined whether the viral decay rates measured by HTA were correlated with the 
degree of immunodeficiency by analyzing CD4 counts for each group of subjects.  The four 
subjects with rapid CSF-compartmentalized variant decay had significantly higher baseline 
CD4 counts (see Table 3.1) compared to the four subjects with slower CSF-
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compartmentalized variant decay (p=0.006 using a two-tailed unpaired t-test).  Thus, in 
subjects with HIV-1-associated neurological disease, viral decay rates are associated with the 
degree of immunodeficiency and CSF pleocytosis.   
 We did not detect an association between CSF pleocytosis and rapid viral decay in the 
CSF for asymptomatic subjects.  The CSF WBC average was calculated for each subject as 
stated above, and the range extended from 0 cells/µl up to 20 cells/µl (Table 3.1).  All 
variants detected in the CSF of asymptomatic subjects decayed rapidly upon the initiation of 
antiretroviral therapy; however, we found that the presence of CSF-compartmentalized 
variants was associated with higher average CSF WBC levels.  All four of the asymptomatic 
subjects that did not have compartmentalized virus had low average CSF WBC counts (4012, 
4030, 4023, 4021), while the three asymptomatic subjects that had detectable CSF-
compartmentalized variants also had higher average CSF WBC levels (5005, 4022, 4014; see 
Table 3.1).  Thus in the asymptomatic subjects the presence of pleocytosis may be associated 
with an early inflammatory response to increased levels of autonomously replicating virus. 
 
Slower decay in neurologically symptomatic subjects is not associated with CNS drug 
penetration, drug resistance mutations, or V3/X4 sequence differences. 
 Some antiretroviral drugs have poor penetration into the CNS (175).  In order to 
determine whether the differential decay we detected by HTA was associated with poor CNS 
drug penetration, we calculated the CNS Penetration Effectiveness (CPE) rank (175) for the 
drug regimens that each of the 15 subjects were receiving at the time of sample collection 
(see Table 3.1).  Drugs that have poor penetration into the CNS were assigned a rank of 0, 
intermediate penetration was assigned a rank of 0.5, and high penetration was assigned a rank 
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of 1 (175).  The four subjects that showed a longer viral half-life by HTA analysis had CPE 
ranks ranging from 2.0 to 2.5, while the other subjects that displayed rapid viral decay had 
CPE ranks from 1.5 (5 subjects) to 3.5 (1 subject).  All subjects with neurological disease had 
CPE ranks above 2.0 except for subject 5003 (CPE rank = 1.5).  A previous study reported 
that CPE ranks below 2.0 were associated with a significant (88%) increase in the ability to 
detect virus in the CSF, and higher CSF viral loads were associated with low CPE ranks 
(175).  All of the subjects with longer viral half-lives had CPE ranks of 2.0 or above, 
suggesting that the slower HIV-1 decay we detected by HTA was not associated with poor 
CNS drug penetration.  Alternatively, there could be infected cells located in parenchymal 
compartments that are less accessible to drugs, but this seems unlikely because the virus still 
has access to the CSF. 
 We also investigated the possibility that slower decay was a result of drug resistance 
mutations present in the viral population in the CSF.  Drug resistance mutations were 
measured for CSF samples of subjects 4013, 5002, 4059, and 7115.  The resistance test was 
conducted for time points after the initiation of drug selection to allow for enrichment of any 
potential drug resistant variants.  Subjects 4013, 5002, and 4059 showed no evidence of 
resistance mutations in reverse transcriptase (RT) or protease that confers resistance to 
antiretroviral drugs (data not shown).  Subject 7115 had the resistance mutation K103N in 
RT, which confers resistance to non-nucleoside RT inhibitors (NNRTI).  However, at the 
time of this study, subject 7115 was not taking an NNRTI, and was instead on a drug 
regimen that included zidovudine, lamivudine, and lopinavir.  Therefore, there is no evidence 
that drug resistance played a role in the slower viral decay detected by HTA in these four 
subjects.  
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 Using the biotin-V3 HTA procedure, we also examined whether slower viral decay 
was associated with V3 sequence differences.  The biotin-HTA is a modification of the 
original HTA method that incorporates a biotin tag into the probe to allow direct sequencing 
of the query strand isolated from the gel (269).  This newly developed HTA procedure 
resolves minor variants in the gel, and then allows the recovery and sequence analysis of both 
major and minor HIV-1 V3 variants from complex viral populations (269).  Following V3 
PCR amplification and HTA analysis, we excised the gel fragments containing the V3 
heteroduplexes, purified the query DNA strand using streptavidin-coated magnetic 
Dynabeads®, and directly sequenced the subsequent V3 PCR products (269).  The migration 
patterns for the V3 heteroduplexes and the inferred V3 amino acid sequence obtained for the 
heteroduplex in each gel band are shown in Figure 3.4.  The biotin-V3 HTA procedure was 
conducted on plasma samples from all subjects at the first time point collected, and CSF 
samples were analyzed for subjects with HIV-associated dementia.  No significant V3 
sequence differences were detected between asymptomatic and symptomatic subjects, or 
between subjects with rapid versus slow decay by HTA (Figure 3.4B).  Only one subject 
(4014) had V3 sequences that were X4-like by the Position-Specific Scoring Matrix (PSSM) 
method (145) of predicting co-receptor usage based on genotype.  We did note that two 
subjects with slower decay by HTA had compartmentalized V3 variants detected in the CSF 
viral population that were much more R5-like by sequence compared to the V3 sequence 
variants detected in the plasma viral population.  However, R5-like V3 sequences were also 
detected in the CSF for HAD subjects with rapid viral decay, indicating that V3 sequence 
differences and co-receptor usage are not responsible for the differential decay detected by 
HTA. 
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DISCUSSION 
 
 There are several lines of evidence that support the idea that HIV-1 can replicate in 
the central nervous system (CNS).  HIV-1-infected macrophages and microglia have been 
detected in the brains of subjects with HIV-1-associated dementia (HAD) at autopsy (9, 161, 
295).  In addition, genetically distinct HIV-1 variants, different from those in the peripheral 
blood, are seen in the CNS of subjects with HAD (64, 65, 218, 242, 256).  These inferences 
can be extended using CSF as a surrogate for the CNS where genetic compartmentalization 
can be detected when comparing blood and CSF viral variants (126, 236, 254, 291), and bulk 
virus in the CSF of subjects initiating HAART can decay with different kinetics compared to 
virus in the blood (68, 69, 119).  Furthermore, it appears that this independent replication is 
relevant, if not causal, of HIV-associated neuropathogenesis.  The extent of 
compartmentalization in the CSF, as measured by the heteroduplex tracking assay, increases 
in subjects with HAD, suggesting more sustained autonomous replication is associated with 
the neurological disease state (126, 254).  Also, slow decay of virus in the CSF compared to 
the blood is associated with subjects with neurological disease, especially HAD subjects, 
suggestive of virus being produced from a different cellular source (68, 69, 119).  In addition 
to viral genetic compartmentalization there are other markers of neuropathogenesis in HIV-1-
infected individuals, such as CSF neopterin (18, 104), CSF light-chain neurofilament protein 
(3, 104, 199), and CSF chemokine levels (32, 33, 155, 203, 276).  In the current work we 
have attempted to combine the observations of viral genetic compartmentalization and 
differential decay in subjects initiating HAART by comparing the rates of decay of variants 
shared between the CSF and the blood versus those variants that were compartmentalized in 
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the CSF.  The goal of this work was to examine the link between compartmentalized virus as 
a marker for autonomous replication in the CNS and the production of virus in the CNS by 
long-lived cells.  
We used heteroduplex tracking assays (HTAs) targeting the variable regions of env to 
identify CSF-compartmentalized variants and variants shared between the CSF and blood 
plasma, and then measured the viral decay kinetics of these two distinct classes of viral 
variants after the initiation of antiretroviral therapy for asymptomatic and neurologically 
symptomatic subjects.  We found that plasma HIV-1 variants decayed rapidly for both 
neurologically asymptomatic and symptomatic subjects, indicating that short-lived cells, 
presumably activated CD4+ T cells, are the predominant source of virus in the periphery 
during all disease stages.  Additionally, shared and compartmentalized variants in the CSF of 
seven asymptomatic subjects decayed rapidly, with a mean half-life of 1.35 and 1.57 days, 
respectively.  These decay rates are consistent with our previous study of four asymptomatic 
subjects (124).  HIV-1 viral load decays in the peripheral blood with the same half-life as a 
productively infected CD4+ T cell (approximately 2 days; (139, 281, 311)), so it is most 
likely that CSF-shared and compartmentalized virus in asymptomatic subjects is originating 
from a short-lived cell type, such as a CD4+ T cell.  The level of HIV-1 compartmentalization 
in the CSF in these asymptomatic subjects varied, and we noted that there was a trend of 
increased CSF pleocytosis in the asymptomatic subjects with greater compartmentalization.   
We also examined HIV-1 decay in subjects with neurological disease that were 
starting HAART.  Rapid viral decay was measured for CSF-compartmentalized variants after 
the initiation of HAART for four HAD subjects (t1/2 mean = 2.27 days), while slow viral 
decay was measured for CSF-compartmentalized variants from the other four subjects with 
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neurological disease (t1/2 range = 9.85 days to no initial decay).  It is known that HIV-1 may 
persist in the CNS during antiretroviral therapy due to insufficient CNS penetration of some 
antiretroviral drugs (103, 107, 239, 272).  We determined that the slow decay detected for 
CSF-compartmentalized variants was not associated with poor CNS drug penetration, the 
presence of drug resistant virus in the CSF, or the detection of X4-like virus genotypes.  It 
has been suggested that HIV-1 produced by long-lived cell lineages such as macrophages, 
microglia, and resting CD4+ T cells most likely decays with a half-life of 14 days or greater 
(279, 281, 311).  The longer half-lives we detected suggest that compartmentalized HIV-1 in 
the CSF of some neurologically symptomatic subjects may be originating from a long-lived 
cell type.   
While slower HIV-1 decay was detected for half of the subjects with neurological 
disease, compartmentalized variants in the CSF of some subjects decayed rapidly.  Further 
analysis revealed that the differential decay measured for CSF-compartmentalized variants in 
subjects with neurological disease was correlated with the degree of CSF pleocytosis.  Four 
of the eight subjects with HIV-associated neurological disease displayed rapid CSF-
compartmentalized variant decay, and this was correlated with higher CSF WBC levels 
(moderate to severe pleocytosis).  The compartmentalized variants detected in the CSF of the 
four other subjects showed slow or biphasic decay after the initiation of HAART, and this 
was associated with lower CSF WBC levels (no or mild pleocytosis).  Additionally, the 
subjects with rapid CSF-compartmentalized variant decay had significantly higher CD4 
counts than subjects with slow compartmentalized variant decay, indicating that subjects with 
slow decay of CSF-compartmentalized virus have increased immunodeficiency.  We suggest 
that more profound immunodeficiency results in fewer lymphocytes trafficking into the CNS, 
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which is consistent with the decreased CSF WBC counts for the subjects with slow decay.  
HIV-1 infection can be associated with CSF pleocytosis in neurologically symptomatic 
subjects, asymptomatic subjects, and individuals lacking any CNS opportunistic infections 
(194).  Additionally, some studies have shown that CSF WBC levels are correlated  with 
CSF HIV-1 RNA concentrations (195, 246, 286), and CSF pleocytosis has been shown to 
decrease after the initiation of antiretroviral therapy (194).  In this current study we found an 
association between the extent of immunodeficiency, CSF pleocytosis and rapid HIV-1 decay 
kinetics for compartmentalized variants in the CSF of neurologically symptomatic subjects, 
although the strength of the interpretation is somewhat limited by our small sample size.  
Taken together, we have developed a model of HIV-1 infection in the CNS in the 
context of neurological disease (Figure 3.5).  The model has several features that incorporate 
viral genetic compartmentalization, CSF pleocytosis, and viral decay rates in the CSF as a 
measure of the virus-producing cell.  First, the majority of the virus detected in the CSF of a 
subset of asymptomatic subjects is imported from the peripheral blood (Figure 3.5A).  HIV-
1-infected CD4+ T cells in the peripheral blood release virus that is detectable in the blood 
plasma and the CSF and that decays rapidly upon the start of antiretroviral therapy, 
representing the relatively fast turnover of uninfected CD4+ T cells.  HIV-1-infected CD4+ T 
cells in the peripheral blood can migrate from the periphery into the CNS and secrete virus in 
the CNS that is genetically similar to virus in the peripheral blood.  No or only mild 
pleocytosis was detected for this group of asymptomatic subjects, and we suggest this 
represents minimal inflammation in the CNS.  It is possible that some CNS HIV-1 variants 
are independently replicating at a low level in these asymptomatic subjects, but we were not 
able to detect these genetic variants above the background of virus recently imported from 
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the periphery.  In these subjects virus decays with the half life of peripheral T cells, the 
presumed source of the virus. 
A second pattern exists for the other asymptomatic subjects and also for a subset of 
the neurologically symptomatic subjects.  There is increased compartmentalization of HIV-1 
in this subset of asymptomatic subjects, and the majority of virus detected in the CSF is 
compartmentalized in HIV-1-infected individuals with severe neurological disease.  In 
addition, both of these groups have increased pleocytosis.  We found that CSF-
compartmentalized variants decayed rapidly upon the initiation of antiretroviral therapy in 
these remaining asymptomatic subjects and in this subset of four subjects with HIV-1-
associated dementia.  It is possible that compartmentalized variants detected in these subjects 
are produced by long-lived cells in the CNS; however the majority of the compartmentalized 
virus is produced by a short-lived cell type.  We propose that compartmentalized virus may 
be maintained by long-lived cells in the CNS and that this virus is amplified by short-lived 
trafficking CD4+ T cells to detectable levels in the CSF for asymptomatic subjects, and to 
high titers in the CSF of HAD subjects (Figure 3.5B).  The elevated level of pleocytosis is 
indicative of an inflammatory response, most likely to the autonomously replicating virus.  
Increased levels of CSF white blood cells may account for the influx of T cells that could be 
the source of the short-lived cells that are amplifying the compartmentalized virus.  We 
would expect that most of the infiltrating T cells are HIV-specific, although some 
lymphocytes may be migrating into the CNS due to a general inflammatory environment.  
The asymptomatic subjects in this group have the hallmarks of viral pathogenesis associated 
with neurological disease and may be at risk for transition to HAD.   
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Third, we detected slow decay of compartmentalized variants in the CSF for the four 
remaining subjects with neurological disease.  These subjects shared the feature of viral 
genetic compartmentalization but did not show high levels of pleocytosis.  Additionally, this 
subject group had the lowest blood CD4+ T cell counts (Table 3.1), indicating a state of 
increased immunodeficiency.  We suggest that these subjects have more profound 
immunodeficiency, which would allow even more extensive viral replication and 
compartmentalization in the CNS (Figure 3.5C).  Increased immunodeficiency would result 
in reduced trafficking of CD4+ T cells into the CNS, so these cells would no longer be 
present to amplify virus from local CNS tissue, consistent with the reduced pleocytosis in 
this group.  The slow decay rate of virus in the CSF in the absence of inflammatory cells 
suggests that compartmentalized HIV-1 in the CNS of these HAD subjects is originating 
from a long-lived cell type, such as perivascular macrophages and/or microglia in the CNS.  
Virus is unlikely to be coming from T cells that are persisting in the absence of immune-
mediated killing since there is still rapid viral decay in the peripheral blood.  The CSF viral 
loads of all four subjects displaying slow decay were high, similar to subjects with rapid viral 
decay, suggesting that a large amount of compartmentalized virus is being produced by 
longer-lived cells in the CNS.  This may suggest that peripheral, uninfected monocytes may 
migrate into the brain parenchyma and differentiate into perivascular macrophages to levels 
that can sustain high viral loads in the CSF.  An influx of monocytes into the CNS could also 
allow the entrance of peripherally-infected monocytes, which would explain the slower decay 
we detected for shared variants in the CSF of these subjects.    
 Our studies support a model where increasing levels of autonomous viral replication 
in the CNS first induces an inflammatory state that then progresses to neurologic disease with 
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increasing immunodeficiency.  More profound immunodeficiency ultimately reveals long-
lived cells that are able to maintain independent replication of virus in the CNS.  Several env 
gene markers have been described in viral sequences taken at autopsy and linked to the 
ability of HIV-1 to infect macrophages (64, 65).  The CSF provides an alternative window on 
these viral sequences where the evolution of the virus and its properties can be followed over 
time and into the disease state.  Viral genetic compartmentalization and other markers of 
CNS inflammation could also play an important role in defining subjects at risk of 
progression to neuropathogenesis in the absence of therapeutic intervention.   
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MATERIALS AND METHODS 
 
Ethics statement. 
This study was conducted according to the principles expressed in the Declaration of 
Helsinki. The study was approved by the Institutional Review Board of the University of 
California at San Francisco.  All subjects provided written informed consent for the 
collection of samples and subsequent analysis. 
 
Subject population and sampling. 
The samples from study subjects used for variant decay analysis were collected 
during previous studies carried out at the University of California at San Francisco.  All 
subjects used in this study were HIV-1-infected subjects that were initiating highly-active 
antiretroviral therapy.  Subjects 4012, 4013, 4014, 5002, 5003, and 5005 were recruited from 
a study examining antiretroviral therapy responses in the CSF, and are described in more 
detail in ref. (289).  Serial blood plasma and cerebrospinal fluid (CSF) samples were 
collected at baseline prior to the start of therapy and at varying intervals thereafter.  Plasma 
and CSF HIV-1 RNA concentrations were determined using the Amplicor HIV Monitor kit 
(Roche).  CSF white blood cell counts were measured by routine methods in the San 
Francisco General Clinical Laboratory.  Drug resistance mutations were analyzed for CSF 
samples of subjects 4013, 5002, 4059, and 7115 using the TRUGENE® HIV-1 Genotyping 
Test Resistance Report using GuideLines™ Rules 12.0 (Bayer HealthCare). 
 
RNA isolation, RT-PCR, and HTA. 
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Viral RNA isolation, RT-PCR, and HTA procedures were conducted as previously 
described (124, 159, 212, 251).  Briefly, viral RNA was isolated from blood plasma and CSF 
samples (140 µl) using the QIAmp Viral RNA kit (Qiagen).  Prior to RNA isolation, all CSF 
samples were centrifuged at 2,500 rpm for 5 minutes to remove any contaminating cellular 
debris.  Samples with viral RNA levels less than 10,000 copies/ml were pelleted (0.5-1.0 ml) 
by centrifugation at 25,000 x g for 1.5 hours prior to RNA isolation to increase template 
number and improve sampling.  Reverse transcription and PCR amplification of the V1/V2, 
V3, and V4/V5 regions of env were conducted with 5 µl of purified RNA (from 60 µl column 
elution volume) using primers that have been previously described for V1/V2 (159, 251), V3 
(269); and V4/V5 (251) and using the Qiagen One-Step RT-PCR kit (Qiagen) as per 
manufacturer’s instructions.   
Heteroduplex annealing reactions were conducted as previously described (159, 212).  
The heteroduplexes were separated by 6% native polyacrylamide gel electrophoresis for 
V1/V2 and V4/V5 HTA (124, 159), and by 12% PAGE for biotin-V3 HTA (269).  The HTA 
probes used in these studies have been previously reported:  V1/V2 Ba-L probe (159, 251), 
V1/V2 JRFL probe (159, 251), V4/V5 NL4-3 probe (124), V4/V5 YU2 probe (251), and the 
V3 Mut-1 probe (269).  The HTA gels were dried under vacuum, and bands were visualized 
by autoradiography.  For the biotin-V3 HTA procedure, the desired labeled bands were 
excised from the dried gels, the DNA was purified from the gel, and the V3 sequence was 
obtained as previously described (269).  Duplicate RT-PCR products were analyzed by HTA 
for each sample to validate sampling and ensure reproducibility of the HTA pattern at each 
time point.  Any time points where the HTA pattern between the two replicates differed 
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significantly (>20%) were not used in the data analysis.  Percent difference values between 
plasma and CSF viral populations were calculated as previously described (159, 251). 
 
Phosphorimager analysis and half-life calculations. 
The dried HTA gels were exposed to a PhosphorImager screen, and the relative abundance of 
each detected viral variant (heteroduplex) was calculated using ImageQuant software 
(Molecular Dynamics).  The variant RNA concentration was calculated by multiplying the 
relative abundance of each individual variant by the total HIV-1 RNA concentration for that 
sample.  Variants in the CSF were considered compartmentalized by HTA if they were either 
unique to the CSF or if they had a substantially higher copy number in the CSF compared to 
the plasma. Compartmentalized variant half-lives were calculated using the time points when 
the viral load initially dropped after the start of antiretroviral therapy.   
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Table 3.1.  Sample characteristics. 
 Cell counts (cells/µl)    
HIV-1 RNA (log10 
copies/ml)a 
Subject 
ID CD4
a CSF WBCb 
ADC 
Stagec Drug Regimen 
CPE 
totald Plasma CSF 
4012 295 13 0 3TC, NVP, NFV, AZT 2.5 5.18 4.39 
4014 1140 20 0 ddI, NVP, d4T 1.5 4.41 4.42 
4021 215 2 0 AZT, 3TC, NFV 1.5 4.97 4.02 
4022 372 18 0 3TC, NFV, AZT 1.5 4.58 4.77 
4023 215 0 0 AZT, 3TC, NFV, EFV 2.0 5.50 3.77 
4030 239 5 0 d4T, 3TC, EFV 1.5 4.86 4.06 
5005 267 19 0 ABC, NVP, SGC, NFV 2.0 5.30 4.99 
4033 173 28 2 IDV, RTV, 3TC, ABC, NVP 3.5 4.83 5.23 
4051 344 26 3 AZT, 3TC, EFV 2.0 5.61 5.41 
5003 234 39 3 NFV, d4T, ABC 1.5 3.31 4.33 
7036 267 150 2 AZT, 3TC, NVP 2.5 5.12 5.37 
4013 148 6 1 3TC, NVP, NFV, d4T 2.0 4.62 4.75 
4059 53 1 3 AZT, 3TC, LPVr 2.5 5.31 5.08 
5002 59 23 3 3TC, NVP, NFV, ABC 2.5 4.24 5.32 
7115 50 9 2 AZT, 3TC, LPVr 2.5 5.87 4.85 
 
 
a = Baseline samples 
b = Average CSF white blood cell counts over the first 14 days of antiretroviral therapy. 
c = ADC staging: (245). 
d = CNS Penetration Effectiveness Rank total.  The CPE ranks for each drug in the regimen 
were summed to get the CPE total. 
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Table 3.2. HIV-1 variant decay. 
 
% HIV-1 RNA decrease 
(days on HAART)  
CSF-
Compartmentalized 
Variant Data 
CSF Shared Variant 
Data  
Subject 
ID Plasma CSF 
Plasma Half-
life (days) 
% CSF 
VLa 
Half-life 
(days)b 
% CSF 
VLa 
Half-life 
(days)b % Diff.
c 
4012 96 (10) 97 (10) 1.36 0 N/A 100 1.73 29 
4014 92 (7) 95 (7) 1.96 83.6 1.9 16.4 1.3 37 
4021 90 (5) 82 (5) 1.2 7 >1.59f 93 1.59 36 
4022 87 (4) 93 (4) 1.01 37 0.75 63 0.79 47 
4023 90 (3) 79 (3) 0.58 0 N/A 100 0.88 58 
4030 90 (3) 90 (3) 1.81 0 N/A 100 1.83 10 
5005 97 (10) 98 (10) 2.27 100 2.04 0 N/A 78 
4033 92 (8) 92 (8) 1.64 77 1.44 23 2.44 72 
4051 95 (10) 94 (10) 2.32 39 2.74 61 2.19 36 
5003 54 (6) 82 (6) 2.69e 94 1.23 6 1.05 88 
7036 99 (25) 99 (25) 2.91 82 3.67 18 2.95 80 
4013 93 (15) 20 (9) 2.32 73 28.5 27 4.3 78 
  76 (15)   3.9  2.0  
4059 98 (14) 62 (14) 2.35 92 9.85 8 5.84 46 
5002 98 (6) Inc. (6)d 1.42 98 No decay 2 No decay 72 
  93 (28)   4.24  1.76  
7115 99 (10) 40 (10) 1.25 47 No decay 53 4.88 65 
  95 (33)   6.4  6.05   
a = Based on the region of env (V1/V2 or V4/V5) that was the most reproducible by two 
independent HTA replicates. 
b = Reported half-lives are the average calculated from decay analyses of two independent 
HTA replicates.  N/A = not applicable. 
c = Percent difference values between plasma and CSF viral populations as measured by 
HTA.  Reported values are the average calculated from two independent HTA replicates (see 
refs. (159, 251) for methods).   
d = Total CSF viral load increased initially for subject 5002. 
e = Total plasma viral decay for subject 5003 was calculated for the drop in viral load from 
days 3 to 6 on HAART.  There was a slight increase in plasma viral load from days 6 to 10 
on HAART, which can be seen in Figure 3.2B, but this increase does not seem to be 
significant.  Although the baseline samples were not available for analysis, we know that the 
baseline plasma viral load was 126,000 copies/ml, and this subject had undetectable viral 
loads in both plasma and CSF by 2 months post-HAART, so there was an overall good 
response to antiretroviral therapy.  The small variation in plasma viral load from days 6 to 10 
on therapy could be explained by a number of technical, pharmacological, and/or biological 
factors.    
f = A compartmentalized variant was detected for subject 4021 in the day 5 CSF sample; 
however, the relative abundance of this variant was less than other bands detected that were 
not reproducible by HTA, indicating that the detection of this band may be due to inefficient 
sampling and low viral load.  It is equally possible that this band represents a reproducible 
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compartmentalized variant that is decaying more slowly than the other variants detected by 
HTA.  Therefore, the half-life for the CSF-compartmentalized variants is listed as >1.59 days 
(a half-life of 1.59 days was measured for CSF shared variants).  
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Figure 3.1. Longitudinal HTA analysis and HIV-1 decay in the blood plasma and CSF 
of asymptomatic subjects.  (A) Longitudinal V1/V2 or V4/V5 HTA analysis of HIV-1 using 
paired blood plasma and CSF samples from 7 asymptomatic subjects that were initiating 
antiretroviral therapy.  The HTA shown for subject 4014 targeted the V1/V2 region of env, 
and the V4/V5 HTA is shown for all other subjects.  Sample time points are listed above each 
HTA gel as days on HAART (DOH) with day 0 indicating the day that antiretroviral therapy 
was started.  CSF-compartmentalized variants are indicated with a filled black circle next to 
the gel image.  The V4/V5 HTA analysis for subject 4021 revealed a compartmentalized 
variant in the day 5 CSF sample, not present in the blood plasma, that was reproducible by 
HTA; however, the relative abundance of this variant (3.6%) was less than that of other 
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bands detected in the same sample that were not reproducible by HTA, indicating that the 
detection of this band may be due to inefficient sampling and low viral load.  
Compartmentalized variants were not detected for three subjects.  (B) HIV-1 decay kinetics 
in the blood plasma and CSF.  Viral variants in the CSF were categorized as either 
compartmentalized or shared between the plasma and CSF for the decay analysis.  Total 
plasma viral load decay is shown in red, CSF-compartmentalized variant decay is denoted by 
the solid blue line, and decay of variants shared between the plasma and CSF is shown by the 
dashed blue line.  It should be noted that in our decay analysis for subject 4012 we assumed 
the viral load at day 0 would be similar to the viral load measured for the baseline samples at 
day -9.   
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Figure 3.2. Longitudinal HTA analysis and HIV-1 decay in blood plasma and CSF of 
neurologically symptomatic subjects.  (A) Longitudinal V4/V5 HTA analysis of HIV-1 in 
paired blood plasma and CSF samples from 1 subject with MCMD (subject 4013) and 7 
subjects with HIV-associated dementia that were initiating HAART.  Plasma (P) and CSF 
sample time points are listed above each HTA gel as days on HAART (DOH), and day 0 
indicates the start of antiretroviral therapy.  CSF-compartmentalized variants are indicated by 
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a filled black circle.  (B, C) HIV-1 decay kinetics in the blood plasma and CSF viral 
populations.  Viral variants in the CSF were categorized as either compartmentalized in the 
CSF or shared between the plasma and CSF.  Total plasma viral load decay is shown in red, 
CSF-compartmentalized variant decay is denoted by the solid blue line, and decay of variants 
shared between the plasma and CSF is shown by the dashed blue line.  Four subjects (4033, 
5003, 7036, 4051) displayed rapid decay in their CSF-compartmentalized variant population 
(shown in panel B), while the other four subjects (4013, 5002, 4059, 7115) had slower decay 
of CSF-compartmentalized variants (shown in panel C).  Subjects 4013, 5002, and 7115 
showed differential decay of CSF-compartmentalized variants where initially the 
compartmentalized variant population decreased very slowly (4013) or increased (5002, 
7115) after the start of therapy, and at subsequent time points began decreasing at a faster 
rate (panel C).  In our decay analysis for subjects 4051 and 7115 we assumed that the viral 
load at day 0 would be similar to the viral load measured for the baseline samples at day -9 
for subject 4051 and at day -25 for subject 7115.  In this regard, subject 7115 was followed 
longitudinally for several years prior to the start of antiretroviral therapy, and the viral loads 
in both the plasma and CSF samples remained relatively constant over time (data not shown). 
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Figure 3.3. Summary of HIV-1 half-lives from asymptomatic and neurologically 
symptomatic subjects.  Half-lives were calculated for total plasma viral load decay 
(Plasma), total CSF viral load decay (CSF), and CSF-compartmentalized variant decay (CSF 
compartmentalized variants).  The half-lives were calculated using the time points when the 
variant load initially dropped after each subject initiated antiretroviral therapy.  All half-lives 
listed in the figure are the average calculated from decay analyses of two independent HTA 
replicates.  Half-lives are listed for the seven new asymptomatic subjects analyzed in this 
study plus four asymptomatic subjects (labeled as 4 Asy.) that were previously reported in 
ref. (124), 1 subject with MCMD (subject 4013), and 7 subjects with HIV-1-associated 
dementia.  The asymptomatic subjects include: 4012 (open green square), 4030 (open 
yellow-green diamond), 5005 (brown square), 4023 (green plus symbol), 4022 (open, 
inverted blue triangle), 4014 (orange rectangle), 4021 (open fuchsia triangle), and 4 Asy. 
(gray circles).  The subjects with HIV-associated neurological disease include: 4033 (purple 
triangle), 5003 (inverted green triangle), 7036 (teal circle), 4051 (open purple circle), 4013 
(blue square), 5002 (red diamond), 4059 (black x symbol), and 7115 (black irregular circle).  
Two different half-lives are listed for subjects 4013, 5002, and 7115 for both total CSF viral 
decay (CSF) and CSF-compartmentalized variant decay (CSF-compartmentalized variants).  
Each of these three subjects showed biphasic decay by HTA analysis, and the half-life data 
point denoted with the asterisk represents the phase 1 half-life (slower), while the half-life 
lacking the asterisk was calculated for phase 2 of decay (faster).  The CSF-
compartmentalized variant population increased initially for subjects 5002 and 7115, so there 
was no decay detected for these subjects during phase 1 and their half-lives are listed on the 
graph as >30 days.  Similarly, the total CSF viral load increased for subject 5002 during 
phase 1 of decay and the half-life is listed on the graph as >30 days.   
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Figure 3.4. Examination of the V3 region of env using the biotin-V3 HTA.  (A) Biotin-V3 
HTA analysis of the baseline samples collected for asymptomatic and neurologically 
symptomatic subjects.  Plasma samples (P) were analyzed for all subjects, and CSF samples 
(C) were analyzed for HAD subjects.  The asterisk indicates the double-stranded probe band, 
and shifted heteroduplex bands are noted with arrowheads and numbers.  (B) Summary table 
of the V3 sequence information obtained using the biotin-V3 HTA procedure.  The desired 
V3 bands were excised from the dried gel, the query strand DNA was purified and PCR 
amplified, and the V3 PCR products from each band were sequenced.  The sample type (P/C; 
P = plasma sample, C = CSF sample), relative abundance (Rel. Ab.), and PSSM score (0 = 
R5-like sequence, 1 = X4-like sequence, N/A = not applicable) for each sequence are listed 
in the table.  Note: the V3 PCR primers used to amplify the V3 products extend into the first 
four and the last three amino acids of the V3 sequence.  The V3 sequences provided do not 
include these amino acids; however, we added the JRFL consensus amino acid sequence to 
the beginning (CTRP) and end (AHC) of each V3 sequence to predict coreceptor usage using 
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PSSM.  Mixtures in the sequence peaks were detected at specific positions in V3 bands from 
subject 4051 plasma and CSF samples, and these mixtures are noted in the reported amino 
acid sequences. 
 
  
 98 
 
 
 
 
Figure 3.5. Model of HIV-1 infection in the central nervous system.  CD4+ T cells are 
represented by open circles, macrophages are represented by the irregularly shaped cells, 
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monocytes are represented by open circles labeled with an M, blood plasma viral variants are 
represented by the red virus particles, and CNS compartmentalized viral variants are 
represented by the blue virus particles.  (A) HIV-1 infection in the CNS of a subset of 
asymptomatic subjects without detectable compartmentalized virus or CSF pleocytosis.  All 
HIV-1 detected in the CSF decays rapidly after the initiation of therapy, suggesting that CSF 
virus is coming from a short-lived cell type.  (B) HIV-1 infection in the CNS of 
asymptomatic and neurologically symptomatic subjects with compartmentalization, high 
CSF pleocytosis and rapid viral decay.  In this model, local CNS virus is able to replicate to 
higher titers during periods of immunodeficiency and stimulate an inflammatory response in 
the CNS.  Uninfected CD4+ T cells that migrate into the CNS can become infected by 
compartmentalized HIV-1 produced by macrophages and microglia in the CNS, and then 
amplify the local CNS-compartmentalized virus to higher concentrations.  Thus, a rapid 
decay rate for compartmentalized virus is detected after the initiation of antiretroviral 
therapy.  (C)  HIV-1 infection in the CNS of neurologically symptomatic subjects with slow 
viral decay.  Our data indicate that compartmentalized variants in the CSF of HAD subjects 
are originating from long-lived macrophages and microglia in the CNS, resulting in a slow 
decay rate for compartmentalized virus.  We propose that periods of profound 
immunodeficiency allow compartmentalized virus in the CNS to replicate to high titers, and 
that in the absence of other lymphocytes (such as CD4+ T cells) peripheral, uninfected 
monocytes may migrate into the brain parenchyma in large numbers and differentiate into 
perivascular macrophages.  These macrophages can then become infected by 
compartmentalized HIV-1 variants in the CNS and support viral replication at detectable 
levels.  
 
 
  
 
CHAPTER FOUR 
 
DISTINCT CELLULAR ORIGINS OF COMPARTMENTALIZED HIV-1 IN THE CSF OF 
SUBJECTS WITH HIV-1-ASSOCIATED DEMENTIA DEFINE TWO CLASSES OF 
VIRAL ENCEPHALITIS 
 
 
Gretja Schnell generated the HIV-1 env amplicons and clones, and conducted the 
phylogenetic analyses and phenotype experiments.  Sarah Joseph established the 293-
Affinofile cell line for the Swanstrom laboratory, and analyzed the CD4 and CCR5 receptor 
densities using flow cytometry.  Richard W. Price and Serena Spudich designed the human 
study protocols and collected the human blood and cerebrospinal fluid samples.  The data 
presented in this chapter are currently in preparation for submission to a peer-reviewed 
journal. 
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ABSTRACT 
 
 Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous 
system (CNS) can lead to the development of HIV-1-associated dementia (HAD).  Viral 
genetic compartmentalization between the periphery and the CNS is associated with HAD, 
and HIV-1 variants isolated from the brain tissue of HAD subjects can infect macrophages.  
We examined the genotypic and phenotypic viral characteristics associated with 
compartmentalized HIV-1 variants in subjects with HIV-1-associated neurological disease 
and in asymptomatic subjects.  Single genome amplification was used to examine HIV-1 
populations in the cerebrospinal fluid (CSF) and the peripheral blood, and compartmentalized 
envelope phenotypes were defined by generating envelope-pseudotyped reporter viruses and 
testing for cellular tropism.  Extensive genetic compartmentalization was detected in the CSF 
HIV-1 populations of subjects with neurological disease, and longitudinal analysis revealed 
that significant compartmentalization in the CSF viral population seems to arise concurrently 
with the development of neurological complications.  We found that distinct cellular origins 
of compartmentalized HIV-1 in the CNS define two classes of viral encephalitis.  
Compartmentalized HIV-1 envelopes in three HAD subjects were dependent on high CD4 
surface expression for infection (class 1).  However, CSF-compartmentalized envelopes from 
an additional four subjects with neurological disease were able to mediate infection of cells 
with a low density of surface CD4 (class 2), and this was correlated with increased 
immunodeficiency.  We propose that increased HIV-1 replication in the CNS/CSF 
compartment stimulates immune cell migration to the CNS, and the degree of 
immunodeficiency may define the cellular origin of the replicating compartmentalized virus.      
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INTRODUCTION 
 
Human immunodeficiency virus type 1 (HIV-1) can invade the central nervous 
system (CNS) shortly after peripheral infection through the migration of infected cells, 
including monocytes and lymphocytes, across the blood-brain barrier (BBB) (197, 216).  
After crossing the BBB, HIV-1 can infect local cells in the CNS and establish an autonomous 
replicating viral population (107, 234).  A subset of HIV-1-infected individuals develops 
mild to severe neurological symptoms associated with HIV-1 infection, including the 
development of HIV-1-associated dementia (HAD) (14, 107, 244, 245).  Compartmentalized 
HIV-1 variants have been detected in the cerebrospinal fluid (CSF) of HIV-1-infected 
individuals spanning all degrees of neurological disease.  Studies examining HIV-1 evolution 
in the CSF using the heteroduplex tracking assay (HTA) found increased viral genetic 
compartmentalization in the CSF of HAD subjects (126, 254), and genetically distinct HIV-1 
variants have been detected in the CNS of subjects with HAD (64, 65, 218, 242, 256), 
suggesting that autonomous viral replication is occurring in the CNS of subjects with more 
severe neurological disease. 
 Several mechanisms have been proposed for HIV-1 transport across the BBB, 
including direct infection of brain endothelial cells (204, 237), transcytosis by endothelial 
cells (10), and the most supported theory of HIV-1 entry via trafficking of HIV-1-infected 
monocytes and lymphocytes across the BBB (107).  Perivascular macrophages and microglia 
in the CNS, which express low receptor densities of CD4, CCR5, and CXCR4, are exposed 
to HIV-1 after viral transport across the BBB.  Previous studies have reported that HIV-1 
variants isolated from the brains of HAD subjects at autopsy can infect macrophages (108, 
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109, 161, 233, 256, 298).  Compartmentalized HIV-1 variants in the CSF were also reported 
to decay slowly with the initiation of therapy in some subjects with HIV-1-associated 
dementia, suggesting a longer-lived cell type as the origin of this virus (271).  In addition, 
several reports have indicated that specific amino acid substitutions in the Env protein are 
associated with HAD and enhanced viral entry in macrophages (62, 64, 65, 108, 243, 256, 
298).  Although the properties of some compartmentalized HIV-1 variants have been 
reported in previous studies, it is still not known how extensive compartmentalization 
develops, or exactly which cell types in the CNS contribute to the production of 
compartmentalized virus in HAD subjects.   
 In this study we conducted an in depth analysis of HIV-1 populations in the CSF of 
HAD subjects by examining HIV-1 genetic compartmentalization and viral evolution 
between the peripheral blood and CSF using single genome amplification.  We also 
examined the phenotypic characteristics of compartmentalized env genes from subjects with 
and without neurological disease to assess the cellular origin of the compartmentalized virus.  
Here we report the detection of extensive genetic compartmentalization between the blood 
and CSF viral populations in subjects with HIV-associated neurological disease, and clonal 
amplification of some CSF variants that are separated phylogenetically from plasma virus.  In 
addition, we report that distinct cellular origins of compartmentalized HIV-1 define two 
classes of viral encephalitis, both of which are associated with neurological dysfunction and a 
clinical diagnosis of HIV-associated neurological disease. 
  
 104 
 
MATERIALS AND METHODS 
 
Study subject population. 
All subjects used in this study were HIV-1-infected subjects that eventually initiated 
highly-active antiretroviral therapy.  The subject samples used for viral genetic 
compartmentalization and envelope phenotype analyses were collected during previous 
studies carried out at the University of California at San Francisco.  Subjects 4012, 4013, 
5002, and 5003 were recruited from a study examining antiretroviral therapy responses in the 
CSF (289).  Serial blood plasma and cerebrospinal fluid (CSF) samples were collected from 
subjects at baseline prior to the start of therapy.  Plasma and CSF samples were collected 
longitudinally from subjects 7036 and 7115 for several years prior to the initiation of therapy.  
Plasma and CSF HIV-1 RNA concentrations were determined using the Amplicor HIV 
Monitor kit (Roche).  Some of the subject sample characteristics have been previously 
reported (271).  The studies were approved by the Committee for Human Research at the 
University of California at San Francisco, and all subjects provided written informed consent 
for the collection of samples. 
 
Viral RNA isolation and single genome amplification. 
HIV-1 RNA was isolated from blood plasma and CSF samples (140 μl) using the 
QIAmp Viral RNA kit (Qiagen).  Samples with viral RNA levels less than 10,000 copies/ml 
were pelleted (0.5-1.0 ml) by centrifugation at 25,000 x g for 1.5 hours prior to RNA 
isolation in order to increase template number.  Prior to RNA isolation, all CSF samples were 
centrifuged at 1,000 x g for 5 minutes to remove contaminating cellular debris.  Viral RNA 
 105 
 
was reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen) with 
oligo(dT) as the primer per the manufacturer’s instructions.  Single genome amplification of 
the full-length HIV-1 env gene through the 3’ U3 region was conducted as previously 
described (154, 220, 262).  Briefly, cDNA was diluted to endpoint and nested PCR (67, 280) 
was conducted using the Platinum Taq High Fidelity polymerase (Invitrogen) as described by 
Salazar-Gonzalez et al. (262).  The primers B5853 UP0 and LTR DN1 were used for the first 
round of PCR, and the primers B5957 UP1 and LTR DN1 were used for the second round of 
PCR (270).  The SGA amplicons were sequenced from the start of V1 through the 
ectodomain of gp41 [Hxb2 numbering of positions 6600-8000].   
 
Phylogenetic and compartmentalization analyses. 
Phylogenetic analysis of cross-sectional and longitudinal plasma and CSF HIV 
sequences was carried out as stated below.  Nucleotide sequences of the env genes were 
aligned using Clustal W (30, 299) or MAFFT software (152).  Maximum likelihood 
phylogenetic trees were generated using PhyML (116) with the following parameters: 
HKY85 nucleotide substitution model, four substitution rate categories, estimation of the 
transition/transversion rate ratio, estimation of the proportion of invariant sites, and 
estimation of the gamma distribution parameter (115).  Compartmentalization of CSF viral 
populations by sequence was determined using the Slatkin-Maddison test for 
compartmentalization (282) by HyPhy software (240) using 10,000 permutations.  Pairwise 
distance was calculated for HIV-1 env sequences in the CSF-compartmentalized population 
for subjects with neurological disease using MEGA 4.1 software (162, 163, 296).  All 
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sequences were subjected to quality control analysis to ensure that sequences from different 
subjects were not mislabeled. 
   
Cells. 
 293T and TZM-bl cells were cultured in Dulbecco's modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum and 100 µg/ml of penicillin and 
streptomycin.  293-Affinofile cells (148) were maintained in DMEM supplemented with 10% 
dialyzed fetal bovine serum (12-14kD dialyzed; Atlanta biologicals) and 50 µg/ml blasticidin 
(D10F/B).   
 
Construction of HIV-1 env clones. 
 HIV-1 RNA was isolated from blood plasma and CSF samples, and the full-length 
env gene was amplified using the single genome amplification method as stated above.  The 
SGA amplicons used in the cloning procedure were selected based on each subjects’ 
phylogenetic tree structure and sequenced from the start of gp120 to the end of gp41.  Since 
the SGA amplicons contained the full-length HIV-1 env gene through the 3’ U3 region of the 
long terminal repeat, an additional PCR was conducted to amplify only the full-length HIV-1 
env gene using the Phusion™ hot start high-fidelity DNA polymerase (Finnzymes) and the 
primers B5957F-TOPO (5’-CACCTTAGGCATCTCCTATGGCAGGAAGAAG-3’) and 
B8904R-TOPO (5’-GTCTCGAGATACTGCTCCCACCC-3’) following the manufacturer’s 
instructions.  HIV-1 env amplicons were then gel purified using the QIAquick gel extraction 
kit (Qiagen).  The purified HIV-1 env genes were cloned into the pcDNA™3.1D/V5-His-
TOPO® expression vector (Invitrogen) using the pcDNA™3.1 directional TOPO® 
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expression kit (Invitrogen) and MAX Efficiency® Stbl2™ competent cells (Invitrogen) as 
per the manufacturer’s instructions.  The cloned env genes were sequenced and screened to 
ensure that the original protein coding sequence was maintained.  
 
Envelope-pseudotyped viruses. 
 100mm x 20mm tissue culture dishes were coated with 10% poly-lysine in phosphate-
buffered saline (PBS) and seeded with 3 x 106 293T cells 24 hours prior to transfection.  
Envelope-pseudotyped luciferase reporter viruses were generated by co-transfection of 293 T 
cells with 3 µg HIV-1 env expression vector and 3 µg of the pNL4-3.LucR-E- plasmid 
(obtained from the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH) (37, 130) using the FuGENE® 6 transfection reagent and protocol (Roche).  
Five hours post-transfection the medium was changed and the cells were incubated at 37°C 
for an additional 48 hours.  Viral supernatants were harvested using a 10 ml syringe, and 
filtered through a 0.45 µm filter, and stored in aliquots at -80°C.   
 
Coreceptor tropism analysis. 
 One day prior to infection, TZM-bl cells were seeded onto 96-well black tissue 
culture plates (2 x 105 cells/well).  Two hours prior to infection the coreceptor inhibitors 
TAK-779 (7, 60) and bicyclam JM-2987 (hydrobromide salt of AMD-3100) (19, 48, 132) 
(both obtained from the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH) were added at concentrations of 2.5 µM and 5 µM using the following 
conditions for each virus: no drug, TAK-779 only, AMD-3100 only, and both drugs.  Cells 
were infected in the presence of drug using 50 µl of viral supernatant per well and 
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spinoculated (2000 rpm) for 2 hours at 37°C.  Infections were incubated for 48 hours at 
37°C, and then the cells were washed twice with PBS and lysed with 50 µl of Reporter lysis 
buffer (Promega).  Luciferase activity was assayed using the Lusiferase assay system 
(Promega) on a Veritas microplate luminometer (Turner Biosystems).  All infections and 
conditions were conducted in triplicate.   
 
293-Affinofile cellular surface expression of CD4 and CCR5. 
 Ninety-six-well plates were seeded with 293-Affinofile cells at a density of 2.5x105 
cells/well.  Twenty-four hours later CD4 and CCR5 expression was induced with tetracycline 
and ponasterone A (ponA), respectively.  Cells were induced in a matrix format for a total of 
24 induction levels with varying amounts of tetracycline (0-0.1 µg/ml) and ponA (0-2 
µM/ml).  Induction was maintained for 18 hours at 37°C, the induction medium was then 
removed and cells were processed by quantitative flow cytometry.  Cells were prepared for 
flow cytometry by staining at room temperature for 30 minutes with either phycoerythin 
(PE)-conjugated anti-human CD4 antibody (clone Q4120, BD Biosciences) or PE-conjugated 
mouse anti-human CCR5 antibody (clone 2D7, BD Biosciences).  Cells were then fixed with 
4% paraformaldehyde, washed and analyzed by flow cytometry.  CD4 and CCR5 receptor 
levels were quantified using QuantiBRITE beads (BD Biosciences). 
 
Single-cycle infection of 293-Affinofile cells. 
  Envelope-pseudotyped luciferase reporter viruses were initially titered on 293-
Affinofile cells expressing the highest drug induction levels for CD4 (0.1 µg/ml tetracycline) 
and CCR5 (2 µM ponA) surface expression.  The amount of pseudotyped virus used in the 
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single-cycle infection assay was normalized to 106 relative light units for infection at the 
highest drug levels tested.  All pseudotyped viruses were used within the linear range of the 
assay, and all infection conditions were assayed in quadruplicate.   
 Two days prior to infection, 96-well black tissue culture plates were coated with 10% 
poly-lysine in PBS and seeded with 293-Affinofile cells (2.5 x 105 cells/well).  Expression of 
CD4 and CCR5 was induced the following day by adding varying concentrations of 
tetracycline and ponasterone A as described above.  Eighteen hours later, the induction 
medium was removed and fresh culture medium containing envelope-pseudotyped virus was 
gently added to the cells.  The infection plates were spinoculated at 2000 rpm for 2 hours at 
37°C, and incubated for an additional 48 hours at 37°C.  Infection medium was then removed 
and the cells were washed twice with PBS and lysed with 50 µl Reporter lysis buffer 
(Promega).  Luciferase activity was assayed using the Luciferase assay system (Promega) on 
a Veritas microplate luminometer (Turner Biosystems). 
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RESULTS 
 
Extensive genetic compartmentalization between blood and CSF HIV-1 populations is 
correlated with HIV-1-associated dementia. 
Viral genetic compartmentalization was examined by conducting single genome 
amplification (SGA) on blood plasma and CSF samples from subjects with varying degrees 
of neurological disease (3 asymptomatic subjects, 1 MCMD subject, 7 HAD subjects; see 
Table 4.1).  Compartmentalization in the CSF was determined based on the phylogenetic tree 
structure and the Slatkin-Maddison test for gene flow between populations.  We found 
varying degrees of compartmentalization in the CSF of three neurologically asymptomatic 
subjects (Figure 4.1; subjects 4030, 4012, and 4021), which is consistent with reports from 
previous studies showing variable amounts of compartmentalized HIV-1 in the CSF of 
asymptomatic subjects (124, 126, 254).  No compartmentalized variants were detected in the 
CSF of subject 4030, indicating extensive equilibration between the blood plasma and the 
CSF compartment.  However, phylogenetic analysis of subject 4030 (Figure 4.1A) revealed 
an HIV-1 population in the blood plasma that was X4-like based on the V3 genotype, and an 
X4-like CSF variant (C16) that appeared to be a recombinant between X4- and R5-like 
variants detected in the peripheral blood (data not shown).  In contrast, the phylogenetic tree 
of subject 4012 revealed a small clustering of CSF variants (Figure 4.1B), and we detected 
increased compartmentalization in the CSF of subject 4021 (Figure 4.1C).   
Significant genetic compartmentalization was detected between the blood plasma and 
CSF HIV-1 populations of eight subjects with HIV-1-associated neurological disease (Table 
4.1; Figure 4.2).  Phylogenetic analysis revealed deep bifurcations and long branch-lengths 
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between the blood plasma and CSF viral populations, indicating that sustained HIV-1 
replication is likely occurring in the CNS of subjects with neurological disease.  Clonal 
amplification was identified for CSF variants that were separated phylogenetically from the 
plasma virus population in three subjects with HAD (subjects 4033, 5003, and 7036; Figure 
4.2A), and this was associated with decreased env diversity in the CSF viral population 
(average pairwise distance within the compartmentalized population: 4033=0.007, 
5003=0.003, 7036=0.002 nucleotide substitutions per site).  In addition, HIV-1 populations 
in the CSF of subject 4051 were somewhat equilibrated with plasma virus based on the 
Slatkin-Maddison test (p=0.0908), although a distinct sub-population of the CSF virus 
appeared to be compartmentalized based on the phylogenetic tree structure (Figure 4.2B).  In 
addition, for two of these subjects (4033 and 5003), sequences from the population that was 
clonally amplified in the CSF also appeared in the blood, suggesting that there was a flow of 
viral genetic information from the CNS to the blood.  Phylogenetic analysis also revealed 
significant compartmentalization between the plasma and CSF HIV-1 populations in four 
additional subjects with neurological disease (Figure 4.2C; subjects 4013, 4059, 5002, and 
7115), which was associated with diverse env sequences in the CSF population (average 
pairwise distance within the compartmentalized population: 4013=0.023, 4059=0.029, 
5002=0.017, 7115=0.02 nucleotide substitutions per site).  These data indicate that 
significant genetic compartmentalization between the blood and CSF HIV-1 population is 
correlated with the development of neurological complications during HIV-1-infection.   
 
Evolution of HIV-1 populations in the CSF prior to the development of HAD. 
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In order to examine the evolution of compartmentalized HIV-1 variants in CNS/CSF 
of subjects with neurological disease, we conducted SGA on longitudinal plasma and CSF 
samples from two HAD subjects prior to the development of dementia (subjects 7036 and 
7115).  At the time of HAD diagnosis (2/18/2004), env sequences detected in the CSF of 
subject 7036 were considered compartmentalized based on the Statkin-Maddison test 
(p<0.0001), and clonal amplification was also detected for some of the compartmentalized 
CSF variants (Figure 4.3).  During our analysis of subject 7115, we detected clonal 
amplification in the CSF viral population two years prior to the development of dementia, 
although this amplified population was lost from the CSF population 6 months later.  
Phylogenetic analysis of env sequences from subject 7115 revealed a cluster of sequences 
derived from the CSF HIV-1 population, and at least one env sequence from each time-point 
was detected in this CSF cluster on the phylogenetic tree.  The CSF viral population was not 
considered compartmentalized at the time of HAD diagnosis for subject 7115 (Slatkin-
Maddison test, p=0.3956); however, one month after HAD diagnosis we detected significant 
compartmentalization between the blood and CSF viral populations (Figure 4.4; Slatkin-
Madditon test, p<0.0001).  These data suggest that an autonomously replicating HIV-1 
population was maintained in the CNS of subject 7115 over the course of at least two years, 
and possibly led to the development of dementia.  Additionally, significant 
compartmentalization in the CSF viral population seems to arise concurrently with the 
development of neurological complications, including HIV-1-associated dementia.   
 
 
Distinct cellular origins define two types of viral encephalitis. 
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 Perivascular macrophages and microglia are the two main cell types that express the 
CD4 receptor in the CNS and are purported to harbor replicating, compartmentalized HIV-1 
variants (108, 109, 161, 233, 256, 298).  We examined the phenotypes of 47 HIV-1 
envelopes from the plasma and CSF viral populations of seven subjects with neurological 
disease, and from two asymptomatic subjects.  Viral coreceptor usage and CD4 density 
dependence were assessed using HIV-1 env genes that were cloned and used to generate 
pseudotyped virus for the phenotype assays.  The cloned env sequences are indicated with an 
asterisk in the subjects’ phylogenetic trees in Figures 4.1 and 4.2.  The HIV-1 envelope 
properties are listed in Table 4.2.   
 To determine envelope coreceptor usage, we infected TZM-bl cells with envelope-
pseudotyped virus in the presence and absence of the CCR5 inhibitor TAK-779 (7, 60) and 
the CXCR4 inhibitor AMD-3100 (19, 48, 132).  Most of the HIV-1 envelopes used the CCR5 
coreceptor to enter cells; however, three envelopes used the CXCR4 coreceptor to enter cells 
(Figure 4.5 and Table 4.2).  All three of the CXCR4-tropic envelopes (4030 P52, 4030 C16, 
and 5002 P10) were predicted based on the V3 genotypes and position-specific scoring 
matrix (PSSM) scores (145) (Table 4.2), including the CSF envelope variant from a 
neurologically asymptomatic subject (4030 C16).  Thus, we conclude that for these subjects 
CXCR4-tropic viruses were not a significant feature of the viral population, especially in the 
CSF. 
 We examined the CD4 and CCR5 densities required for efficient virus entry into 
target cells in order to evaluate the cellular tropism of the plasma and CSF-derived HIV-1 
envelopes.  293-Affinofile cells are a dual-inducible cell line where CD4 expression is 
controlled by tetracycline and CCR5 expression is controlled by ponasterone A (148).  We 
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infected 293-Affinofile cells expressing different densities of CD4 and CCR5 in a matrix 
format using envelope-pseudotyped luciferase reporter virus, and measured luciferase 
activity to assess virus entry into cells.  All HIV-1 envelopes had efficient entry into cells 
expressing a high density of CD4 on the cell surface (106,083 or 121,088 molecules/cell), 
and viral infection was also positively correlated with CCR5 surface expression at a high 
CD4 density, although in all cases infectivity varied only two-fold over the range of CCR5 
densities tested (Figure 4.6 and data not shown).   
 We also examined the ability of HIV-1 envelopes to mediate entry into cells with low 
CD4 surface expression (1,315 or 2,630 molecules/cell) and found that some envelopes could 
efficiently enter cells expressing low CD4 density, whereas infection by other HIV-1 
envelopes was dependent on high levels of CD4 surface expression.  HIV-1 envelopes from 
the plasma and CSF of two asymptomatic subjects did not infect cells expressing low CD4 
receptor densities, regardless of the CCR5 surface expression (Figure 4.7), indicating that 
these envelopes have a more T cell-tropic phenotype.  Envelope phenotype characterization 
for subjects with HIV-associated neurological disease revealed two distinct classes of viral 
encephalitis (termed class 1 and class 2) associated with extensive genetic 
compartmentalization and the clinical diagnosis of dementia (Fisher’s exact test, p=0.03).   
 Class 1 viral encephalitis was linked to a dependence on high amounts of CD4 
surface expression for viral attachment and entry into cells (n=3 subjects).  All of the 
envelopes derived from the blood plasma viral populations of subjects 4033, 5003, and 7036 
required high CD4 densities for viral infection of 293-Affinofile cells (Figure 4.8A).  In 
addition, HIV-1 envelopes derived from the CSF-compartmentalized population could not 
infect cells with low amounts of CD4 surface expression, indicating that the 
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compartmentalized variants in these subjects have a more T cell-tropic phenotype and likely 
did not originate from CNS macrophages (Figure 4.8A and Table 4.2). 
 Class 2 viral encephalitis was linked with the ability of compartmentalized CSF 
variants to use low densities of CD4 and CCR5 for cell attachment and entry (n=4 subjects).  
HIV-1 envelopes from the blood virus populations of subjects 4013, 4059, 5002, and 7115 
required high CD4 surface expression for infection of 293-Affinofile cells.  However, 
envelopes from the CSF-compartmentalized HIV-1 populations efficiently infected cells with 
low CD4 density, indicating that these compartmentalized envelopes have a macrophage-
tropic phenotype (Figure 4.8B and Table 4.2).  Two envelopes (4059 P21 and P28) from the 
plasma population of subject 4059 had some infectivity on low CD4 density cells, suggesting 
that some plasma variants in this subject have a more macrophage-topic phenotype, although 
not to same degree as the compartmentalized CSF variants (Figure 4.8B).  We also examined 
one CSF-derived envelope from subject 5002 that was not part of the compartmentalized 
viral population based on the phylogenetic tree structure (5002 C6).  This CSF envelope 
variant was not able to infect cells with a low CD4 surface expression and had the same CD4 
and CCR5 phenotype as the plasma HIV-1 variants, suggesting that the macrophage-tropic 
phenotype was specific to the compartmentalized HIV-1 variants in the CSF population.   
In addition, we analyzed CD4 counts as a measure of the degree of immunodeficiency for 
subjects with class 1 and class 2 viral encephalitis.  The four subjects with class 2 viral 
encephalitis had significantly lower CD4 counts at the time that extensive 
compartmentalization was detected in the CSF compared to subjects with class 1 encephalitis 
(p=0.01 using a two-tailed unpaired t-test).  We also examined whether any HIV-1 genetic 
markers were associated with viral envelope phenotypes, and we found that a Q170K/R 
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amino acid substitution in the V1/V2 linker region of envelope was associated with the 
ability to infect low CD4 density cells (Figure 4.9; p=0.0002 using a Fisher’s exact test). 
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DISCUSSION 
 
 HIV-1 replication in the central nervous system (CNS) is thought to occur in 
perivascular macrophages and microglia within the brain parenchyma (9, 161, 295).  These 
local cells express low receptor densities of CD4 and CCR5 (177, 309), and can maintain 
productive HIV-1 infection (164, 241, 257).  Brain-derived HIV-1 envelopes from subjects 
with encephalitis can have increased macrophage tropism and low CD4 dependence 
compared to envelopes obtained from lymph node tissue (63, 233, 256, 298).  The 
development of HIV-1-associated dementia (HAD) has also been correlated with increased 
HIV-1 genetic compartmentalization between the CNS/CSF and the peripheral blood (64, 65, 
126, 218, 236, 242, 254, 256, 291), suggesting that independent viral evolution in the CNS is 
linked with the clinical development of dementia.  In the current study we have examined 
HIV-1 envelope genotypes and phenotypes associated with the clinical diagnosis of HAD.  
The goal of this work was to examine the viral characteristics associated with dementia, and 
to determine whether compartmentalized HIV-1 populations in the CSF of HAD subjects 
originate from local cells in the CNS. 
 In this study we used single genome amplification (SGA) to compare HIV-1 
populations in the blood and CSF of chronically-infected subjects with varying degrees of 
neurological disease.  Cross-sectional SGA analyses revealed significant 
compartmentalization in the CSF population associated with increased neurological disease.  
Our longitudinal SGA analyses of two HAD subjects also indicated that compartmentalized 
HIV-1 variants were maintained over a two year period as minor viral variants in the CSF 
population, and significant compartmentalization occurred concurrently with the 
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development of neurological disease.  Finally, we examined compartmentalized HIV-1 
envelope phenotypes from subjects with neurological disease and found that distinct cellular 
origins of compartmentalized virus define two classes of viral encephalitis associated with 
the clinical diagnosis of dementia. 
 Previously we had examined CSF-compartmentalized variant decay after the 
initiation of antiretroviral therapy in subjects with and without neurological disease (271).  In 
this previous study, we found that compartmentalized HIV-1 variants in the CSF decay 
slowly after the initiation of HAART and originate from long-lived cells in some subjects 
with HAD (271).  However, in a subset of HAD subjects we found that CSF-
compartmentalized HIV-1 variants decay rapidly after the start of therapy, indicating that in 
these subjects the virus was originating from a short-lived cell type (271).  In our current 
study, we used a subset of the same subject population and report that envelope phenotypes 
of compartmentalized HIV-1 variants in the CSF of HAD subjects revealed two classes of 
viral encephalitis.  Class 1 viral encephalitis was associated with a high CD4 density-
dependence of the compartmentalized virus for cell entry, while class 2 viral encephalitis was 
associated with the ability of CSF-compartmentalized HIV-1 variants to infect low CD4 
density cells (Figure 4.8).  The same subjects that displayed class 1 viral encephalitis 
(subjects 4033, 5003, and 7036) also had pleocytosis and CSF-compartmentalized HIV-1 
variants that decayed rapidly after the initiation of therapy in our previous study (271).  
These data show that the compartmentalized virus in some HAD subjects is originating from 
a short-lived cell type and the envelopes have a T cell-tropic phenotype, indicating that the 
compartmentalized population is replicating in CD4+ T cells (high CD4 surface expression), 
either within the CNS or the CSF.  Conversely, the subject group that displayed class 2 viral 
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encephalitis (subjects 4013, 4059, 5002, and 7115) had CSF-compartmentalized HIV-1 
variants that decayed slowly after the initiation of antiretroviral therapy (271).  This indicates 
that the CSF-compartmentalized HIV-1 population in another group of neurologically 
symptomatic subjects is originating from a long-lived cell type, and the envelopes in this 
viral population have a macrophage-tropic phenotype, suggesting that the population is being 
maintained by autonomous viral replication in perivascular macrophages and/or microglia 
(low CD4 surface expression) within the CNS. 
 As noted above, we previously correlated the rapid decay of compartmentalized HIV-
1 variants with high CSF pleocytosis (white blood cells in the CSF) in subjects with 
neurological disease (271).  Increased amounts of infiltrating CD4+ T cells would provide a 
reservoir for increased viral replication and population expansion, which correlates with the 
clonal amplification that we detected in the compartmentalized populations in some of these 
subjects.  In addition, we know from our longitudinal analyses of HIV-1 evolution in subjects 
7036 and 7115 that although compartmentalized HIV-1 variants are maintained as minor 
variants in the CSF population over several years, at some point a rapid expansion of specific 
CSF variants occurs which leads to significant genetic compartmentalization, and in these 
subjects this event was associated with clinical symptoms of neurological disease (Figures 
4.3 and 4.4).  It is possible that class 1-associated compartmentalized variants are maintained 
in perivascular macrophages and/or microglia in the CNS and amplified by infiltrating CD4+ 
T cells; however, this scenario seems unlikely considering the T cell-tropic phenotype of 
these compartmentalized envelopes which indicates that these HIV-1 variants have been 
replicating in CD4+ T cells.   
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 The concept of extensively compartmentalized HIV-1 variants replicating in short-
lived CD4+ T cells in the CNS conflicts with current ideas about the origins of 
compartmentalized virus in the CNS.  HIV-1 envelopes isolated from brain tissue of some 
subjects with dementia have macrophage-tropic phenotypes (63, 233, 256, 298), and are 
thought to persist and evolve in brain-resident macrophages.  SIV studies of CNS infection 
detected only infiltrating SIV-specific CD8+ T cells in the brains of infected monkeys, but 
found no CD4+ T cells (188-190, 308).  However, migration of CD4+ T cells into the CNS is 
known to be important in the clearance of RNA virus infections in the CNS from both 
neurons and glial cells (110).  Trafficking CD4+ T cells have been reported in the CNS 
during infection of other neurotropic viruses, including rabies (74, 235, 258) and Sindbis 
virus (12).  Additionally, a recent study reported that chronic brain infection by mouse 
hepatitis virus (strain JHM) resulted in long-term persistence of virus-specific CD4+ and 
CD8+ T cells in the CNS, and these cell populations were maintained by migration of 
peripheral virus-specific and naïve T cells into the CNS (325).   
We propose that the presence of viral antigen, especially during periods of increased 
HIV-1 replication in the CNS/CSF compartment, would drive the migration of CD4+ T cells 
into the CNS/CSF and lead to persistence and evolution of compartmentalized virus.  The 
down-regulation of CD4 after infection with HIV-1 could explain the absence of CD4+ T 
cells in the CNS of SIV-infected animals, in addition to rapid killing of these cells by the 
virus.  Studies involving rabies virus have also shown regional brain tissue differences in 
BBB permeability and lymphocyte trafficking in the CNS, and increased CD4+ T cell 
infiltration was observed in the cerebellum compared to the cerebral cortex (235, 258).  CD4+ 
T cell-driven replication of compartmentalized HIV-1 may occur in a specific anatomical 
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location with the CNS.  Another possibility is that the majority of the T cell-driven 
compartmentalized virus replication and evolution is occurring in the CSF.  Even under 
normal physiological conditions, the CSF contains ~3 leukocytes/µl and the majority of these 
cells are T cells, with an increased ratio of CD4+ to CD8+ T cells relative to the peripheral 
blood (248).  Since we used the CSF as a surrogate for virus in the CNS, we cannot rule out 
the possibility that the T cell-tropic compartmentalized virus we measured for subjects 4033, 
5003, and 7036 may be replicating in the CSF. 
 Slow decay of compartmentalized HIV-1 in the CSF was previously reported for a 
subset of neurologically symptomatic subjects after the initiation of HAART (68, 120, 271, 
289).  In addition, slow decay was associated with increased immunodeficiency and no/low 
CSF pleocytosis in these subjects (subjects 4013, 4059, 5002, and 7115) (271).  We found 
that compartmentalized HIV-1 envelopes from subjects with slow viral decay also had a low 
CD4 density tropism (class 2 viral encephalitis), indicating that these variants are originating 
from longer-lived macrophages within the CNS.  The detection of macrophage-tropic 
envelopes in the CSF population was also correlated with increased immunodeficiency based 
on peripheral CD4 counts.  Decreased amounts of circulating CD4+ T cells would result in 
reduced trafficking of CD4 cells into the CSF and brain tissue, which is consistent with the 
reduced CSF pleocytosis detected in these subjects (271).   
The lack of CD4+ T cells in these subjects (4013, 4059, 5002, and 7115) may explain 
the expansion of macrophage-topic HIV-1 variants in the CNS during a period of increased 
viral replication. T cell-tropic and macrophage-topic HIV-1 variants likely co-exist within a 
complex CNS viral population and are continuously evolving in isolation from the peripheral 
blood population.  Increased HIV-1 replication would stimulate immune cell migration to the 
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CNS, and a common mechanism of immune control for viral CNS infections involves the 
migration of CD4+ and CD8+ T cells into the CNS to control and clear the infection (110).  
HIV-1-infected subjects with increased immunodeficiency lack substantial numbers of 
peripheral CD4+ T cells, leading to the absence of these cells in the CNS.  Furthermore, it has 
been proposed that events in the periphery may lead to increased CNS invasion of infected 
and uninfected monocytes, and differentiation of these cells into perivascular macrophages in 
the brain parenchyma (80).  Supporting this idea, previous studies have reported an increase 
in the total number of brain perivascular macrophages in subjects with HIVE (81, 82, 105) 
and in SIV-infected macaques with significant compartmentalization in the CSF (123).  
Increased numbers of perivascular macrophages would select for the outgrowth of 
macrophage-tropic HIV-1 variants from the CNS population during periods of increased 
immunodeficiency; however, we were not able to examine cell populations in the CNS due to 
the lack of brain tissue from our subject population.   
Previous studies have reported that different amino acid substitutions in the Env 
protein are associated with macrophage tropism and dementia.  Studies by Dunfee et al. (64, 
65) have reported that the HIV Envs variant N283 and D386 were found more frequently in 
brain-derived env sequences from HAD subjects and had enhanced viral entry in 
macrophages (64).  Another study identified amino acid residues on the CD4 binding loop 
flanks and residues in the V3 loop that conferred macrophage tropism to HIV-1 envelopes 
(62).  Basic amino acid substitutions in the V1/V2 linker of HIV-1 envelope have also been 
reported in the CSF-compartmentalized populations of primary infection subjects (270).  We 
found that a Q170K/R amino acid substitution in the V1/V2 linker region of envelope was 
associated with the ability to infect low CD4 density cells (Figure 4.9).  A substitution from 
 123 
 
glutamine to lysine is difficult and requires a C to A nucleotide transversion, which suggests 
that viral adaptation for low CD4 usage is enhancing the frequency of K170 in some 
envelopes.  One possibility is that K170 enhances HIV-1 envelope binding to the sulfated 
polysaccharide heparan sulfate (HS) on the surface of macrophages.  Studies mapping the HS 
domains of HIV-1 gp120 have reported an HS binding domain in the V1/V2 linker from 
amino acids 166 to 171 (43).  Heparan sulfate is thought to enhance gp120 coreceptor 
binding (306), and one study reported that HS binding was necessary for efficient HIV-1 
attachment to macrophages while CD4 binding was required for complete attachment and 
viral entry (264).  Polyanionic compounds (such as HS) are known to bind to basic amino 
acid residues in proteins, and the K170 envelope variant may enhance HS binding to 
facilitate HIV-1 attachment and entry into low CD4 density cells.  However, additional 
studies are necessary to discern the role K170 plays in HIV-1 attachment and entry. 
 In conclusion, our study defines two distinct classes of viral encephalitis, T cell-
driven vs. macrophage-driven replication, leading to HIV-1 genetic compartmentalization in 
the CNS/CSF and the development of severe clinical neurological symptoms.  Class 1 viral 
encephalitis was associated with compartmentalized HIV-1 variants with a high CD4 density 
dependence for cell entry.  Neurologically symptomatic subjects with class 2 viral 
encephalitis had compartmentalized HIV-1 envelopes that displayed a low CD4 tropism.  
Future studies examining HIV-1 populations in paired blood, CSF, and brain tissue from 
HAD subjects with and without HIVE will help determine whether there are physiological 
differences in brain pathology between subjects with class 1 and class 2 viral encephalitis.  
This study illustrates the complex patterns of HIV-1 evolution in the CNS over the course of 
infection, and more studies will be required to understand the events leading up to extensive 
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compartmentalization in the CNS and clinical dementia.  Our results suggest that increased 
HIV-1 replication and subsequent inflammation in the CNS/CSF compartment lead to 
clinical dementia, and the degree of immunodeficiency may define the cellular origin of the 
replicating compartmentalized virus.   
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Table 4.1.  Subject characteristics and CSF compartmentalization. 
  
Cell counts 
(cells/µl)  
HIV-1 RNA 
(log10 copies/ml)   
Subject 
ID Sample date CD4 
CSF 
WBCa 
ADC 
Stageb Plasma CSF 
CSF 
compartmentc 
Slatkin-
Maddisond 
4012 9/3/1997 295 16 0 5.18 4.39 Eq p=0.1705 
4021 11/5/1998 215 0 0 4.97 4.02 Some Comp p=0.002 
4030 9/16/1999 239 4 0 4.86 4.06 Eq p=0.1516 
4013 11/17/1997 148 10 1 4.62 4.75 Comp p<0.0001 
4033 1/12/2000 173 28 2 4.83 5.23 Comp, Amp p=0.0021 
4051 8/20/2004 344 12 3 5.61 5.41 Some Comp p=0.0908 
4059 8/16/2006 53 1 3 5.31 5.08 Comp p<0.0001 
5002 10/17/1997 59 4 3 4.24 5.32 Comp p<0.0001 
5003 11/3/1997 234 46 3 3.31 4.33 Comp, Amp p<0.0001 
7036 10/31/2002 327 20 0 4.67 3.89 Uneq p=0.0049 
 4/28/2003 324 30 0 4.97 4.41 Eq p=0.7113 
 2/18/2004 267 240 2 5.12 5.37 Comp, Amp p<0.0001 
7115 7/8/2002 145 7 0 4.68 4.43 Amp p=0.0083 
 12/3/2002 108 24 0 4.76 4.85 Some Comp p=0.0256 
 4/8/2004 50 12 2 5.87 4.85 Eq p=0.3956 
 5/11/2004 66 6 2 3.46 4.63 Comp p<0.0001 
 6/3/2004 150 7 3 2.97 3.54 n/a  
 
a= CSF white blood cell counts (cells/µl) 
b= ADC staging: (245). 
c=HIV-1 population characteristics in the CSF compartment. Eq=equilibration with the blood 
plasma; Uneq=discordance between the CSF and blood plasma without substantial 
compartmentalization; Some Comp=a subpopulation of the CSF is compartmentalized; 
Comp=significant compartmentalization in the CSF; Amp=clonal amplification of variants 
detected in the CSF; n/a=not applicable.  The classification of clonal amplification was 
determined by calculating the average overall pairwise distance (nucleotide substitutions per 
site) between env sequences in the compartmentalized HIV-1 population for subjects with 
neurological disease (subject 4013, 0.023; subject 4033, 0.007; subject 4051, 0.03; subject 
4059, 0.029; subject 5002, 0.017; subject 5003, 0.003; subject 7036, sample date 2/18/2004, 
0.002; subject 7115, sample date 7/8/2002, 0.002; subject 7115, sample date 5/11/2004, 
0.02).  A CSF HIV-1 population with an average pairwise distance <0.01 was considered to 
have clonal amplification. 
d=Slatkin-Maddison test for gene flow between populations.  A p-value <0.05 indicates 
statistically significant compartmentalization between the blood and CSF HIV-1 populations. 
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Table 4.2. Cellular tropism characteristics of envelope-pseudotyped viruses. 
Subject 
ID 
Sample 
date 
Env 
clone 
PSSM 
scorea 
Coreceptor 
phenotype 
High 
CD4, 
low 
CCR5b 
High 
CD4, 
high 
CCR5c 
Low 
CD4, 
low 
CCR5d 
Low 
CD4, 
high 
CCR5e 
Comp. 
virus 
decayf 
M-
tropicg  Ba-L 0 R5 51.8 100 14.3 18.0  
T cell-
tropic  
JR-
CSF 0 R5 66.5 100 0.3 0.4  
4012 9/3/1997 P1 0 R5 52.7 100 1.7 2.2 n/a 
  P37 0 R5 53.3 100 2.3 3.2  
  C8 0 R5 33.8 100 0.4 0.7  
  C11 0 R5 57.4 100 1.2 1.3  
4030 9/16/1999 P52 1 X4 107.1 100 1.8 1.2  
  P56 0 R5 53.8 100 1.3 1.4 n/a 
  C11 0 R5 52.6 100 0.6 0.7  
  C16 1 X4 112.9 100 4.1 2.9  
  C23 0 R5 54.4 100 3.0 3.5  
4033 1/12/2000 P9 0 R5 63.7 100 3.5 3.1 rapid 
  P10 0 R5 62.3 100 0.7 0.5  
  P13 0 R5 57.1 100 0.1 0.1  
  C10 0 R5 49.0 100 2.1 3.0  
  C15 0 R5 58.6 100 1.0 1.1  
  C24 0 R5 63.4 100 0.9 1.1  
5003 11/3/1997 P18 0 R5 49.4 100 1.3 1.6 rapid 
  P33 0 R5 54.2 100 1.3 1.8  
  P44 0 R5 57.9 100 0.1 0.1  
  C4 0 R5 47.3 100 0.9 1.2  
  C18 0 R5 37.8 100 0.5 0.8  
7036 2/18/2004 P9 0 R5 52.4 100 0.1 0.2 rapid 
  C3 0 R5 44.4 100 0.3 0.5  
  C7 0 R5 52.4 100 0.3 0.4  
  C33 0 R5 56.0 100 1.1 1.2  
4013 11/17/1997 P9 0 R5 69.5 100 0.4 0.4 slow 
  P32 0 R5 68.8 100 0.4 0.4  
  P44 0 R5 69.6 100 0.3 0.3  
  C7 0 R5 61.1 100 19.3 22.9  
  C11 0 R5 55.9 100 10.7 10.8  
  C23 0 R5 56.3 100 25.5 28.4  
4059 8/16/2006 P21 0 R5 67.1 100 11.7 13.6 slow 
  P26 0 R5 64.6 100 0.3 0.4  
  P28 0 R5 68.6 100 6.9 7.9  
  C6 0 R5 57.2 100 25.0 34.9  
  C12 0 R5 58.7 100 19.5 23.6  
  C19 0 R5 58.6 100 13.7 17.4  
5002 10/17/1997 P10 1 X4 100.4 100 1.3 1.0 slow 
  P13 0 R5 67.6 100 0.5 0.4  
  P18 0 R5 56.7 100 0.7 0.9  
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  C1 0 R5 56.7 100 19.9 26.1  
  C13 0 R5 49.9 100 12.6 19.1  
  C6 0 R5 47.9 100 1.7 2.1  
7115 5/11/2004 P6 0 R5 43.5 100 0.05 0.07 slow 
  P17 0 R5 58.6 100 1.1 1.2  
  C3 0 R5 60.2 100 21.0 32.5  
  C15 0 R5 53.7 100 16.5 20.9  
  C21 0 R5 63.6 100 23.1 31.2  
 
a=Position-specific scoring matrix score, ref. (145). (0 = R5-like sequence, 1 = X4-like 
sequence) 
b=CD4 density: 106,083 molecules/cell, CCR5 density: 2,529 molecules/cell (subjects 4012, 
4030, 5003, 7036, 7115; 5002 clones P13, C6, C13); CD4 density: 121,088 molecules/cell, 
CCR5 density: 6,156 (subjects 4013, 4033, 4059; 5002 clones P10, P18, C1) 
c= CD4 density: 106,083 molecules/cell, CCR5 density: 53,498 molecules/cell (subjects 
4012, 4030, 5003, 7036, 7115; 5002 clones P13, C6, C13); CD4 density: 121,088 
molecules/cell, CCR5: 90,462 molecules/cell (subjects 4013, 4033, 4059; 5002 clones P10, 
P18, C1) 
d= CD4 density: 1,315 molecules/cell, CCR5 density: 2,529 molecules/cell (subjects 4012, 
4030, 5003, 7036, 7115; 5002 clones P13, C6, C13); CD4 density: 2,630 molecules/cell, 
CCR5 density: 6,156 molecules/cell (subjects 4013, 4033, 4059; 5002 clones P10, P18, C1) 
e= CD4 density: 1,315 molecules/cell, CCR5 density: 53,498 molecules/cell (subjects 4012, 
4030, 5003, 7036, 7115; 5002 clones P13, C6, C13); CD4 density: 2,630 molecules/cell, 
CCR5 density: 90,462 molecules/cell (subjects 4013, 4033, 4059; 5002 clones P10, P18, C1) 
f= CSF-compartmentalized variant decay based on previously published data (271) 
g=Macrophage-tropic control envelope 
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Figure 4.1. Phylogenetic analysis of plasma and CSF HIV-1 populations for 
neurologically asymptomatic subjects. (A) Phylogenetic tree of HIV-1 env sequences for 
subject 4030, which displays equilibration between blood plasma and CSF HIV-1 
populations.  The open red circle illustrates the node of divergence for an X4-tropic 
population in the blood plasma.  (B) Phylogenetic tree of HIV-1 env sequences for subject 
4012.  A small group of CSF sequences cluster together in the tree, but the blood and CSF 
populations were considered equilibrated. (C) Phylogenetic tree of HIV-1 env sequences for 
subject 4021, which displays some compartmentalization in the CSF population.  The open 
blue circles illustrate the node of divergence for the compartmentalized CSF sequences.  
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SGA amplicons were first aligned, and a maximum-likelihood phylogenetic tree was 
constructed using PhyML.  Bootstrap numbers ≥70 are indicated at the appropriate nodes.  
Sequences obtained from the CSF are labeled with solid blue circles, and plasma sequences 
are labeled with solid red rectangles on the tree.  Genetic distance between sequences is 
indicated by the distance scale bar at the bottom of the tree.  HIV-1 env sequences that were 
selected for phenotypic analysis are indicated with asterisks.   
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Figure 4.2. Phylogenetic analysis of plasma and CSF HIV-1 populations for 
neurologically symptomatic subjects.  (A) Phylogenetic trees of HIV-1 env sequences for 
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subjects 4033, 5003, and 7036, which display significant compartmentalization and clonal 
amplification in the CSF HIV-1 population.  (B) Phylogenetic tree of HIV-1 env sequences 
for subject 4051.  A subset of the CSF population was considered compartmentalized.  (C) 
Phylogenetic trees of HIV-1 env sequences for subjects 4013, 4059, 5002, and 7115, which 
display significant compartmentalization in the CSF HIV-1 population.  The open blue 
circles illustrate the node of divergence for the compartmentalized CSF sequences.  SGA 
amplicons were first aligned, and a maximum-likelihood phylogenetic tree was constructed 
using PhyML.  Bootstrap numbers ≥70 are indicated at the appropriate nodes.  Sequences 
obtained from the CSF are labeled with solid blue circles, and plasma sequences are labeled 
with solid red rectangles on the tree.  Genetic distance between sequences is indicated by the 
distance scale bar at the bottom of the tree.  HIV-1 env sequences that were selected for 
phenotypic analysis are indicated with asterisks.   
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Figure 4.3.  Longitudinal phylogenetic analysis of subject 7036 HIV-1 populations. 
Phylogenetic circle tree of plasma and CSF HIV-1 env sequences from sample dates 
10/31/2002 (plasma=light pink triangle; CSF=pale blue circle), 4/28/2003 (plasma=dark 
salmon triangle; CSF=medium blue circle with dark outline), and 2/18/2004 (plasma=bright 
red triangle; CSF=royal blue circle).  The compartmentalized env sequences in the CSF are 
indicated by the black curved line, and CSF sequences that were clonally amplified on 
2/18/2004 are indicated by the black brackets. The open blue circle illustrates the node of 
divergence for the compartmentalized CSF sequences.  Genetic distance between sequences 
is indicated by the scale bar.  HIV-1 env sequences that were selected for phenotypic analysis 
are indicated with asterisks.   
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Figure 4.4.  Longitudinal phylogenetic analysis of subject 7115 HIV-1 populations. 
Phylogenetic circle tree of plasma and CSF HIV-1 env sequences from sample dates 
7/8/2002 (plasma=light pink triangle; CSF=pale blue circle), 12/3/2002 (plasma=pink 
triangle with dark pink outline; CSF=medium blue circle with dark outline), 4/8/2004 
(plasma=light-red triangle; CSF=blue-gray circle), 5/11/2004 (plasma=bright red triangle; 
CSF=royal blue circle), and 6/3/2004 (CSF=navy blue circle with black outline).  The 
compartmentalized env sequences in the CSF are indicated by the black curved line, and the 
open blue circle illustrates the node of divergence for the compartmentalized CSF sequences.  
CSF sequences that were clonally amplified on 7/8/2002 are indicated by the black brackets. 
Genetic distance between sequences is indicated by the scale bar.  HIV-1 env sequences that 
were selected for phenotypic analysis are indicated with asterisks.   
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Figure 4.5. Coreceptor tropism of HIV-1 envelope-pseudotyped reporter viruses.  TZM-
bl cells were infected with pseudotyped virus in the presence of no drug (red bar), the CCR5 
inhibitor TAK-779 only (green bar), the CXCR4 inhibitor AMD-3100 only (blue bar), or 
both drugs (purple bar).  Infection was normalized for background, and luciferase activity for 
infection in the absence of drug was normalized to 100%.  The Ba-L envelope was used as a 
macrophage-tropic control envelope, and the JR-CSF envelope was used as a T cell-tropic 
control envelope.  A pseudotyped virus that was inhibited by TAK-779 but not by AMD-
3100 was considered to use the CCR5 coreceptor for cell entry.  A pseudotyped virus that 
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was inhibited by AMD-3100 but not by TAK-779 was considered to use the CXCR4 
coreceptor for cell entry.  Infection was inhibited for all pseudotyped viruses when both 
drugs were present.  Results shown are from the average of three replicates. 
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Figure 4.6. HIV-1 envelopes from the plasma and CSF of all subjects efficiently infect 
cells with a high CD4 surface expression.  293-Affinofile cells expressing high levels of 
CD4 (106,083 or 121,088 molecules/cell) and varying levels of CCR5 were infected with 
envelope-pseudotyped reporter viruses.  Infection was normalized to 100% for each virus for 
luciferase activity on cells with the highest surface expression of CD4 and CCR5.  The CCR5 
densities are listed in units of molecules/cell.  The Ba-L envelope was used as a macrophage-
tropic control envelope, and the JR-CSF envelope was used as a T cell-tropic control 
envelope.  Results shown are from the average of four replicates.    
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Figure 4.7. HIV-1 envelopes from the plasma and CSF of neurologically asymptomatic 
subjects do not infect cells with a low CD4 surface expression.  293-Affinofile cells 
expressing a low density of CD4 (1,315 molecules/cell) and varying levels of CCR5 were 
infected with envelope-pseudotyped reporter viruses.  Infection was normalized to 100% for 
luciferase activity on cells with the highest surface expression of CD4 and CCR5.  The CD4 
and CCR5 densities are listed in units of molecules/cell.  The Ba-L envelope was used as a 
macrophage-tropic control envelope, and the JR-CSF envelope was used as a T cell-tropic 
control envelope.  Results shown are from the average of four replicates. 
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Figure 4.8. HIV-1 envelopes from the plasma and CSF of neurologically symptomatic 
subjects differ in their ability to infect cells with a low CD4 surface expression.  (A)  
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Envelopes from the plasma and CSF-compartmentalized HIV-1 populations of some HAD 
subjects do not infect low CD4 density cells.  (B) Envelopes from the CSF-
compartmentalized HIV-1 population of some neurologically symptomatic subjects 
efficiently infect low CD4 density cells.  Envelope clone 5002 C6 was selected from the non-
compartmentalized viral population in the CSF.  293-Affinofile cells expressing a low 
density of CD4 (1,315 or 2,630 molecules/cell) and varying levels of CCR5 were infected 
with envelope-pseudotyped reporter viruses.  Infection was normalized to 100% for 
luciferase activity on cells with the highest surface expression of CD4 and CCR5.  The CD4 
and CCR5 densities are listed in units of molecules/cell.  The Ba-L envelope was used as a 
macrophage-tropic control envelope, and the JR-CSF envelope was used as a T cell-tropic 
control envelope.  Results shown are from the average of four replicates. 
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Figure 4.9. Lysine at position 170 in the HIV-1 envelope is associated with the ability to 
enter cells with a low CD4 surface expression.  HIV-1 Env sequences were aligned and 
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compared with the HXB2 Env.  The amino acid sequences for HXB2 positions 161 to 180 
are shown for each HIV-1 envelope that was phenotyped, and residues identical to the HXB2 
reference sequence are displayed as dashes.  Env position 170 is highlighted in yellow, and 
HIV-1 envelopes with the ability to infect low CD4 density cells are indicated by the black 
line.
  
 
CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
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 Neurological complications resulting from HIV-1 infection of the central nervous 
system (CNS) have been documented over the course of the AIDS epidemic.  HIV-1-
associated dementia (HAD) is a severe neurological disease resulting in both mental and 
motor impairment, and even milder cases of neurological dysfunction have a substantial 
impact on the quality of life for affected individuals.  HIV-1 genetic compartmentalization 
has been detected in the brains of HAD subjects at autopsy (64, 65, 218, 242, 256), and in the 
cerebrospinal fluid (CSF) of HAD subjects sampled over the course of infection (126, 236, 
254, 291).  In addition, evidence from previous studies indicates that HIV-1 variants are 
replicating in perivascular macrophages and possibly microglia in the CNS (40, 82, 108, 109, 
161, 233, 256, 295, 298, 315).  However, after almost thirty years of research it is still 
unclear how HIV-1 induces neurological disease and why a subset of HIV-1-infected 
individuals develop HAD and others do not. 
One of the main objectives for this dissertation was discerning the viral characteristics 
associated with CNS compartmentalization and clinical dementia.  The projects outlined in 
this dissertation focused on characterizing HIV-1 genetic compartmentalization in the 
CNS/CSF over the course of HIV-1 infection, including when compartmentalization begins 
during the course of infection and how HIV-1 populations in the plasma and CSF evolve 
over time.  I also defined the cellular origin of compartmentalized HIV-1 variants in the CSF, 
and examined the genotypic and phenotypic differences between compartmentalized and 
non-compartmentalized HIV-1 variants in subjects with HAD or no neurological symptoms.   
In Chapter Two I assessed HIV-1 genetic compartmentalization between viral 
populations in the peripheral blood and CSF during primary HIV-1 infection.  Using newer 
techniques such as single genome amplification and sequence analysis of the full length env 
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gene, I was able to show that compartmentalization can occur in the CSF of primary infection 
subjects in part through persistence of the putative transmitted parental variant, or via viral 
genetic adaptation to the CNS environment.  I also found through longitudinal analyses that 
compartmentalization in the CSF can be resolved during infection, demonstrating the 
dynamic nature of HIV-1 infection in the CNS early after transmission.  To my knowledge, 
this is the first study to report the detection of compartmentalized HIV-1 variants in the CSF 
of primary infection subjects.  Now that I have generated full-length HIV-1 env variants from 
11 primary infection subjects with and without compartmentalization in the CSF, it is 
important to continue these studies by cloning the env genes and examining differences in 
viral Env protein phenotypes.   
Although differences exist between HIV-1 env genotypes in the blood and CSF 
populations of primary infection subjects with compartmentalization, it is possible that the 
envelope phenotypes do not differ this soon after HIV-1 transmission.  Studies examining 
compartmentalized variants during chronic infection have reported differences in viral 
phenotypes between HIV-1 variants in the periphery and the CNS, including macrophage-
tropic brain-derived envelopes and T cell-tropic lymph node-derived envelopes (108, 109, 
233, 298).  Current ideas postulate that macrophage tropism evolves later during the course 
of disease because macrophage-tropic envelopes have not been detected early during the 
course of infection.  I found that genetic differences can occur between the peripheral and 
CNS HIV-1 populations during primary infection, and it is important to determine whether 
viral genetic adaptation in the CSF during primary HIV-1 infection correlates with viral 
phenotypic adaptation to the CNS environment, which would indicate enhanced HIV-1 
replication in the brain. 
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The studies I conducted in Chapter Two also have implications for the clinical 
treatment of HIV-1 infection.  Guidelines for the administration of antiretroviral drugs are 
not well defined for primary HIV-1 infection, and my results suggest that subjects with 
compartmentalization of viral variants in the CSF during primary infection should be 
considered for early antiretroviral therapy to reduce viral replication in the CNS.  In order to 
understand the dynamic nature of HIV-1 infection in the CNS and the development of 
neuropathogenesis, HIV researchers will need to follow subjects from the early stages of 
primary infection through the chronic stage of disease.  Compartmentalization late in 
infection likely indicates a loss of control of viral replication in the periphery and is 
associated with HAD (126).  The detection of CSF-compartmentalized variants during 
primary HIV-1 infection may identify subjects that will have HIV-associated neurological 
problems later during infection; however, longitudinal studies will be necessary to answer 
this question and provide additional answers for clinicians regarding antiretroviral therapy 
during the early stages of infection. 
The focus of Chapter Three was to examine the source of compartmentalized HIV-1 
in the CNS of subjects with neurological disease and in neurologically-asymptomatic 
subjects who were initiating antiretroviral therapy.  These studies used the heteroduplex 
tracking assay (HTA) to identify compartmentalized variants in the CSF and then measure 
the viral decay kinetics of individual variants after the initiation of antiretroviral therapy.  In 
subjects with neurological disease, I found that compartmentalized variant decay kinetics 
were associated with the degree of CSF pleocytosis and immunodeficiency.  Rapid decay of 
CSF-compartmentalized variants in HAD subjects was associated with high CSF pleocytosis, 
whereas slow decay measured for CSF-compartmentalized variants in subjects with 
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neurological disease was correlated with low peripheral CD4 cell count and reduced CSF 
pleocytosis.  The longer half-lives I detected suggest that compartmentalized HIV-1 in the 
CSF of some neurologically symptomatic subjects may be originating from a long-lived cell 
type such as perivascular macrophages and microglia in the brain.   
In Chapter Four I went a step further and examined the viral genotypes and 
phenotypes associated with the CSF-compartmentalized variants with differential decay 
rates.  In this study I used SGA to generate full-length env genes from compartmentalized 
and non-compartmentalized variants in chronically-infected subjects with varying degrees of 
neurological disease.  The cross-sectional SGA analyses revealed significant 
compartmentalization in the CSF population associated with increased neurological disease.  
Finally, the envelope phenotype characterization for subjects with HIV-associated 
neurological disease revealed two distinct classes of viral encephalitis (termed class 1 and 
class 2) associated with extensive genetic compartmentalization and the clinical diagnosis of 
dementia.   
The new data generated from the studies in Chapter Four establish a cohesive new 
argument about the source of compartmentalized virus in the CNS of HAD subjects.  I found 
that class 1 viral encephalitis was associated with a dependence on high CD4 density for 
infection of compartmentalized viruses (T cell-tropic), while class 2 viral encephalitis was 
associated with the ability of CSF-compartmentalized variants to infect low CD4 density 
cells (macrophage-tropic).  These new phenotype data provide a link between 
compartmentalized virus decay kinetics and cell tropism.  The subjects that displayed class 1 
viral encephalitis (subjects 4033, 5003, and 7036) also had CSF-compartmentalized HIV-1 
variants that decayed rapidly after the initiation of therapy (Chapter Three).  These data 
 147 
 
suggest that the compartmentalized virus in some HAD subjects is originating from a short-
lived cell type and indicates that the compartmentalized population is most likely replicating 
in CD4+ T cells in the CNS.  The subject group that displayed class 2 viral encephalitis 
(subjects 4013, 4059, 5002, and 7115) also had CSF-compartmentalized HIV-1 variants that 
decayed slowly after the initiation of antiretroviral therapy (271).  This indicates that the 
CSF-compartmentalized HIV-1 population in another group of neurologically symptomatic 
subjects is originating from a long-lived cell type and suggests that the population is being 
maintained by autonomous viral replication in perivascular macrophages and/or microglia 
within the CNS.  The results described in Chapter Four also suggested that the degree of 
immunodeficiency may define the cellular origin of the compartmentalized virus since the 
four subjects with class 2 viral encephalitis had significantly lower peripheral CD4+ T cell 
counts compared to subjects with class 1 encephalitis.  Based on the data generated in 
Chapter Four, I have developed a simple model where compartmentalized HIV-1 variants are 
maintained in the CSF of HAD subjects by either T cell-driven viral replication (class 1 
encephalitis) or macrophage-driven viral replication (class 2 encephalitis; see Figure 5.1). 
Our studies illustrate a complex pattern of HIV-1 evolution in the CNS over the 
course of infection.  Future longitudinal studies will need to focus on the events leading up to 
extensive compartmentalization in the CNS in order to understand how two distinct 
evolutionary pathways lead to clinical dementia.  Currently in the literature it is generally 
accepted that viral replication in local CNS cells contributes to the development of 
neurological disease.  One study by Harrington et al. (124) reported that compartmentalized 
HIV-1 variants in the CSF of neurologically asymptomatic subjects are originating from 
short-lived cells in the CNS.  The studies presented in this dissertation have added to this 
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body of literature and demonstrated that viral replication maintained by both infiltrating 
CD4+ T cells and local perivascular macrophages/microglia contributes to neurological 
disease.   
Subjects diagnosed with HAD can be divided into two groups based on 
neuropathology detected in brain tissue.  After years of research, it is apparent that some 
HAD subjects have a striking lack of pathology and tissue damage in the brain, while other 
HAD subjects have HIV-1 encephalitis characterized by pathological tissue damage and the 
presence of multinucleated giant cells of the macrophage/microglia origin (22, 23, 208).  It is 
currently unknown why some subjects with severe dementia lack any brain pathology, and 
the absence of tissue damage in the CNS suggests that viral replication and inflammation in 
the CNS of these subjects is causing neuronal dysfunction rather than irreversible cell 
damage.  Based on my recent findings, I propose that HIV-1-infected subjects with class 1 
viral encephalitis will have little to no brain pathology, while subjects with class 2 viral 
encephalitis will have tissue damage and pathology commonly seen with HIVE.  Future 
studies are necessary to test this hypothesis, and a comprehensive analysis examining HIV-1 
populations in paired blood, CSF, and brain tissue from HAD subjects with and without 
HIVE will help determine whether there are differences in brain pathology between subjects 
with class 1 and class 2 viral encephalitis.   
The discovery that viral replication within two distinct cell types can lead to clinical 
dementia is novel and indicates that in addition to macrophage-tropic variants, T cell-tropic 
HIV-1 variants are also able to persist in the CNS/CSF compartment and cause neurological 
dysfunction.  Future studies may reveal differences in the clinical outcome between class 1 
and class 2 encephalitis that could lead to different antiretroviral therapy regimens between 
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the two subject groups.  If class 2 viral encephalitis is associated with HIVE and 
neuropathology, HAD subjects with macrophage-tropic compartmentalized variants may 
need more aggressive therapy regimens to fully suppress HIV-1 replication in the CNS.  
Conversely, T cell-tropic CSF-compartmentalized variants may be associated with better 
neurological recovery during therapy.  In either case, the association between a specific 
encephalitis class and clinical neurological prognosis would be beneficial for both clinicians 
and HIV-infected patients.  A genetic marker to distinguish T cell-tropic versus macrophage-
tropic compartmentalized variants would be the simplest clinical test, although the 
commercially available phenotype assay could be altered to examine Env tropism differences 
since the compartmentalized populations in the CSF were dominated by either T cell-tropic 
or macrophage-tropic variants. 
 Future studies and experiments are necessary to conclusively determine the 
differences between class 1 and class 2 viral encephalitis associated with HIV-1 neurological 
disease.  The studies presented in Chapter Four are limited by a small set of patient samples, 
so the addition of more paired blood and CSF samples from subjects with neurological 
disease will be necessary to increase the significance of the results.  In addition, the studies 
discussed in this dissertation focused on neurological disease associated with only subtype B 
HIV-1 infections.  HIV-1 subtype C is responsible for the most infections worldwide, so it is 
imperative that future studies examine CNS viral populations in subjects infected with 
subtype C HIV-1, although these studies are obviously more difficult to conduct due to the 
infrastructure limitations in Africa where subtype C is most prevalent.  The findings 
regarding viral replication differences in the CNS during subtype B infection may translate to 
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subtype C infections in the CNS, but future experiments will be needed to answer this 
question. 
 Additional phenotype experiments need to be conducted using the Env-pseudotyped 
viruses generated in Chapter Four to elucidate the exact differences between low CD4 and 
high CD4 dependence for viral infection.  Low CD4 usage by HIV-1 envelopes is associated 
with the ability to infect macrophages (63, 298).  The phenotype experiments in Chapter Four 
were conducted in a human cell-line, so the next step is to examine the ability of the different 
envelopes to infect primary human monocyte-derived macrophages.  I also need to determine 
when macrophage-tropic envelopes evolve during the course of HIV-1 infection in the CNS.  
I have generated full-length env genes from longitudinal plasma and CSF samples prior to the 
development of HAD for subject 7115.  Low CD4-tropic envelopes were detected in the CSF 
population of subject 7115 after HAD diagnosis.  I found that some of the CSF envelopes 
from earlier time points during infection had viral genotypes very similar to the low CD4-
using envelopes.  The phenotypes of these earlier CSF viruses need to be examined to 
determine when macrophage-tropic HIV-1 variants evolved prior to the development of 
dementia.   
Envelope conformation differences also need to be investigated for T cell-tropic and 
macrophage-tropic HIV-1 envelopes.  I postulate that HIV-1 envelopes with the ability to 
infect at low CD4 densities will have a more open and exposed CD4 binding pocket 
compared to envelopes with a high CD4 dependence.  HIV-1 envelopes with the ability to 
use low CD4 densities are thought to have a greater CD4 affinity, allowing for envelope 
attachment on target cells with low CD4 surface expression.  Future experiments need to 
compare the CD4 affinity differences between T cell-tropic and macrophage-tropic HIV-1 
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envelopes from the blood and CSF.  One possible experiment would be to incubate envelope-
pseudotyped viruses with varying amounts of soluble CD4 and then infect high CD4 density 
cells.  HIV-1 envelopes with a greater affinity to CD4 will remain bound to the soluble CD4 
molecules and infection will be inhibited.   
Previous studies have also reported that brain-adapted HIV-1 envelopes have 
enhanced sensitivity to neutralizing antibodies (196, 284).  An exposed CD4 binding pocket 
would result in increased neutralizing antibody sensitivity, which may explain why 
macrophage-tropic envelopes are not commonly found in the peripheral blood.  The CNS is 
an immune-privileged site where antibodies are not common, and this creates an environment 
that is favorable for the evolution of macrophage-tropic HIV-1 variants.  I can examine the 
neutralization sensitivity of different HIV-1 envelopes using heterologous antibodies 
targeting the V3 loop and the CD4 binding site of the envelope.  HIV-1 envelopes with a 
more exposed CD4 binding pocket should have increased sensitivity to both V3 antibodies 
and antibodies targeting the CD4 binding site.  In addition, serum samples were collected 
from all of the subjects used in our chronic infection studies.  Thus, I will be able to analyze 
the sensitivity of different envelopes to autologous antibodies as well in future experiments. 
 Studies investigating the three-dimensional structure of HIV-1 envelope have been 
hindered by the constant variation in envelope conformation when it is not bound to the CD4 
receptor.  The crystal structure has only been solved for monomeric gp120 bound to the CD4 
molecule with most of the variable loops truncated (165, 166), although more recently the 
structure of gp120 with the V3 loop attached was also solved (142).  The structure has also 
been solved for an unliganded, fully glycosylated SIV gp120 monomer (missing the V1/V2 
and V3 loops), which has provided a comparison for the HIV-1 gp120 structure (29).  In 
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addition, the natural structure of gp160 is a trimer on the surface of virions; however, soluble 
gp120 is monomeric and does not form stable trimers.  All of these setbacks in envelope 
structural biology have resulted in most studies using indirect measurements to identify 
differences in envelope conformations.  Until the HIV field is able to solve the trimeric 
structure of envelope, there will continue to be holes not only in CNS HIV biology, but also 
in areas of HIV transmission and vaccine research.   
 Now that I have reported differences in HIV-1 envelope cell tropism for CNS 
variants, further studies are needed to examine the evolution of other HIV-1 genes in 
different cell types.  The 3’ LTR and Nef genes were amplified along with the full-length env 
genes during the SGA procedure in our studies.  Some preliminary analyses have been 
conducted on the 3’ LTR region of the HIV-1 genome, and LTR compartmentalization seems 
to correlate with the envelope compartmentalization pattern I reported in Chapter Four (W. 
Ince, unpublished observation).  Previous studies have found that cellular transcription 
factors interact with specific domains located in the HIV-1 5’ LTR and help drive 
transcription from the provirus (230).  The cellular transcription factors that interact with the 
HIV-1 LTR are thought to be different based on whether HIV is replicating in a CD4+ T cell 
versus a macrophage.  Even though the LTR sequences I generated only contains the U3 
region of the provirus LTR, functional studies will help determine any differences in cellular 
transcription factor binding sites between T cell-tropic versus macrophage-tropic HIV-1 
variants.  Longitudinal studies comparing both LTR and envelope evolution in the CNS will 
help identify which gene evolves towards macrophage-tropism first, although I predict that 
envelope evolution for entry into macrophages occurs prior to changes in the LTR.   
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 Finally, replication and fitness differences need to be assessed for compartmentalized 
and non-compartmentalized HIV-1 variants in subjects with neurological disease.  Full-
length, replication competent HIV-1 clones should be generated for a subset of the envelopes 
that were tested in Chapter Four.  In particular, a T cell-tropic variant and a macrophage-
tropic variant from one subject should be compared to examine the kinetics of viral spread 
and replication in different cell types, and to examine relative fitness in competition 
experiments.  Although the generation of full-length HIV-1 clones is extremely difficult due 
to the presence of nicks in the genomic RNA, it would be interesting to take this idea one 
step further by generating full-length virus clones of CSF-compartmentalized variants from 
different longitudinal time points pre- and post-HAD diagnosis.  In the analysis of subject 
7115, I found a viral population with macrophage-tropic envelope characteristics at one 
month post-HAD diagnosis, and similar viral genotypes were detected two years prior to the 
development of dementia as a minor portion of the CSF viral population.  One possibility is 
that envelope macrophage tropism determinants evolve first, and then over time other 
portions of the HIV-1 genome evolve towards enhanced replication in cells of the 
monocyte/macrophage lineage.  By studying full-length HIV-1 genomes I would be able to 
capture any replication advantages that may not be apparent from studies only focusing on 
envelope.   
 Neurological complications resulting from HIV-1 infection of the CNS will continue 
to be a problem for HIV-1-infected individuals, even in the era of HAART.  HIV-1 infection 
and replication in the CNS are complex events, and a lot about this process is still unknown.  
Future longitudinal studies will need to focus on the evolutionary events leading up to 
significant HIV-1 compartmentalization in the CNS/CSF and the development of 
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neurological disease.  New technologies and studies are required to solve the crystal structure 
of the HIV-1 gp160 trimer, and a complete understanding of the three-dimensional 
interactions of HIV-1 envelope with both the cellular receptors and neutralizing antibodies is 
necessary to generate an effective vaccine or therapy.  Finally, further studies into the 
neuropathogenesis of HIV-1 may reveal that increased replication fitness combined with the 
degree of immunodeficiency explain the course of neurological disease during HIV-1 
infection. 
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Figure 5.1. Model of HIV-1 in the CNS during class 1 and class 2 viral encephalitis. 
CD4+ T cells are represented by open circles, perivascular macrophages/microglia are 
represented by the irregularly shaped cells, red virus particles represent the blood plasma 
HIV-1 variants, and blue virus particles represent the CNS compartmentalized HIV-1 
variants.  Class 1 and class 2 viral encephalitis both occur in subjects with neurological 
disease that have significant CNS compartmentalization.  Class 1 encephalitis is associated 
with high CSF pleocytosis, rapid decay of compartmentalized variants after the initiation of 
therapy, and a T cell-tropic phenotype of the compartmentalized variants.  Class 2 
encephalitis is associated with no/low CSF pleocytosis, increased immunodeficiency, slow 
decay of compartmentalized variants after the initiation of therapy, and a macrophage-tropic 
phenotype of the compartmentalized variants.  We propose that the compartmentalized 
population in the CNS of subjects with class 1 encephalitis is T cell-tropic and HIV-1 
replication maintained by T cells, while the CNS-compartmentalized population in subjects 
with class 2 encephalitis is macrophage-tropic and HIV-1 replication is maintained by long-
lived perivascular macrophages and/or microglia in the CNS. 
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APPENDIX 
 
IDENTIFICATION AND RECOVERY OF MINOR HIV-1 VARIANTS USING THE 
HETERODUPLEX TRACKING ASSAY AND BIOTINYLATED PROBES 
 
 
Reprinted from: Schnell, G., W.L. Ince, and R. Swanstrom. 2008. Identification and 
Recovery of Minor HIV-1 Variants Using the Heteroduplex Tracking Assay and Biotinylated 
Probes. Nucleic Acids Res 36:e146. 
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ABSTRACT 
 
We describe a method to identify and recover minor human immunodeficiency virus 
type 1 (HIV-1) sequence variants from a complex population.  The original heteroduplex 
tracking assay (HTA) was modified by incorporating a biotin tag into the probe to allow for 
direct sequence determination of the query strand.  We used this approach to recover 
sequences from minor HIV-1 variants in the V3 region of the env gene, and to identify minor 
drug-resistant variants in pro.  The biotin-HTA targeting of the V3 region of env allowed us 
to detect minor V3 variants, of which forty-five percent were classified as CXCR4-using 
viruses.  In addition, the biotin-protease HTA was able to detect mixtures of wild type 
sequence and drug resistance mutations in four subjects that were not detected by bulk 
sequence analysis.  The biotin-HTA is a robust assay that first separates genetic variants then 
allows direct sequence analysis of major and minor variants. 
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INTRODUCTION  
 
Genetically unstable organisms present a special challenge to therapeutic 
intervention.  Genetic instability coupled with large population sizes leads to population 
diversity that can harbor advantageous mutations in the face of changing selective pressures.  
Our knowledge about genetic complexity is always limited by our ability to sample minor 
variants within the population.  One example of this phenomenon is the human 
immunodeficiency virus type 1 (HIV-1), which maintains genetic diversity in its population 
that can impact evolution of escape from immune selection, drug resistance, and changes in 
target cell specificity (36).  
 Several approaches are available for sampling genetic complexity.  Bulk sequence 
analysis of the total population suffers from limited sensitivity, and cannot reliably detect 
variants that comprise less than approximately 25% of the population (170, 220).  A strategy 
of cloning a PCR product generated from a complex population followed by sequencing 
individual clones is limited by the number of clones analyzed, and the accurate detection of 
minor variants in the population requires a large sampling of clones (183, 220).  Allele-
specific PCR can detect variants in the 0.1-1% range, and although there is no information 
about linkage to other sequence variation (122, 222), further analysis of the allele-specific 
product can generate some linkage information (147).  More recent pyrosequencing 
approaches offer deep sequencing capability, although the high error rate necessitates 
oversampling of sequences which reduces sensitivity, and bioinformatics approaches are 
necessary to handle the large data output (191). 
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 An alternative approach to dissecting genetic diversity is the heteroduplex tracking 
assay (HTA).  The HTA is a gel-based assay that separates viral variants based on sequence 
differences, and can resolve variants that comprise as little as 1-3% of the total viral 
population (49, 51, 52).  In this assay, the desired genomic region is amplified by PCR, and a 
radioactively labeled probe is annealed to the PCR products.  Heteroduplexes are generated 
between the probe and PCR products, and any insertions, deletions, or clustered mutations 
will result in a bend or kink in the DNA helix, conferring an altered migration through a non-
denaturing polyacrylamide gel.  However, this approach is limited in that it is not linked to 
direct sequence analysis. 
 In this report we describe a modification of the HTA strategy that couples the ability 
to separate genetic variants in a gel-based assay with direct sequence analysis of the 
separated variants.  The ability to directly sequence the query strand of each heteroduplex in 
the gel was accomplished by adding a biotinylated-nucleotide tag to the radiolabeled probe 
strand.  Using the biotinylated probe, we were able to purify the labeled heteroduplex and 
subsequently separate the query strand from the probe. The purified query strand was then 
subjected to PCR amplification and conventional sequence analysis.  We used this approach 
to identify sequences from minor variants in the V3 region of the HIV-1 env gene that predict 
changes in target cell tropism, and to examine the heterogeneity of the pro gene population 
during the evolution of resistance to protease inhibitors. 
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MATERIALS AND METHODS 
 
Plasma samples.   
All plasma samples were obtained as excess tissue samples and with Institutional 
Review Board approval.  Samples for the V3 studies were from subjects in a ritonavir 
efficacy study (27), and were provided by Dale Kempf (Abbott Laboratories) unlinked to 
personal identifiers.  Samples for the protease studies were entry time-point plasma samples 
obtained from subjects in the ACTG 359 clinical trial (117).   
 
Plasmids and probes.   
The V3 Mut-1 probe plasmid was generated using the V3JR-FL plasmid pJN27 
developed by Nelson et al. (212).  A BamHI restriction site located upstream of the probe 
insert in pJN27 was destroyed, and the EcoRI site located at the start of the probe sequence 
was mutated to a new BamHI site using the Quikchange site-directed mutagenesis strategy.  
The 5'-GATC-3' overhang after BamHI cleavage permits sequential labeling of the antisense 
strand in a fill-in reaction with biotin-labeled dGTP and 35S-dATP.  To limit PCR 
amplification of the probe sequence from the isolated heteroduplex, the upstream V3 PCR 
primer binding site in the pJN27 plasmid was mutated, reducing the efficiency of 
amplification by 1000 fold.  The final sequence of the V3 Mut-1 probe at the upstream V3 
boundary was 5’-GATCCGGCTTGAATCTGTAGAAATTAATTGTACACGACAAAA…-
3’.  The final probe sequence at the downstream V3 boundary in the probe is 5'-
…CATTGTAACATTAGTAGAGCAAAAAAGCCGAATTAATTCTGCA-3’.  Introduced 
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nucleotide changes are indicated by bolded and underlined letters, and plasmid sequence 
included in the V3 probe is shown in italics.   
 The pR-EBm protease probe plasmid was generated from the multiple-site-specific 
HTA probe pR-EB previously described by Resch, et al. (250).  The site-directed 
mutagenesis procedure described above was used to generate the pR-EBm probe.  The probe 
was modified for this study by introducing base mismatches in the upstream PCR primer 
binding site to limit amplification from the probe sequence from the isolated heteroduplex.  
Additionally, a BamHI site was introduced at the 3’ end to accommodate biotin- and radio-
labeling of the sense strand. The 5’ probe sequence is 5’-
TATGGATAACTAAAGGAAGCTCTATTAGATACTGGCT…-3’, and the 3’ probe 
sequence is 5’-…TCAGATTGGTTGCACTTTAAATTTTCCATCG(biotin-dGTP)(S35-
dATP)-3’.  Introduced nucleotide changes are indicated by bolded, underlined letters, and 
plasmid sequence included in the probe is shown in italics.   
 
Probe labeling.   
The V3 Mut-1 probe plasmid (10 μg) was digested with BamHI (60 μl total volume) 
followed by a fill-in reaction with 4 nmol Biotin-11-dGTP (PerkinElmer), 0.05 mCi [α-35S]-
dATP (1250 Ci/mmol; PerkinElmer), 20 units of the Klenow fragment of DNA polymerase I, 
and 0.6 μl of 1M DTT.  The reaction was incubated for 15 minutes at room temperature 
followed by the addition of 1.4 µl 0.5M EDTA and heat inactivation for 15 minutes at 80°C.  
The excess nucleotides were then removed using the Qiagen PCR Purification kit (Qiagen), 
and the V3 Mut-1 probe was released from the vector by PstI digestion.  The pR-EBm probe 
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plasmid was labeled using the same procedure, except that after purification the pR-EBm 
probe was released from the vector by NdeI digestion. 
 
RNA isolation, RT-PCR, and heteroduplex tracking assay.   
Procedures for viral RNA isolation from plasma, RT-PCR, and the HTA were 
conducted as previously described (212, 250).  Briefly, viral RNA was isolated from blood 
plasma (140 μl) using the QIAmp Viral RNA kit (Qiagen).  Reverse transcription and PCR 
amplification of the 140 bp V3 amplicon were conducted with 5 μl of purified RNA (from 50 
μl column elution volume) and the primers HIVV3F (Hxb2 7142-7171 [5’-
GAATCTGTAGAAATTAATTGTACAAGACCC-3’]) and HIVV3R (Hxb2 7239-7211 [5’-
CCATTTTGCTCTACTAATGTTACAATGT-3’]) by using the Qiagen One-Step RT-PCR 
kit (Qiagen) as per manufacturer’s instructions.  Amplification of a 247-bp region of pro was 
conducted using the procedure stated above and the primers PRAMPUP (Hxb2 2305-2334 
[5'-AACTAAAGGAAGCTCTATTAGATACAGGAG-3']) and PRAMPDW (Hxb2 2551-
2525 [5'-GGAAAATTTAAAGTGCAACCAATCTGA-3']).  Heteroduplex annealing 
reactions consisted of 1 µl of 10x annealing buffer (159, 212), 0.1 μg biotinylated and 
radioactively-labeled probe, and 8 μl of unpurified PCR product.  The reactions were 
denatured and the DNA was annealed at room temperature to allow heteroduplex formation.  
The heteroduplexes were separated by native polyacrylamide gel electrophoresis (as 
described in ref. 14 and 15), and the separated heteroduplexes were visualized by 
autoradiography.  The relative abundance of each detected heteroduplex was determined by 
exposing the HTA gel to a phosphorimager screen, and the percent abundance of each variant 
was calculated using ImageQuant software (Molecular Dynamics).   
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Band extraction, DNA purification, and sequence analysis.   
The dried HTA gels were aligned with the exposed autoradiography film, and the 
desired labeled bands were excised from the gel.  The gel fragment was transferred to a 
sterile 1.5 ml microcentrifuge tube.  Crush & Soak buffer (120 μl; 500 mM NH4OAc, 0.1% 
SDS, 0.1 mM EDTA) was then added, and the tubes were incubated at 37°C overnight.  
After incubation, the tubes were centrifuged for 2 minutes at 14,000 rpm to pellet any gel 
fragments, and the supernatants were transferred to a 96-well PCR plate.  Streptavidin-coated 
Dynabeads® (Invitrogen) (5 μl per reaction) were washed twice then resuspended in the 
same volume in 2x B&W buffer (10 mM Tris-HCl [pH 7.5], 1 mM EDTA, 2M NaCl).  The 
bead suspension was then aliquoted into a clean 96-well PCR plate (5 μl per well).  The plate 
containing the beads was placed on the magnet for 1 minute and the supernatant was 
removed.  The plate was removed from the magnet, and the beads were resuspended in 80 μl 
of 2x B&W buffer.  An equal volume (80 μl) of the gel-extracted heteroduplex product was 
then added to the beads.  The plate was then incubated for 17 minutes at room temperature in 
a MixMate shaker (Eppendorf) at 700 rpm to prevent the beads from settling.  After the 
incubation, the plate was placed on the magnet for 2 minutes, and the supernatant was 
removed and discarded.  The beads were washed three times in 1x B&W buffer (20 μl), and 
then washed twice in 1x SSC (pH 7.0; 50 μl).  After the last wash, the beads were 
resuspended in 20 μl of freshly prepared 0.15M NaOH and incubated for 5 minutes at room 
temperature to denature the heteroduplexes.  The plate was then placed on the magnet for 1 
minute, and the supernatant containing the denatured query strand was transferred to a clean 
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96-well PCR plate.  The supernatant was neutralized by adding 2.4 μl of 10x TE (pH 7.5) and 
2.4 μl of 1.25M acetic acid.   
 The purified query strand DNA was then amplified with the Platinum Taq DNA 
Polymerase High Fidelity PCR kit (Invitrogen) as per the manufacturer’s instructions, using 
2 μl DNA and the PCR primers described above.  The V3 sequencing primers are V3SeqF 
(Hxb2 7147-7176 [5’-TGTAGAAATTAATTGTACAAGACCCAACAA-3’]) and V3SeqR 
(Hxb2 7234-7205 [5’-TTTGCTCTACTAATGTTACAATGTGCTTGT-3’]).  The protease 
PCR primers described above were used to sequence the pro PCR products.  Bulk 
sequencing was also conducted on the original PCR products amplified from viral RNA.  
GenBank accession numbers FJ347037-FJ347099.
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RESULTS 
 
Biotinylated probes and HTA allow the identification and recovery of minor HIV-1 
variants from a complex population.  
The HTA is capable of separating diverse genetic variants in a gel-based format (49, 
51, 52, 159, 212, 250).  We have modified the original HTA method to permit direct 
sequence determination of the query strand of the target heteroduplex and adapted the 
approach to a 96-well plate format.  To accomplish direct sequencing of the query strand we 
incorporated a biotin tag into the probe strand (see Materials and Methods) to allow for the 
purification of the labeled heteroduplex followed by the separation of the query and probe 
strands (Figure A.1).   
In this approach a query PCR product is generated, annealed to a radiolabeled/biotin-
labeled probe, and the heteroduplexes are resolved by native polyacrylamide gel 
electrophoresis.  Gel slices containing the labeled heteroduplexes are then excised from dried 
polyacrylamide gel using X-ray film that had been exposed to the gel as a guide.  The excised 
gel slices are rehydrated and soaked overnight to recover heteroduplex DNA from the gel 
fragments.  The biotin-tagged heteroduplexes are then purified away from the gel fragments 
and any unlabeled co-migrating DNA (i.e. heteroduplexes formed between the unlabeled 
PCR products) by binding the labeled heteroduplexes to streptavidin-coated magnetic 
Dynabeads®, followed by washing.  The query DNA strand in the heteroduplex is then 
eluted from the probe DNA with dilute NaOH, which allows the probe strand to remain 
attached to the magnetic beads and thus removed from the solution.  The purified query DNA 
strand is then used as the template in another round of PCR amplification, and the PCR 
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product is sequenced using standard technology.  Below we describe the application of this 
approach to the sequence-based identification of HIV-1 variants that enter cells using the 
CXCR4 coreceptor, and of variants that encode drug resistance in subjects failing therapy 
with a protease inhibitor, in each case resolving these variants from genotypic mixtures. 
 
Minor X4 variants are identified and recovered using a biotinylated-V3 HTA probe.  
We analyzed the V3 region of env for 34 HIV-1-infected subjects with CD4+ T cell 
counts less than 150 cells/µl to test the ability of our biotin-HTA method to detect and 
recover minor V3 variants in complex viral populations.  Figure A.2A shows the separation 
of genotypic mixtures of the V3 region of the env gene in the HTA gel (211, 212).  We were 
able to obtain V3 sequence from 63 of the 69 visible heteroduplexes in the polyacrylamide 
gels, and phosphorimager analysis was used to define the relative fraction of each variant.  
For these subjects the average number of variants was two variants per subject, and the 
number of variants ranged from 1 (12 subjects) up to 5 (1 subject).    
 We used the modified 11/25 rule (140, 249) and the position-specific scoring matrix 
(PSSM) (145) to predict the coreceptor usage of these V3 sequences based on the viral 
genotype.  A total of 63 V3 sequences were generated for these 34 subjects, of which 48 
corresponded to an R5-using genotype and 15 corresponded to an X4-using genotype (Figure 
A.2 and data not shown).  The biotin-V3 HTA method recorded the presence of minor R5 or 
X4 V3 variants (defined as less than 30% of the total population) in 18 of the 34 subjects, 
and a total of 26 bands with a relative abundance of less than 30% were excised and 
sequenced.  We obtained sequence for 20 of the bands while we failed to obtain sequence for 
6 bands.  The relative abundance of the 6 variants for which sequence was not obtained 
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ranged from 0.1% to 13% of the total population, with the failure to obtain usable sequence 
attributable to either very low abundance or near co-migration.  Of the 20 minor V3 
sequences we recovered, nine were classified as X4-using viruses.  We were able to detect 
two of these minor X4 sequences as mixtures in bulk sequence analysis, while the other 
seven minor X4 variants were not detected by bulk sequence analysis due to low relative 
abundance.  All of the V3 variants that were extracted from the gel and PCR amplified 
migrated to the same position in the gel as the original band amplified from viral RNA (data 
not shown).  One limitation of this procedure is that major bands in the gel trail upwards, and 
PCR products of minor variants that migrate right above a major variant in the gel may 
contain a small amount of the major variant.  However, in most cases (55 out of 69 variants) 
the V3 sequence obtained from the PCR products had clean peaks, and the major variant was 
not detected in the sequence analysis (data not shown).  For the remaining fourteen variants 
that had multiple peaks present in the sequence analysis, and also displayed a large amount of 
the contaminating major variant, purified samples were re-amplified and purified again to 
obtain the target sequence.  Using this enrichment method, we were able to determine the 
sequence of eight additional variants.  Overall, we were able to obtain clear sequence for 
approximately 90% of all bands detected and approximately 75% of all detected bands 
representing less than 30% of the population, and the use of biotin-HTA resolved all 
mixtures seen with bulk sequence analysis. 
In order to further examine the sensitivity and specificity of the biotin-HTA, several 
control experiments were conducted.  First, we mixed together two V3 PCR products at 
varying ratios and then separated the mixtures using the biotin-V3 HTA.  The bands were 
then excised from the gel, purified, and sequenced.  In this control experiment we were able 
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to obtain sequence from a band that represented as little as 1.5% of the total population 
(Figure A.3A).  Sequence was not obtained from the band representing 0.5% of the 
population; however, we did not reamplify the product in this case which can allow increased 
sensitivity of detection, as described above.  To address specificity, single genome 
amplification (SGA) (262) of the env gene was conducted on blood plasma from subject 
1314 in order to compare the relative abundance of variants determined using biotin-HTA to 
sampling of the viral population by sequencing individual viral templates.  We generated and 
sequenced ten SGA amplicons and compared the V3 regions to the sequences identified 
using the biotin-V3 HTA.  The ten amplicons represented two migration patterns in the V3-
HTA, with seven of the amplicons having one migration rate (shown as amplicons 1.1 and 
1.2 in Figure A.3B), and three of the amplcons having the other migration rate (labeled 
amplicon 2 in Figure A.3B).  This closely approximated the ratio of 73% and 27% for these 
two bands as determined by V3-HTA (Figure A.3C), and this result is consistent with a 
similar control done previously with a V1/V2-HTA probe (159).  The altered migration of 
heteroduplexes in the HTA is based on sequence differences between the strands, especially 
clustered mutations and insertion/deletions, with variable sensitivity to detect isolated point 
mutations.  This feature can be seen in the sequence differences between the bands that were 
resolved by the biotin V3-HTA (amplicons 1 and 2, Figure A.3C), but the comigration of 
sequences that differed by only a few nucleotides (amplicons 1.1 and 1.2, Figure A.3C).  In 
this case the level of variability in the isolated HTA band was revealed as a mixed peak in the 
sequence chromatogram when that band was isolated and sequenced (data not shown). 
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Minor protease drug-resistant variants are detected using a biotinylated-protease HTA 
probe. 
We have applied the biotin-HTA to separate HIV-1 pro variants, encoding the viral 
protease, and to sequence these variants to detect mutations that confer resistance to protease 
inhibitors.  The biotin-protease HTA is a modification of the previously described multiple 
site-specific HTA (MSS-HTA) (250) (see Materials and Methods) with the probe designed to 
query mutations at protease codon positions 46, 48, 54, 82, 84, and 90.  We used both our 
own bulk sequence analysis and the biotin-protease HTA to screen nineteen subjects who had 
previously failed therapy that included the protease inhibitor IDV.  A total of ten subjects had 
no primary resistance mutations by either method, although some had viral genotypes that 
included polymorphic mutations that can become enriched with therapy (277) (data not 
shown) (Stanford Database, http://hivdb.stanford.edu/).  The remaining nine subjects all 
exhibited primary resistance mutations (Stanford database, http://hivdb.stanford.edu/).  For 
three of these subjects we detected a homogeneous population by both methods (data not 
shown).  The results of the biotin-HTA analysis and the bulk sequence analysis for the 
remaining 6 subjects are shown in Figure A.4.   
Bulk sequence analysis was able to identify mutations in variants that comprised as 
little as 28% of the population (Figure A.4, subject 18, band 1), but also missed mutations 
that existed in variants making up as much as 45% of the population (Figure A.4; subject 4, 
band 1), perhaps due to poor incorporation of the chain terminating nucleotide at that 
position.  In contrast, using the biotin-HTA approach we were able to identify primary 
resistance mutations at the query positions in 3 subjects (subject 4, band 1; subject 16, band 
1; and subject 22, bands 1 and 2) that were not detected in bulk sequencing (Figure A.4).  
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Exclusive linkage between resistance mutations I54V and V82A was established in one 
subject (Figure A.4; subject 18, band 1).  The least abundant variant we identified comprised 
4% of the total population (Figure A.4B; subject 16, band 3), although this variant differed 
by only 1 synonymous change from the bulk sequence (data not shown).  Resistance 
mutations were sometimes identified as mixtures in excised bands (Figure A.4; subject 4, 
band 1; subject 16, band 1; subject 18, band 4).  This can result from either trailing of 
products from a major lower band, or, in the case of positions that the probe was not 
designed to query, the inability of the probe to distinguish between variants at that position 
(Figure A.4; subject 18, band 4; subject 19, bands1-3).  Despite existing as mixtures in these 
cases, resistance mutations were enriched, and therefore detected, in electrophoretically 
separated variants when they were otherwise not detected by bulk sequence analysis.  One 
subject had a resistance mutation (subject 15, V82A – not shown) that was detected in a 
separate clinically approved bulk sequence analysis protocol but not in the HTA analysis, 
while three other subjects displayed resistance mutations that were detected by HTA but not 
by the clinically approved analysis (Figure A.4; subject 4, V82A; subject 16 and 18, I54V). 
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DISCUSSION 
 
The biotin-HTA allows for the detection and direct sequence analysis of multiple 
variants in a complex population.  Using the biotin-HTA targeting the V3 region of env, we 
were able to detect and directly determine the sequence of 20 minor (less than 30% 
abundance) R5 and X4 viral variants, of which forty-five percent were classified as X4-using 
viruses.  In addition, we used a biotin-protease HTA to detect and sequence specific drug 
resistance mutations in pro in nineteen subjects failing treatment with an HIV-1 protease 
inhibitor.  Fifteen of the nineteen subjects had matching genotypes for the clinical screening 
data and the HTA analysis, while three subjects displayed resistance mutations that were 
detected by HTA but not by a clinically approved bulk sequence analysis.   
An RNA heteroduplex generator-tracking assay (RNA-HTA) has been developed that 
uses a degradable RNA probe to allow direct sequence analysis of the query strand, which 
was tested by examining HIV-1 variants with drug-resistance mutations in the protease 
coding domain (151).  Using this method, variants that comprised 1% of the total population 
were identified and subjected to sequence analysis.  One drawback of the RNA-HTA method 
is that unlabeled DNA-DNA heteroduplexes generated from variants within the PCR product 
can comigrate with the labeled RNA-DNA heteroduplexes, going undetected in the gel but 
giving rise to sequence mixtures during the subsequent amplification and sequence analysis.  
Our biotin-HTA method introduces the ability to purify specifically the biotin/radiolabeled 
probe:PCR product heteroduplexes from unlabeled PCR product heteroduplexes that might 
migrate to the same location in the polyacrylamide gel.  Similar to what Kapoor et al. saw in 
their studies (151), we also find that major variants trail upwards in the gel and can be 
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detected in the PCR products extracted from upper bands.  In the case that an unreadable 
sequence is detected using the biotin-HTA procedure, it is possible to simply reamplify the 
now enriched mixture and run another biotin-HTA followed by sequence analysis.   
In a control experiment we were able to obtain sequence information from a band that 
comprised 1.5% of the signal, and as seen previously (159), the HTA provides sampling that 
is similar to that obtained by other methods but has the advantage of being able to query 
many more templates than these other methods (Figure A.3).  During the analysis of the 
subject samples, we were able to obtain the sequence of a variant that represented 0.5% of 
the total population (subject 1007, Figure A.2B) by running the extracted V3 PCR product on 
another biotin-HTA and re-amplifying the purified product, thus allowing for further 
enrichment of the minor variant.  A useful comparison of the potential utility of the HTA is 
as follows.  If one were to sequence 300 clones (assuming they are derived from independent 
templates in the PCR amplification), there is a 95% chance of detecting variants present at a 
1% level.  In this case detection of presence is more robust than the estimate of relative 
abundance; also, the amount of work essentially increases linearly as the number of clones 
analyzed increases.  HTA is able to detect signals in the 1% range in the gel-based detection 
system.  However, sampling quality can be significantly better since this approach is not 
limited by the number of templates sampled, i.e. sampling 300 templates is as easy as 
sampling 3000 templates.  This allows the HTA approach to measure more accurately the 
relative abundance of even minor species in those circumstances where larger numbers of 
templates are available to be sampled, and to validate their abundance by comparing repeat 
amplifications.   
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 Different HIV-1 entry inhibitors are being explored as possible drugs to block HIV-1 
infection and to treat current infections.  Several CCR5-inhibitors are approved or in 
development for the treatment of HIV-1 infection, including maraviroc (Pfizer) (59, 76) and 
vicriviroc (Schering Plough) (118, 293).  CCR5-inhibitors work by binding the CCR5 
coreceptor to block the entry of HIV-1.  CXCR4-using viruses are naturally resistant to these 
CCR5-binding drugs and therefore this class of inhibitor is not indicated for subjects with X4 
variants.  In addition, coreceptor switching has been documented in several subjects using 
CCR5-inhibitors, although the level of CXCR4-emerging viruses was lower than expected 
(76, 313).  In the subjects where CXCR4-using viruses emerged after treatment with a CCR5 
inhibitor, phylogenetic analysis showed that these variants were a result of the outgrowth of a 
minor CXCR4-using variant that was present prior to the initiation of drug therapy (313).  
The biotin-V3 HTA that we have developed can detect and genotype minor V3 variants in 
the range of 1.5% of the total HIV-1 population, and could be used as an initial genotypic 
screen for CXCR4-using variants in people considering CCR5-inhibitor drug therapy.   
 Additionally, genotypic testing for the presence of resistance mutations is the 
standard-of-care for people initiating and failing therapy (Guidelines for the use of 
antiretroviral agents in HIV-1-infected adults and adolescents, U.S. D.H.H.S., 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf).  The biotin-protease 
HTA provides an example where complex mixtures of sequences can be examined with 
greater sensitivity to detect resistance mutations.  The biotin-HTA methods used here for the 
detection and direct sequence analysis of minor HIV-1 variants should be applicable to other 
complex viral and non-viral populations where increased sensitivity of detection of minor 
genetic variants is important.  
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Figure A.1.  The biotin-HTA strategy.  (A) The region of interest is PCR amplified from 
the HIV-1 genome and mixed with a biotinylated probe to generate heteroduplexes between 
the probe and PCR product.  The heteroduplexes are then separated by polyacrylamide gel 
electrophoresis based on DNA bending.  The single-stranded probe band is denoted by the 
asterisk (*), and the double-stranded probe band is denoted by double asterisks (**).  The 
labeled heteroduplexes are excised from the dried polyacrylamide gel.  (B) The gel fragments 
are soaked overnight to recover heteroduplex DNA from the gel fragments.  (C) The 
supernatant containing the biotin-tagged heteroduplexes is then incubated with streptavidin-
coated magnetic Dynabeads®.  The biotin-tagged heteroduplexes bind to the streptavidin-
coated magnetic Dynabeads®, and contaminants are removed by washing.  (D) The query 
DNA strand in the heteroduplex is eluted from the probe DNA with dilute NaOH, which 
allows the probe strand to remain attached to the magnetic beads.  (E) The purified query 
strand is then used as template in another round of PCR amplification, and the PCR product 
is sequenced using standard technology.   
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Figure A.2.  Identification and recovery of minor V3 variants using a biotinylated-V3 
HTA.  (A) Biotin-V3 HTA gel for 9 representative subjects.  The asterisk (*) indicates the 
single-stranded probe band, double asterisks (**) indicate the double-stranded probe band, 
the plus sign (+) indicates background bands, and arrowheads indicate shifted heteroduplex 
bands.  (B) The numbered bands were extracted, purified, and sequenced to determine the V3 
sequence of each band.  It is important to note that the V3 PCR primers we used to amplify 
the V3 products extend into the first four and the last three amino acids of the V3 sequence, 
and the V3 sequences provided in Figure A.2 and GenBank (Acc. # FJ347037-FJ347099) do 
not include these amino acids.  However, to accurately predict coreceptor usage using PSSM 
we added the JRFL consensus amino acid sequence to the beginning (CTRP) and end (AHC) 
of each V3 sequence.  The relative abundance (Rel. Ab.) and PSSM score (0 = R5-like 
sequence, 1 = X4-like sequence, N/A = not applicable) for each sequence are listed in panel 
b. 
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Figure A.3.  Examination of the sensitivity of the biotin-V3 HTA. (A) Mixtures of two V3 
PCR products were separated by the biotin-V3 HTA.  The bands were cut from the gel, 
purified, and sequenced.  The plus sign (+) indicates bands for which sequence was obtained, 
and the minus sign (-) indicates a band for which the sequence was not obtained.  The 
asterisk (*) indicates the single-stranded probe band, and double asterisks (**) indicate the 
double-stranded probe band.  (B, C) Single genome amplification (SGA) of the env gene was 
conducted on subject 1314.  The migration of three different SGA-V3 PCR products and the 
original 1314 V3 PCR product are shown in panel b.  The V3 amino acid sequence of the 
extracted bands and the SGA amplicons, the relative abundance (Rel. Ab.), and number of 
SGA amplicons (N) are listed in panel c.    
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Figure A.4.  Detection of minor protease inhibitor resistance mutations using a 
biotinylated-protease HTA.  (A) Protease-specific MSS-HTA gel for 6 representative 
subjects.  Double asterisks (**) indicate the double stranded probe band and arrowheads 
indicate shifted heteroduplex bands. (B) Numbered bands were extracted and sequenced to 
identify the predicted amino acid at the positions indicated.  For each subject, the bulk PCR 
sequence is listed above the band sequences.  Mixtures are indicated where identified by 
sequencing.  The relative abundance of each band is listed in the right-most column as a 
percentage of the total.  The amino acids inferred from the bulk sequence for subject 4 
represent the wild-type consensus.  Amino acid positions which the probe was designed to 
query are in bold (46, 48, 54, 82, 84, 90).  Shaded amino acids represent positions at which 
heterogeneity was identified by HTA but not by bulk sequence analysis. 
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